Solid forms, salts and methods of preparation of CDK2 inhibitors

By developing solid forms and salts of compounds of formula (I), the problem of lack of CDK2 targeted inhibitors in the prior art is solved, and effective CDK2 inhibitors and treatment methods are provided, which improves the therapeutic effect on CDK2-related diseases.

CN119072470APending Publication Date: 2024-12-03INCYTE CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380035631.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-07
Filing Date
2023-03-07
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art has not yet developed effective CDK2 targeting inhibitors, especially for cancers associated with CDK2 dysregulation, and there is a lack of novel CDK2 inhibitors and methods for preparing their solid forms.

Method used

The solid form of the compound of formula (I) and its salts are provided, including free bases, maleate, benzenesulfonate, methanesulfonate, etc., prepared by cooling or evaporation method for inhibiting CDK2, and the preparation method includes React and slurry in different solvent components.

Benefits of technology

Effective inhibition of CDK2 is achieved, and a drug form is provided for the treatment of CDK2-related diseases, which improves the targeted therapeutic effect of CDK2.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119072470A_ABST
    Figure CN119072470A_ABST
Patent Text Reader

Abstract

The present application provides solid forms and salts of compounds of formula (I): # imgabs0 # pharmaceutical compositions thereof, methods of using the same to treat diseases or conditions associated with CDK2, and methods of making the compounds of formula (I) and the solid forms and salts.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims the benefit of priority to U.S. Provisional Application No. 63 / 317,308, filed on March 7, 2022, which is incorporated by reference in its entirety.

[0002] Sequence Listing

[0003] This application contains a sequence listing, which has been submitted electronically as an XML file named 20443-0746WO1_SL_ST26.xml. The XML file was created on March 6, 2023 and is 5,121 bytes in size. The contents of the XML file are hereby incorporated by reference in their entirety. Technical Field

[0004] The present application relates to solid forms and salts of CDK2 inhibitors, pharmaceutical compositions thereof, methods of using the same to treat diseases or conditions associated with CDK2, and methods of preparing the compounds of formula (I) and the solid forms and salts thereof. Background Art

[0005] Cyclin-dependent kinases (CDKs) are a family of serine / threonine kinases. CDKs heterodimerize with regulatory subunits called cyclins to become fully activated and regulate key cellular processes, including cell cycle progression and cell division (Morgan, DO, Annu Rev Cell Dev Biol, 1997.13:261-91). Uncontrolled proliferation is a hallmark of cancer cells. Disorders of CDK activity are associated with abnormal regulation of the cell cycle and have been detected in almost all forms of human cancer (Sherr, CJ, Science, 1996.274(5293):1672-7).

[0006] CDK2 is of particular interest because the disorder of CDK2 activity often occurs in a variety of human cancers. CDK2 plays a vital role in promoting G1 / S transition and S phase progression. CDK2 and cyclin E (CCNE) complex phosphorylates members of the retinoblastoma pocket protein family (p107, p130, pRb), leading to E2F transcription factor derepression, G1 / S transition-related gene expression and transition from G1 to S phase (Henley, SA and FADick, Cell Div, 2012, 7 (1): page 10). This in turn enables CDK2 / cyclin A activation, which phosphorylates endogenous substrates that allow DNA synthesis, replication and centrosome replication (Ekholm, SV and SI Reed, Curr Opin Cell Biol, 2000.12 (6): 676-84). It has been reported that the CDK2 pathway affects tumor formation mainly through amplification and / or overexpression of CCNE1 and mutations that inactivate endogenous inhibitors of CDK2, such as p27, respectively (Xu, X. et al., Biochemistry, 1999. 38(27):8713-22).

[0007] CCNE1 copy number gain and overexpression have been identified in ovarian, gastric, endometrial, breast and other cancers and are associated with poor outcomes in these tumors (Keyomarsi, K. et al., N Engl J Med, 2002. 347(20):1566-75; Nakayama, N. et al., Cancer, 2010. 116(11):2621-34; Au-Yeung, G. et al., Clin Cancer Res, 2017. 23(7):1862-1874; Rosen, DG et al., Cancer, 2006. 106(9):1925-32). It has been reported that amplification and / or overexpression of CCNE1 also leads to resistance to trastuzumab in HER2+ breast cancer and resistance to CDK4 / 6 inhibitors in estrogen receptor-positive breast cancer (Scaltriti, M. et al., Proc Natl Acad Sci USA, 2011. 108(9):3761-6; Herrera-Abreu, MT et al., Cancer Res, 2016. 76(8):2301-13). Various approaches targeting CDK2 have been shown to induce cell cycle arrest and tumor growth inhibition (Chen, YN et al., Proc Natl Acad Sci USA, 1999. 96(8):4325-9; Mendoza, N. et al., Cancer Res, 2003. 63(5):1020-4). Inhibition of CDK2 has also been reported to restore sensitivity to trastuzumab treatment in resistant HER2+ breast tumors in preclinical models (Scaltriti, supra).

[0008] In cancers associated with dysregulated CDK2 activity, these data provide a theoretical basis for considering CDK2 as a potential target for new drug development. In the past decade, there has been increasing attention to the development of CDK selective inhibitors. Despite great efforts, there are no approved agents targeting CDK2 to date (Cicenas, J. et al., Cancers (Basel), 2014.6 (4): p. 2224-42). Therefore, the industry still needs to discover new forms of CDK2 inhibitors and methods for preparing such inhibitors and solid forms. The present application relates to this demand and other needs. Summary of the invention

[0009] The present disclosure relates in particular to solid forms of compounds of formula (I):

[0010]

[0011] It is Form I, Form II or Form III.

[0012] The present disclosure also provides a salt of the compound of formula (I), which is selected from:

[0013] A monomaleate salt of the compound of formula (I);

[0014] Dibenzenesulfonate salt of the compound of formula (I);

[0015] A monomethanesulfonate salt of a compound of formula (I);

[0016] A ditoluenesulfonate salt of a compound of formula (I);

[0017] The monohydrochloride salt of the compound of formula (I); and

[0018] The dihydrochloride salt of the compound of formula (I).

[0019] The present disclosure also provides a pharmaceutical composition comprising a solid form of a compound of formula (I) as described herein and a pharmaceutically acceptable carrier. The present disclosure also provides a pharmaceutical composition comprising a salt of a compound of formula (I) as described herein and a pharmaceutically acceptable carrier.

[0020] The present disclosure also provides a method of inhibiting CDK2, comprising contacting the CDK2 with a solid form of formula (I) as described herein. The present disclosure also provides a method of inhibiting CDK2, comprising contacting the CDK2 with a salt of a compound of formula (I) as described herein.

[0021] The present disclosure also provides a method of inhibiting CDK2 in a patient, the method comprising administering to the patient a solid form of a compound of formula (I) as described herein. The present disclosure also provides a method of inhibiting CDK2 in a patient, the method comprising administering to the patient a salt of a compound of formula (I) as described herein.

[0022] The present disclosure also provides a method for treating a disease or condition associated with CDK2 in a patient, the method comprising administering to the patient a solid form of a compound of formula (I) as described herein. The present disclosure also provides a method for treating a disease or condition associated with CDK2 in a patient, the method comprising administering to the patient a salt of a compound of formula (I) as described herein.

[0023] The present disclosure also provides a solid form of a compound of formula (I) as described herein, for use in any of the methods described herein. The present disclosure also provides a salt of a compound of formula (I) as described herein, for use in any of the methods described herein.

[0024] The present disclosure also provides the use of a solid form of a compound of formula (I) as described herein for the preparation of a medicament for use in any of the methods described herein. The present disclosure also provides the use of a salt of a compound of formula (I) as described herein for the preparation of a medicament for use in any of the methods described herein.

[0025] The present disclosure also provides a method of preparing a solid form of a compound of formula (I) as described herein, the method comprising cooling a solution of a compound of formula (I) in a solvent component comprising ethanol and water.

[0026] The present disclosure also provides methods for preparing salts of compounds of formula (I) as described herein.

[0027] The present disclosure also provides a method for preparing a compound of formula (I) as described herein or a pharmaceutically acceptable salt thereof, a solid form of a compound of formula (I) as described herein, or a salt of a compound of formula (I) as described herein, the method comprising:

[0028] The compound of formula (1c):

[0029]

[0030] With the compound of formula (1b):

[0031]

[0032] or a salt thereof via a Buchwald coupling reaction to form a compound of formula (1a):

[0033]

[0034] Where X 1 It is a halogen group. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 Shown is the XRPD pattern of Form I of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) free base.

[0036] Figure 2 Shown is a DSC thermogram of Form I of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) free base.

[0037] Figure 3Shown is a TGA thermogram of Form I of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) free base.

[0038] Figure 4 Shown is the XRPD pattern of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) maleate.

[0039] Figure 5 Shown is the DSC thermogram of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) maleate.

[0040] Figure 6 Shown is the TGA thermogram of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) maleate.

[0041] Figure 7 Shown is the XRPD pattern of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) benzenesulfonate.

[0042] Figure 8 Shown is the DSC thermogram of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) benzenesulfonate.

[0043] Fig. 9 Shown is the TGA thermogram of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) benzenesulfonate.

[0044] Fig.10Shown is the XRPD pattern of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) methanesulfonate.

[0045] Fig.11 Shown is the DSC thermogram of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) methanesulfonate.

[0046] Fig.12 Shown is the TGA thermogram of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) methanesulfonate.

[0047] Fig.13 Shown is the XRPD pattern of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) tosylate salt.

[0048] Fig.14 Shown is the DSC thermogram of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) tosylate salt.

[0049] Fig.15 Shown is the TGA thermogram of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) tosylate salt.

[0050] Fig.16 Shown is the XRPD pattern of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) monohydrochloride.

[0051] Fig.17Shown is the DSC thermogram of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) monohydrochloride.

[0052] Fig.18 Shown is the TGA thermogram of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) monohydrochloride.

[0053] Fig.19 Shown is the XRPD pattern of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) dihydrochloride.

[0054] Fig. 20 Shown is the DSC thermogram of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) dihydrochloride.

[0055] Fig.21 Shown is the TGA thermogram of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) dihydrochloride.

[0056] Fig. 22 Shown is the XRPD pattern of Form II of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) free base.

[0057] Fig.23 Shown is a DSC thermogram of Form II of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) free base.

[0058] Fig.24Shown is a TGA thermogram of Form II of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) free base.

[0059] Fig.25 Shown is the XRPD pattern of Form III of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) free base.

[0060] Fig.26 Shown is a DSC thermogram of Form III of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) free base.

[0061] Fig. 27 Shown is a TGA thermogram of Form III of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) free base.

[0062] Fig.28 Shown is the XRPD pattern of Form I of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) free base.

[0063] Fig.29 Shown is a DSC thermogram of Form I of crystalline 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I)) free base. DETAILED DESCRIPTION

[0064] Solid forms and salts

[0065] The present application provides, inter alia, a solid form of a compound of formula (I):

[0066]

[0067] It is Form I. Form I is the free base of the compound of formula (I). In some embodiments, the solid form is non-solvated. In some embodiments, the solid form is crystalline.

[0068] In some embodiments, the solid form has at least one XRPD peak, expressed as 2-theta (± 0.2°), selected from 7.3, 10.5, 12.8, 14.5, 15.2, 16.4, 20.3, 21.3, 21.6, and 27.0.

[0069] In some embodiments, the solid form has at least two XRPD peaks, expressed as 2-theta (± 0.2°), selected from 7.3, 10.5, 12.8, 14.5, 15.2, 16.4, 20.3, 21.3, 21.6, and 27.0.

[0070] In some embodiments, the solid form has at least three XRPD peaks, expressed as 2-theta (± 0.2°), selected from 7.3, 10.5, 12.8, 14.5, 15.2, 16.4, 20.3, 21.3, 21.6, and 27.0.

[0071] In some embodiments, the solid form has at least four XRPD peaks, expressed as 2-theta (± 0.2°), selected from 7.3, 10.5, 12.8, 14.5, 15.2, 16.4, 20.3, 21.3, 21.6, and 27.0.

[0072] In some embodiments, the solid form has at least five XRPD peaks, expressed as 2-theta (± 0.2°), selected from 7.3, 10.5, 12.8, 14.5, 15.2, 16.4, 20.3, 21.3, 21.6, and 27.0.

[0073] In some embodiments, the solid form has at least ten XRPD peaks, expressed as 2-theta (± 0.2°), selected from 7.3, 10.5, 12.8, 14.5, 15.2, 16.4, 20.3, 21.3, 21.6, and 27.0.

[0074] In some embodiments, the solid form has at least one XRPD peak, expressed as 2-theta (± 0.2°), selected from 7.5, 13.0, 14.7, 15.3, 16.2, 16.6, 20.5, 20.8, 21.4, 23.3, 24.0, and 27.1.

[0075] In some embodiments, the solid form has at least two XRPD peaks, expressed as 2-theta (± 0.2°), selected from 7.5, 13.0, 14.7, 15.3, 16.2, 16.6, 20.5, 20.8, 21.4, 23.3, 24.0, and 27.1.

[0076] In some embodiments, the solid form has at least three XRPD peaks, expressed as 2-theta (± 0.2°), selected from 7.5, 13.0, 14.7, 15.3, 16.2, 16.6, 20.5, 20.8, 21.4, 23.3, 24.0, and 27.1.

[0077] In some embodiments, the solid form has at least four XRPD peaks, expressed as 2-theta (± 0.2°), selected from 7.5, 13.0, 14.7, 15.3, 16.2, 16.6, 20.5, 20.8, 21.4, 23.3, 24.0, and 27.1.

[0078] In some embodiments, the solid form has at least five XRPD peaks, expressed as 2-theta (± 0.2°), selected from 7.5, 13.0, 14.7, 15.3, 16.2, 16.6, 20.5, 20.8, 21.4, 23.3, 24.0, and 27.1.

[0079] In some embodiments, the solid form has at least ten XRPD peaks, expressed as 2-theta (± 0.2°), selected from 7.5, 13.0, 14.7, 15.3, 16.2, 16.6, 20.5, 20.8, 21.4, 23.3, 24.0, and 27.1.

[0080] In some embodiments, the solid form has substantially Figure 1 XRPD pattern shown in .

[0081] In some embodiments, the solid form has substantially Fig.28 XRPD pattern shown in .

[0082] In some embodiments, the solid form has an endothermic peak with an onset temperature (±3°C) of 191.7°C and a maximum value of 193.6°C.

[0083] In some embodiments, the solid form has an endothermic peak with an onset temperature (±3°C) of 191.3°C and a maximum value of 193.3°C.

[0084] In some embodiments, the solid form has substantially Figure 2 DSC thermogram shown in .

[0085] In some embodiments, the solid form has substantially Fig.29 DSC thermogram shown in .

[0086] In some embodiments, the solid form has substantially Figure 3 TGA thermogram shown in .

[0087] The application also provides a solid form of a compound of formula (I), which is form II. Form II is the free base of the compound of formula (I). In some embodiments, the solid form is non-solvated. In some embodiments, the solid form is crystalline.

[0088] In some embodiments, the solid form has at least one XRPD peak, expressed as 2-theta (± 0.2°), selected from 5.8, 7.6, 11.4, 12.5, 14.4, 17.2, 17.9, and 25.3.

[0089] In some embodiments, the solid form has at least two XRPD peaks, expressed as 2-theta (± 0.2°), selected from 5.8, 7.6, 11.4, 12.5, 14.4, 17.2, 17.9, and 25.3.

[0090] In some embodiments, the solid form has at least three XRPD peaks, expressed as 2-theta (± 0.2°), selected from 5.8, 7.6, 11.4, 12.5, 14.4, 17.2, 17.9, and 25.3.

[0091] In some embodiments, the solid form has at least four XRPD peaks, expressed as 2-theta (± 0.2°), selected from 5.8, 7.6, 11.4, 12.5, 14.4, 17.2, 17.9, and 25.3.

[0092] In some embodiments, the solid form has at least five XRPD peaks, expressed as 2-theta (± 0.2°), selected from 5.8, 7.6, 11.4, 12.5, 14.4, 17.2, 17.9, and 25.3.

[0093] In some embodiments, the solid form has at least ten XRPD peaks, expressed as 2-theta (± 0.2°), selected from 5.8, 7.6, 11.4, 12.5, 14.4, 17.2, 17.9, and 25.3.

[0094] In some embodiments, the solid form has substantially Fig. 22 XRPD pattern shown in .

[0095] In some embodiments, the solid form has an endothermic peak with an onset temperature (±3°C) of 191.0°C and a maximum value of 193.4°C.

[0096] In some embodiments, the solid form has substantially Fig.23 DSC thermogram shown in .

[0097] In some embodiments, the solid form has substantially Fig.24 TGA thermogram shown in .

[0098] The application also provides a solid form of a compound of formula (I), which is form III. Form III is the free base of the compound of formula (I). In some embodiments, the solid form is solvated. In some embodiments, the solid form is a 1,4-dioxane solvate. In some embodiments, the stoichiometric ratio of the compound of formula (I) to 1,4-dioxane in the 1,4-dioxane solvate of the compound of formula (I) is 4:1. In some embodiments, the solid form is crystalline.

[0099] In some embodiments, the solid form has at least one XRPD peak, expressed as 2-theta (± 0.2°), selected from 5.5, 9.8, 10.5, 12.1, 13.9, 16.3, 19.8, 22.0, 24.4, and 27.3.

[0100] In some embodiments, the solid form has at least two XRPD peaks, expressed as 2-theta (± 0.2°), selected from 5.5, 9.8, 10.5, 12.1, 13.9, 16.3, 19.8, 22.0, 24.4, and 27.3.

[0101] In some embodiments, the solid form has at least three XRPD peaks, expressed as 2-theta (± 0.2°), selected from 5.5, 9.8, 10.5, 12.1, 13.9, 16.3, 19.8, 22.0, 24.4, and 27.3.

[0102] In some embodiments, the solid form has at least four XRPD peaks, expressed as 2-theta (± 0.2°), selected from 5.5, 9.8, 10.5, 12.1, 13.9, 16.3, 19.8, 22.0, 24.4, and 27.3.

[0103] In some embodiments, the solid form has at least five XRPD peaks, expressed as 2-theta (± 0.2°), selected from 5.5, 9.8, 10.5, 12.1, 13.9, 16.3, 19.8, 22.0, 24.4, and 27.3.

[0104] In some embodiments, the solid form has at least ten XRPD peaks, expressed as 2-theta (± 0.2°), selected from 5.5, 9.8, 10.5, 12.1, 13.9, 16.3, 19.8, 22.0, 24.4, and 27.3.

[0105] In some embodiments, the solid form has substantially Fig.25 XRPD pattern shown in .

[0106] In some embodiments, the solid form has an endothermic peak with an onset temperature (±3°C) of 192.6°C and a maximum value of 194.3°C.

[0107] In some embodiments, the solid form has substantially Fig.26 DSC thermogram shown in .

[0108] In some embodiments, the solid form has substantially Fig. 27 TGA thermogram shown in .

[0109] The present application also provides salts of compounds of formula (I):

[0110]

[0111] It is selected from the group consisting of monomaleate of the compound of formula (I); dibenzenesulfonate of the compound of formula (I); monomethanesulfonate of the compound of formula (I); xylenesulfonate of the compound of formula (I); monohydrochloride of the compound of formula (I); and dihydrochloride of the compound of formula (I).

[0112] In some embodiments, the salt is a monomaleate salt of the compound of formula (I). In some embodiments, the monomaleate salt is crystalline.

[0113] In some embodiments, the monomaleate salt has at least one XRPD peak, expressed as 2-theta (±0.2°), selected from 10.4, 11.6, 12.0, 14.1, 15.1, 17.2, 18.1, 19.1, 21.3, 21.9, 22.9, 24.2, and 25.9.

[0114] In some embodiments, the monomaleate salt has at least two XRPD peaks, expressed as 2-theta (±0.2°), selected from 10.4, 11.6, 12.0, 14.1, 15.1, 17.2, 18.1, 19.1, 21.3, 21.9, 22.9, 24.2, and 25.9.

[0115] In some embodiments, the monomaleate salt has at least three XRPD peaks, expressed as 2-theta (±0.2°), selected from 10.4, 11.6, 12.0, 14.1, 15.1, 17.2, 18.1, 19.1, 21.3, 21.9, 22.9, 24.2, and 25.9.

[0116] In some embodiments, the monomaleate salt has at least four XRPD peaks, expressed as 2-theta (±0.2°), selected from 10.4, 11.6, 12.0, 14.1, 15.1, 17.2, 18.1, 19.1, 21.3, 21.9, 22.9, 24.2, and 25.9.

[0117] In some embodiments, the monomaleate salt has at least five XRPD peaks, expressed as 2-theta (±0.2°), selected from 10.4, 11.6, 12.0, 14.1, 15.1, 17.2, 18.1, 19.1, 21.3, 21.9, 22.9, 24.2, and 25.9.

[0118] In some embodiments, the monomaleate salt has at least ten XRPD peaks, expressed as 2-theta (±0.2°), selected from 10.4, 11.6, 12.0, 14.1, 15.1, 17.2, 18.1, 19.1, 21.3, 21.9, 22.9, 24.2, and 25.9.

[0119] In some embodiments, the monomaleate salt has substantially Figure 4 XRPD pattern shown in .

[0120] In some embodiments, the monomaleate salt has an endothermic peak with an onset temperature (±3°C) of 180.4°C and a maximum temperature (±3°C) of 181.8°C.

[0121] In some embodiments, the monomaleate salt has substantially Figure 5 DSC thermogram shown in .

[0122] In some embodiments, the monomaleate salt has substantially Figure 6 TGA thermogram shown in .

[0123] In some embodiments, the salt is a dibenzenesulfonate salt of a compound of formula (I). In some embodiments, the dibenzenesulfonate salt is crystalline.

[0124] In some embodiments, the dibenzenesulfonate salt has at least one XRPD peak, expressed as 2-theta (±0.2°), selected from 6.3, 9.9, 12.1, 12.6, 15.9, 17.4, 18.7, 19.0, 19.6, and 25.1.

[0125] In some embodiments, the dibenzenesulfonate salt has at least two XRPD peaks, expressed as 2-theta (±0.2°), selected from 6.3, 9.9, 12.1, 12.6, 15.9, 17.4, 18.7, 19.0, 19.6, and 25.1.

[0126] In some embodiments, the dibenzenesulfonate salt has at least three XRPD peaks, expressed as 2-theta (±0.2°), selected from 6.3, 9.9, 12.1, 12.6, 15.9, 17.4, 18.7, 19.0, 19.6, and 25.1.

[0127] In some embodiments, the dibenzenesulfonate salt has at least four XRPD peaks, expressed as 2-theta (±0.2°), selected from 6.3, 9.9, 12.1, 12.6, 15.9, 17.4, 18.7, 19.0, 19.6, and 25.1.

[0128] In some embodiments, the dibenzenesulfonate salt has at least five XRPD peaks, expressed as 2-theta (±0.2°), selected from 6.3, 9.9, 12.1, 12.6, 15.9, 17.4, 18.7, 19.0, 19.6, and 25.1.

[0129] In some embodiments, the dibenzenesulfonate salt has at least ten XRPD peaks, expressed as 2-theta (±0.2°), selected from 6.3, 9.9, 12.1, 12.6, 15.9, 17.4, 18.7, 19.0, 19.6, and 25.1.

[0130] In some embodiments, the dibenzenesulfonate salt has substantially Figure 7 XRPD pattern shown in .

[0131] In some embodiments, the dibenzenesulfonate salt has an endothermic peak with an onset temperature (±3°C) of 160.4°C and a maximum temperature (±3°C) of 163.4°C.

[0132] In some embodiments, the dibenzenesulfonate salt has substantially Figure 8 DSC thermogram shown in .

[0133] In some embodiments, the dibenzenesulfonate salt has substantially Fig. 9 TGA thermogram shown in .

[0134] In some embodiments, the salt is a mono-methanesulfonate salt of a compound of formula (I). In some embodiments, the mono-methanesulfonate salt is crystalline.

[0135] In some embodiments, the mono-mesylate salt has at least one XRPD peak, expressed as 2-theta (±0.2°), selected from 4.8, 7.0, 11.9, 14.1, 14.9, 17.7, 18.9, 20.2, 22.1, and 26.1.

[0136] In some embodiments, the mono-mesylate salt has at least two XRPD peaks, expressed as 2-theta (±0.2°), selected from 4.8, 7.0, 11.9, 14.1, 14.9, 17.7, 18.9, 20.2, 22.1, and 26.1.

[0137] In some embodiments, the mono-mesylate salt has at least three XRPD peaks, expressed as 2-theta (±0.2°), selected from 4.8, 7.0, 11.9, 14.1, 14.9, 17.7, 18.9, 20.2, 22.1, and 26.1.

[0138] In some embodiments, the mono-mesylate salt has at least four XRPD peaks, expressed as 2-theta (±0.2°), selected from 4.8, 7.0, 11.9, 14.1, 14.9, 17.7, 18.9, 20.2, 22.1, and 26.1.

[0139] In some embodiments, the mono-mesylate salt has at least five XRPD peaks, expressed as 2-theta (±0.2°), selected from 4.8, 7.0, 11.9, 14.1, 14.9, 17.7, 18.9, 20.2, 22.1, and 26.1.

[0140] In some embodiments, the mono-mesylate salt has at least ten XRPD peaks, expressed as 2-theta (±0.2°), selected from 4.8, 7.0, 11.9, 14.1, 14.9, 17.7, 18.9, 20.2, 22.1, and 26.1.

[0141] In some embodiments, the mono-mesylate salt has substantially Fig.10 XRPD pattern shown in .

[0142] In some embodiments, the monomethanesulfonate salt has a first endothermic peak with a maximum temperature (±3°C) of 61.1°C and a second endothermic peak with an onset temperature (±3°C) of 134.4°C and a maximum temperature (±3°C) of 150.1°C.

[0143] In some embodiments, the mono-mesylate salt has substantially Fig.11 DSC thermogram shown in .

[0144] In some embodiments, the mono-mesylate salt has substantially Fig.12 TGA thermogram shown in .

[0145] In some embodiments, the salt is a xylenesulfonate salt of a compound of formula (I). In some embodiments, the xylenesulfonate salt is crystalline.

[0146] In some embodiments, the xylenesulfonate salt has at least one XRPD peak, expressed as 2-theta (± 0.2°), selected from the group consisting of 5.7, 7.8, 8.1, 9.3, 13.7, 13.9, 16.2, 18.8, and 20.6.

[0147] In some embodiments, the xylenesulfonate salt has at least two XRPD peaks, expressed as 2-theta (± 0.2°), selected from 5.7, 7.8, 8.1, 9.3, 13.7, 13.9, 16.2, 18.8, and 20.6.

[0148] In some embodiments, the xylenesulfonate salt has at least three XRPD peaks, expressed as 2-theta (±0.2°), selected from 65.7, 7.8, 8.1, 9.3, 13.7, 13.9, 16.2, 18.8, and 20.6.

[0149] In some embodiments, the xylenesulfonate salt has at least four XRPD peaks, expressed as 2-theta (±0.2°), selected from 5.7, 7.8, 8.1, 9.3, 13.7, 13.9, 16.2, 18.8, and 20.6.

[0150] In some embodiments, the xylenesulfonate salt has at least five XRPD peaks, expressed as 2-theta (±0.2°), selected from 5.7, 7.8, 8.1, 9.3, 13.7, 13.9, 16.2, 18.8, and 20.6.

[0151] In some embodiments, the xylenesulfonate salt has at least eight XRPD peaks, expressed as 2-theta (± 0.2°), selected from 5.7, 7.8, 8.1, 9.3, 13.7, 13.9, 16.2, 18.8, and 20.6.

[0152] In some embodiments, the xylene sulfonate salt has substantially Fig.13 XRPD pattern shown in .

[0153] In some embodiments, the xylene sulfonate salt has an exothermic peak with an onset temperature (±3°C) of 99.6°C and a maximum temperature (±3°C) of 110.5°C, and an endothermic peak with an onset temperature (±3°C) of 216.1°C and a maximum temperature (±3°C) of 218.7°C.

[0154] In some embodiments, the xylene sulfonate salt has substantially Fig.14 DSC thermogram shown in .

[0155] In some embodiments, the xylene sulfonate salt has substantially Fig.15 TGA thermogram shown in .

[0156] In some embodiments, the salt is a monohydrochloride salt of a compound of formula (I). In some embodiments, the monohydrochloride salt is crystalline.

[0157] In some embodiments, the mono-hydrochloride salt has at least one XRPD peak, expressed as 2-theta (± 0.2°), selected from 5.7, 8.5, 11.3, 14.1, 15.0, 18.4, 19.3, 20.5, 21.8, 22.8, and 25.7.

[0158] In some embodiments, the mono-hydrochloride salt has at least two XRPD peaks, expressed as 2-theta (± 0.2°), selected from 5.7, 8.5, 11.3, 14.1, 15.0, 18.4, 19.3, 20.5, 21.8, 22.8, and 25.7.

[0159] In some embodiments, the mono-hydrochloride salt has at least three XRPD peaks, expressed as 2-theta (±0.2°), selected from 5.7, 8.5, 11.3, 14.1, 15.0, 18.4, 19.3, 20.5, 21.8, 22.8, and 25.7.

[0160] In some embodiments, the mono-hydrochloride salt has at least four XRPD peaks, expressed as 2-theta (±0.2°), selected from 5.7, 8.5, 11.3, 14.1, 15.0, 18.4, 19.3, 20.5, 21.8, 22.8, and 25.7.

[0161] In some embodiments, the mono-hydrochloride salt has at least five XRPD peaks, expressed as 2-theta (±0.2°), selected from 5.7, 8.5, 11.3, 14.1, 15.0, 18.4, 19.3, 20.5, 21.8, 22.8, and 25.7.

[0162] In some embodiments, the mono-hydrochloride salt has at least ten XRPD peaks, expressed as 2-theta (± 0.2°), selected from 5.7, 8.5, 11.3, 14.1, 15.0, 18.4, 19.3, 20.5, 21.8, 22.8, and 25.7.

[0163] In some embodiments, the monohydrochloride salt has substantially Fig.16 XRPD pattern shown in .

[0164] In some embodiments, the monohydrochloride salt has an endothermic peak with an onset temperature (±3°C) of 196.0°C and a maximum temperature (±3°C) of 212.2°C.

[0165] In some embodiments, the monohydrochloride salt has substantially Fig.17 DSC thermogram shown in .

[0166] In some embodiments, the monohydrochloride salt has substantially Fig.18 TGA thermogram shown in .

[0167] In some embodiments, the salt is the dihydrochloride salt of the compound of formula (I). In some embodiments, the dihydrochloride salt is crystalline.

[0168] In some embodiments, the dihydrochloride salt has at least one XRPD peak, expressed as 2-theta (± 0.2°), selected from 9.9, 10.7, 12.3, 13.0, 14.0, 15.2, 19.9, 21.8, 22.3, and 24.8.

[0169] In some embodiments, the dihydrochloride salt has at least two XRPD peaks, expressed as 2-theta (±0.2°), selected from 9.9, 10.7, 12.3, 13.0, 14.0, 15.2, 19.9, 21.8, 22.3, and 24.8.

[0170] In some embodiments, the dihydrochloride salt has at least three XRPD peaks, expressed as 2-theta (±0.2°), selected from 9.9, 10.7, 12.3, 13.0, 14.0, 15.2, 19.9, 21.8, 22.3, and 24.8.

[0171] In some embodiments, the dihydrochloride salt has at least four XRPD peaks, expressed as 2-theta (±0.2°), selected from 9.9, 10.7, 12.3, 13.0, 14.0, 15.2, 19.9, 21.8, 22.3, and 24.8.

[0172] In some embodiments, the dihydrochloride salt has at least five XRPD peaks, expressed as 2-theta (± 0.2°), selected from 9.9, 10.7, 12.3, 13.0, 14.0, 15.2, 19.9, 21.8, 22.3, and 24.8.

[0173] In some embodiments, the dihydrochloride salt has at least ten XRPD peaks, expressed as 2-theta (± 0.2°), selected from 9.9, 10.7, 12.3, 13.0, 14.0, 15.2, 19.9, 21.8, 22.3, and 24.8.

[0174] In some embodiments, the dihydrochloride salt has substantially Fig.19 XRPD pattern shown in .

[0175] In some embodiments, the dihydrochloride salt has an endothermic peak with an onset temperature (±3°C) of 182.1°C and a maximum temperature (±3°C) of 206.4°C.

[0176] In some embodiments, the dihydrochloride salt has substantially Fig. 20 DSC thermogram shown in .

[0177] In some embodiments, the dihydrochloride salt has substantially Fig.21 TGA thermogram shown in .

[0178] Different forms of the same substance have different bulk properties related to, for example, hygroscopicity, solubility, stability, etc. Forms with high melting points generally have good thermodynamic stability, which is beneficial for extending the shelf life of drug formulations containing solid forms. Forms with lower melting points are generally less thermodynamically stable, but are advantageous in that they have increased water solubility, which translates into increased drug bioavailability. Less hygroscopic forms are desirable for their stability to heat and humidity and resistance to degradation during long-term storage.

[0179] In some embodiments, the solid form or salt of the compound of formula (I) provided herein is crystalline. As used herein, "crystallization" means a certain lattice configuration of a crystalline material. Different crystalline forms of the same material generally have different lattices (e.g., unit cells), which are attributed to different physical properties unique to each crystalline form. In some cases, different lattice configurations have different water contents or solvent contents.

[0180] As used herein, "slurrying" means forming a mixture of insoluble material in a liquid.

[0181] Solid forms and salt forms can be identified by solid state characterization methods, for example, by X-ray powder diffraction (XRPD). Other characterization methods such as differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), dynamic vapor sorption (DVS), solid state NMR, etc. further help identify the form and help determine stability and solvent / water content.

[0182] The XRPD spectrum of reflection (peak) is generally regarded as the fingerprint of a specific solid form. It is well known that the relative intensity of XRPD peaks can vary greatly, which depends in particular on the sample preparation technique, crystal size distribution, various filters used, sample installation procedures and the specific instrument used. In some cases, depending on the type or setting of the instrument, new peaks may be observed or existing peaks may disappear. As used herein, the term "peak" refers to a reflection with a relative height / intensity of at least about 4% of the maximum peak height / intensity. In addition, instrument changes and other factors can affect 2-θ values. Therefore, peak assignments (such as those reported herein) can vary ± about 0.2 ° (2-θ)), and the terms "substantially" and "about" as used herein in the context of XRPD are intended to cover the above-mentioned changes.

[0183] Likewise, temperature readings associated with DSC, TGA or other thermal experiments can vary by about ±3°C depending on the instrument, specific setup, sample preparation, etc. Therefore, solid forms or salts reported herein as having a DSC thermogram "substantially" as shown in any of the Figures, or the term "about", should be understood to encompass this variation.

[0184] In some embodiments, the solid form or salt described herein are substantially separated. "Substantially separated" means that the solid form or salt are at least partially or substantially separated from the environment in which the solid form or salt is formed or detected. Partial separation can include, for example, a composition rich in the solid form or salt described herein. Substantially separation can include a composition containing at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, at least about 90% by weight, at least about 95% by weight, at least about 97% by weight or at least about 99% by weight of the solid form or salt described herein.

[0185] Preparation method

[0186] The present application also provides a method for preparing a solid form (Form I), the method comprising cooling a solution of a compound of formula (I) in a solvent component comprising ethanol and water.

[0187] In some embodiments, the solvent component comprises about 5% to about 20% water and about 80% to about 95% ethanol. In some embodiments, the solvent component comprises about 5% to about 10% water and about 90% to about 95% ethanol. In some embodiments, the solvent component comprises about 6% water and about 94% ethanol. In some embodiments, the solvent component comprises about 10% water and about 90% ethanol.

[0188] In some embodiments, the solution is cooled to a temperature of 0°C ± 3°C.

[0189] In some embodiments, the solution is prepared by heating a slurry of the compound of formula (I) in the solvent component prior to said cooling.

[0190] The application also provides a method for preparing a solid form (Form II), the method comprising evaporating a solution of a compound of formula (I) in a solvent selected from CH2Cl2, CH3CN, EtOH and IPA at 25°C. In some embodiments, the solvent is CH2Cl2. In some embodiments, the solvent is CH3CN. In some embodiments, the solvent is EtOH. In some embodiments, the solvent is IPA.

[0191] The present application also provides a method for preparing a solid form (Form III), the method comprising evaporating a solution of a compound of formula (I) in 1,4-dioxane at 25°C.

[0192] Also provided is a method for preparing Form III, comprising preparing a saturated or nearly saturated solution of a compound of formula (I) in 1,4-dioxane at 25°C; quenching the solution to a temperature of about -20°C to about -30°C; and precipitating a solid form (Form III).

[0193] The present application also provides a method for preparing a salt form of the compound of formula (I), wherein the salt form is selected from monomaleate, dibenzenesulfonate, monomethanesulfonate, ditoluenesulfonate, monohydrochloride and dihydrochloride.

[0194] A method for preparing a monomaleate of a compound of formula (I) is provided in the present application, the method comprising reacting the compound of formula (I) with maleic acid. In some embodiments, relative to 1 equivalent of the compound of formula (I), about 1 equivalent to about 2 equivalents of maleic acid are used. In some embodiments, relative to 1 equivalent of the compound of formula (I), about 1 equivalent to about 1.5 equivalents of maleic acid are used. In some embodiments, relative to 1 equivalent of the compound of formula (I), about 1 equivalent to about 1.2 equivalents of maleic acid are used. In some embodiments, the reaction of the compound of formula (I) with maleic acid is carried out in a solvent component. In some embodiments, the solvent component comprises alcohol and halogenated alkane. In some embodiments, the solvent component comprises about 30% by weight to about 70% by weight of halogenated alkane and about 30% by weight to about 70% by weight of alcohol. In some embodiments, the solvent component comprises about 40% by weight to about 60% by weight of halogenated alkane and about 40% by weight to about 60% by weight of alcohol. In some embodiments, the solvent component comprises about 45% by weight to about 55% by weight of halogenated alkanes and about 45% by weight to about 55% by weight of alcohol. In some embodiments, the halogenated alkanes are chlorinated alkanes. In some embodiments, the solvent component comprises dichloromethane and methanol. In some embodiments, the solvent component comprises about 30% by weight to about 70% by weight of dichloromethane and about 30% by weight to about 70% by weight of methanol. In some embodiments, the solvent component comprises about 40% by weight to about 50% by weight of dichloromethane and about 40% by weight to about 50% by weight of methanol. In some embodiments, the solvent component comprises about 45% by weight to about 55% by weight of dichloromethane and about 45% by weight to about 55% by weight of methanol. In some embodiments, the solvent component comprises 1:1 dichloromethane: methanol.

[0195] In some embodiments, after said reacting of the compound of formula (I) with maleic acid, said method further comprises removing the solvent component and then slurrying the product of said reaction in acetone.

[0196] In some embodiments, the method for preparing the monomaleate of the compound of formula (I) comprises reacting the compound of formula (I) with maleic acid in a solvent component comprising dichloromethane and methanol, and then evaporating the solvent component. In some embodiments, the solvent component comprises 1:1 dichloromethane:methanol. In some embodiments, the compound of formula (I) is dissolved in the solvent component before adding maleic acid. In some embodiments, the solvent component is evaporated from the solution at room temperature. In some embodiments, the solution is evaporated to dryness. In some embodiments, evaporating the solvent component produces a solid. In some embodiments, acetone is added to the resulting solid, followed by filtering.

[0197] A method for preparing a dibenzenesulfonate of a compound of formula (I) is provided in the present application, the method comprising reacting the compound of formula (I) with benzenesulfonic acid. In some embodiments, relative to 1 equivalent of the compound of formula (I), benzenesulfonic acid of about 1 equivalent to about 2 equivalents is used. In some embodiments, relative to 1 equivalent of the compound of formula (I), benzenesulfonic acid of about 1 equivalent to about 1.5 equivalents is used. In some embodiments, relative to 1 equivalent of the compound of formula (I), benzenesulfonic acid of about 1 equivalent to about 1.2 equivalents is used. In some embodiments, the reaction of the compound of formula (I) with benzenesulfonic acid is carried out in a solvent component. In some embodiments, the solvent component comprises alcohol and halogenated alkane. In some embodiments, the solvent component comprises about 30% by weight to about 70% by weight of halogenated alkane and about 30% by weight to about 70% by weight of alcohol. In some embodiments, the solvent component comprises about 40% by weight to about 60% by weight of halogenated alkane and about 40% by weight to about 60% by weight of alcohol. In some embodiments, the solvent component comprises about 45% by weight to about 55% by weight of halogenated alkanes and about 45% by weight to about 55% by weight of alcohol. In some embodiments, the halogenated alkanes are chlorinated alkanes. In some embodiments, the solvent component comprises dichloromethane and methanol. In some embodiments, the solvent component comprises about 30% by weight to about 70% by weight of dichloromethane and about 30% by weight to about 70% by weight of methanol. In some embodiments, the solvent component comprises about 40% by weight to about 50% by weight of dichloromethane and about 40% by weight to about 50% by weight of methanol. In some embodiments, the solvent component comprises about 45% by weight to about 55% by weight of dichloromethane and about 45% by weight to about 55% by weight of methanol. In some embodiments, the solvent component comprises 1:1 dichloromethane: methanol.

[0198] In some embodiments, after said reacting of the compound of formula (I) with benzenesulfonic acid, said method further comprises removing a solvent component, and then slurrying the product of said reaction in acetonitrile.

[0199] In some embodiments, after the reaction of the compound of formula (I) with benzenesulfonic acid, the method further comprises removing the solvent component, and then slurrying the product of the reaction in acetone.

[0200] In some embodiments, the method for preparing the dibenzenesulfonate of the compound of formula (I) comprises reacting the compound of formula (I) with benzenesulfonic acid in a solvent component comprising dichloromethane and methanol, and then evaporating the solvent component. In some embodiments, the solvent component comprises 1:1 dichloromethane:methanol. In some embodiments, the compound of formula (I) is dissolved in the solvent component before adding benzenesulfonic acid. In some embodiments, the solvent component is evaporated from the solution at room temperature. In some embodiments, the solution is evaporated into a first oily substance. In some embodiments, acetonitrile is added to the first oily substance, and the solution is evaporated into a second oily substance. In some embodiments, acetonitrile is evaporated from the solution at room temperature. In some embodiments, acetone is added to the second oily substance to form a solution, and the solution is slurried into a solid. In some embodiments, the solution is slurried at room temperature. In some embodiments, the solid is filtered.

[0201] A method for preparing a monomethanesulfonate of a compound of formula (I) is provided in the present application, the method comprising reacting the compound of formula (I) with methanesulfonic acid. In some embodiments, relative to 1 equivalent of the compound of formula (I), methanesulfonic acid of about 1 equivalent to about 2 equivalents is used. In some embodiments, relative to 1 equivalent of the compound of formula (I), methanesulfonic acid of about 1 equivalent to about 1.5 equivalents is used. In some embodiments, relative to 1 equivalent of the compound of formula (I), methanesulfonic acid of about 1 equivalent to about 1.2 equivalents is used. In some embodiments, the reaction of the compound of formula (I) with methanesulfonic acid is carried out in a solvent component. In some embodiments, the solvent component comprises alcohol and halogenated alkane. In some embodiments, the solvent component comprises about 30% by weight to about 70% by weight of halogenated alkane and about 30% by weight to about 70% by weight of alcohol. In some embodiments, the solvent component comprises about 40% by weight to about 60% by weight of halogenated alkane and about 40% by weight to about 60% by weight of alcohol. In some embodiments, the solvent component comprises about 45% by weight to about 55% by weight of halogenated alkanes and about 45% by weight to about 55% by weight of alcohol. In some embodiments, the halogenated alkanes are chlorinated alkanes. In some embodiments, the solvent component comprises dichloromethane and methanol. In some embodiments, the solvent component comprises about 30% by weight to about 70% by weight of dichloromethane and about 30% by weight to about 70% by weight of methanol. In some embodiments, the solvent component comprises about 40% by weight to about 50% by weight of dichloromethane and about 40% by weight to about 50% by weight of methanol. In some embodiments, the solvent component comprises about 45% by weight to about 55% by weight of dichloromethane and about 45% by weight to about 55% by weight of methanol. In some embodiments, the solvent component comprises 1:1 dichloromethane: methanol.

[0202] In some embodiments, after said reacting of the compound of formula (I) with methanesulfonic acid, the method further comprises removing the solvent component and then slurrying the product of said reaction in acetone.

[0203] In some embodiments, the method for preparing the monomethanesulfonate of the compound of formula (I) comprises reacting the compound of formula (I) with methanesulfonic acid in a solvent component comprising dichloromethane and methanol, and then evaporating the solvent component. In some embodiments, the solvent component comprises 1:1 dichloromethane:methanol. In some embodiments, the compound of formula (I) is dissolved in the solvent component before adding methanesulfonic acid. In some embodiments, the solvent component is evaporated from the solution at room temperature. In some embodiments, the solution is evaporated into an oily substance. In some embodiments, acetone is added to the oily substance to form a solution, and the solution is slurried into a solid. In some embodiments, the solution is slurried at room temperature. In some embodiments, the solid is filtered.

[0204] The present application provides a method for preparing a xylene sulfonate salt of a compound of formula (I), the method comprising reacting the compound of formula (I) with p-toluenesulfonic acid. In some embodiments, the p-toluenesulfonic acid is a monohydrate. In some embodiments, relative to 1 equivalent of the compound of formula (I), about 1 equivalent to about 2 equivalents of p-toluenesulfonic acid are used. In some embodiments, relative to 1 equivalent of the compound of formula (I), about 1 equivalent to about 1.5 equivalents of p-toluenesulfonic acid are used. In some embodiments, relative to 1 equivalent of the compound of formula (I), about 1 equivalent to about 1.2 equivalents of p-toluenesulfonic acid are used. In some embodiments, the reaction of the compound of formula (I) with p-toluenesulfonic acid is carried out in a solvent component. In some embodiments, the solvent component comprises an alcohol and a halogenated alkane. In some embodiments, the solvent component comprises about 30% by weight to about 70% by weight of a halogenated alkane and about 30% by weight to about 70% by weight of an alcohol. In some embodiments, the solvent component comprises about 40% by weight to about 60% by weight of a halogenated alkane and about 40% by weight to about 60% by weight of an alcohol. In some embodiments, the solvent component comprises about 45% by weight to about 55% by weight of halogenated alkanes and about 45% by weight to about 55% by weight of alcohol. In some embodiments, the halogenated alkanes are chlorinated alkanes. In some embodiments, the solvent component comprises dichloromethane and methanol. In some embodiments, the solvent component comprises about 30% by weight to about 70% by weight of dichloromethane and about 30% by weight to about 70% by weight of methanol. In some embodiments, the solvent component comprises about 40% by weight to about 50% by weight of dichloromethane and about 40% by weight to about 50% by weight of methanol. In some embodiments, the solvent component comprises about 45% by weight to about 55% by weight of dichloromethane and about 45% by weight to about 55% by weight of methanol. In some embodiments, the solvent component comprises 1:1 dichloromethane: methanol.

[0205] In some embodiments, after the reaction of the compound of formula (I) with p-toluenesulfonic acid, the method further comprises removing the solvent component, and then slurrying the product of the reaction in acetonitrile.

[0206] In some embodiments, after the reaction of the compound of formula (I) with p-toluenesulfonic acid, the method further comprises removing the solvent component, and then slurrying the product of the reaction in acetone.

[0207] In some embodiments, the method for preparing the xylene sulfonate salt of the compound of formula (I) comprises reacting the compound of formula (I) with p-toluenesulfonic acid monohydrate in a solvent component comprising dichloromethane and methanol, and then evaporating the solvent component. In some embodiments, the solvent component comprises 1:1 dichloromethane:methanol. In some embodiments, the compound of formula (I) is dissolved in the solvent component before adding p-toluenesulfonic acid monohydrate. In some embodiments, the solvent component is evaporated from the solution at room temperature. In some embodiments, the solution is evaporated into an oil. In some embodiments, acetonitrile is added to the first oil, and the solution is evaporated into an oil / semi-solid. In some embodiments, acetonitrile is evaporated from the solution at room temperature. In some embodiments, acetone is added to the oil / semi-solid to form a solution, and the solution is slurried into a solid. In some embodiments, the solution is slurried at room temperature. In some embodiments, the solid is filtered.

[0208] A method for preparing a monohydrochloride salt of a compound of formula (I) is provided in the present application, the method comprising reacting the compound of formula (I) with hydrochloric acid. In some embodiments, relative to 1 equivalent of the compound of formula (I), about 1 equivalent to about 2 equivalents of hydrochloric acid are used. In some embodiments, relative to 1 equivalent of the compound of formula (I), about 1 equivalent to about 1.5 equivalents of hydrochloric acid are used. In some embodiments, relative to 1 equivalent of the compound of formula (I), about 1 equivalent to about 1.2 equivalents of hydrochloric acid are used. In some embodiments, the reaction of the compound of formula (I) with hydrochloric acid is carried out in a solvent component. In some embodiments, the solvent component comprises an alcohol and a halogenated alkane. In some embodiments, the solvent component comprises about 30% by weight to about 70% by weight of a halogenated alkane and about 30% by weight to about 70% by weight of an alcohol. In some embodiments, the solvent component comprises about 40% by weight to about 60% by weight of a halogenated alkane and about 40% by weight to about 60% by weight of an alcohol. In some embodiments, the solvent component comprises about 45% by weight to about 55% by weight of halogenated alkanes and about 45% by weight to about 55% by weight of alcohol. In some embodiments, the halogenated alkanes are chlorinated alkanes. In some embodiments, the solvent component comprises dichloromethane and methanol. In some embodiments, the solvent component comprises about 30% by weight to about 70% by weight of dichloromethane and about 30% by weight to about 70% by weight of methanol. In some embodiments, the solvent component comprises about 40% by weight to about 50% by weight of dichloromethane and about 40% by weight to about 50% by weight of methanol. In some embodiments, the solvent component comprises about 45% by weight to about 55% by weight of dichloromethane and about 45% by weight to about 55% by weight of methanol. In some embodiments, the solvent component comprises 1:1 dichloromethane: methanol.

[0209] In some embodiments, after the reaction of the compound of formula (I) with hydrochloric acid, the method further comprises removing the solvent component, and then slurrying the product of the reaction in acetone.

[0210] In some embodiments, the method for preparing the monohydrochloride salt of the compound of formula (I) comprises reacting the compound of formula (I) with about 1 to about 1.5 equivalents of hydrochloric acid in a solvent component comprising dichloromethane and methanol, and then evaporating the solvent component. In some embodiments, the solvent component comprises 1:1 dichloromethane:methanol. In some embodiments, the compound of formula (I) is dissolved in the solvent component before adding hydrochloric acid. In some embodiments, the hydrochloric acid is a 6M aqueous hydrochloric acid solution. In some embodiments, the solvent component is evaporated from the solution at room temperature. In some embodiments, the solution is evaporated to dryness. In some embodiments, evaporating the solvent component produces a solid.

[0211] A method for preparing a dihydrochloride salt of a compound of formula (I) is provided in the present application, the method comprising reacting the compound of formula (I) with hydrochloric acid. In some embodiments, relative to 1 equivalent of the compound of formula (I), about 2 equivalents to about 3 equivalents of hydrochloric acid are used. In some embodiments, relative to 1 equivalent of the compound of formula (I), about 2 equivalents to about 2.5 equivalents of hydrochloric acid are used. In some embodiments, relative to 1 equivalent of the compound of formula (I), about 2 equivalents to about 2.2 equivalents of hydrochloric acid are used. In some embodiments, the reaction of the compound of formula (I) with hydrochloric acid is carried out in a solvent component. In some embodiments, the solvent component comprises an alcohol and a halogenated alkane. In some embodiments, the solvent component comprises about 30% by weight to about 70% by weight of a halogenated alkane and about 30% by weight to about 70% by weight of an alcohol. In some embodiments, the solvent component comprises about 40% by weight to about 60% by weight of a halogenated alkane and about 40% by weight to about 60% by weight of an alcohol. In some embodiments, the solvent component comprises about 45% by weight to about 55% by weight of halogenated alkanes and about 45% by weight to about 55% by weight of alcohol. In some embodiments, the halogenated alkanes are chlorinated alkanes. In some embodiments, the solvent component comprises dichloromethane and methanol. In some embodiments, the solvent component comprises about 30% by weight to about 70% by weight of dichloromethane and about 30% by weight to about 70% by weight of methanol. In some embodiments, the solvent component comprises about 40% by weight to about 50% by weight of dichloromethane and about 40% by weight to about 50% by weight of methanol. In some embodiments, the solvent component comprises about 45% by weight to about 55% by weight of dichloromethane and about 45% by weight to about 55% by weight of methanol. In some embodiments, the solvent component comprises 1:1 dichloromethane: methanol.

[0212] In some embodiments, after the reaction of the compound of formula (I) with hydrochloric acid, the method further comprises removing the solvent component, and then slurrying the product of the reaction in acetone.

[0213] In some embodiments, the method for preparing the dihydrochloride salt of the compound of formula (I) comprises reacting the compound of formula (I) with hydrochloric acid in an amount of about equivalent to about 2.5 equivalents in a solvent component comprising dichloromethane and methanol, and then evaporating the solvent component. In some embodiments, the solvent component comprises 1:1 dichloromethane:methanol. In some embodiments, the compound of formula (I) is dissolved in the solvent component before adding hydrochloric acid. In some embodiments, the hydrochloric acid is a 6M aqueous hydrochloric acid solution. In some embodiments, the solvent component is evaporated from the solution at room temperature. In some embodiments, the solution is evaporated to dryness.

[0214] In some embodiments, acetone is added to the resulting solid, followed by filtration.

[0215] The present application also provides a method for preparing a compound of formula (I) or a solid form or salt thereof. Therefore, the present application provides a method for preparing: a compound of formula (I) or a pharmaceutically acceptable salt thereof; a solid form of a compound of formula (I) (which is form I, form II or form III); or any salt of a compound of formula (I) as described herein, the method comprising:

[0216] The compound of formula (1c):

[0217]

[0218] With the compound of formula (1b):

[0219]

[0220] or a salt thereof via a Buchwald coupling reaction to form a compound of formula (1a):

[0221]

[0222] Where X 1 It is a halogen group.

[0223] In some embodiments, X 1 For Br.

[0224] In some embodiments, the compound of formula (1b) or a salt thereof is an HCl salt. In some embodiments, the Buchwald coupling reaction comprises reacting a compound of formula (1c) with a compound of formula (1b) or a salt thereof in the presence of a Buchwald catalyst or precatalyst and a base.

[0225] In some embodiments, the Buchwald catalyst or precatalyst is a palladium catalyst. In some embodiments, the palladium catalyst or precatalyst is [(2-di-tert-butylphosphino-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl)] methanesulfonate palladium (II) (t-BuBrett Phos Pd G3), [tBuBrettPhos Pd(allyl)]OTf (Pd-175), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)] palladium (II) (XPhos-Pd-G2), [(4,5-bis(diphenylphosphino)-9,9-dimethylxanthene)-2-(2'-amino-1,1'-biphenyl)] methanesulfonate palladium (II) (XantPhos Pd G3), tBuBrettPhos Pd G3, SPhos Pd G3, A Pd G3, BrettPhos Pd G3, tBuXPhosPd G3, [(1,3,5,7-tetramethyl-6-phenyl-2,4,6-trioxa-6-phosphaadamantane)-2-(2'-amino-1,1'-biphenyl)]methanesulfonate palladium(II), JackiePhos Pd G3, CPhos Pd G3, RuPhos Pd G3, APhos Pd G3, RockPhos Pd G3, AdBrettPhos Pd G3, neopentyl(t-Bu)2P Pd G3, TrixiePhos Pd G3, N-XantPhos Pd G3, DTBPF-Pd-G3, DPPF Pd G3, DavePhos-Pd-G3, (t-Bu)2PhP Pd G3, rac-BINAP-Pd-G3, CyJohnPhos Pd G3, MorDalphos Pd G3, Josiphos SL-J009-1 Pd G3, P(Cy3)Pd G3, Me3(OMe)tBuXPhos-Pd-G3, 4MetBuXPhos Pd G3, (t-Bu)PhCPhos Pd G3, CyJohnPhosPd G3, methylsulfonyl[(tri-tert-butylphosphine)-2-(2-aminobiphenyl)]palladium(II), DTBPF-Pd-G3, P(o-tol)3PdG3, VPhos Pd G3, QPhos Pd G3, RuPhos Pd G4, SPhos Pd G4, BrettPhos Pd G4, XPhos PdG4, APhos Pd G4, rac-BINAP Pd G4, P(t-Bu)3Pd G4, (t-Bu)PhCPhos Pd G4, cataCXium PdG4, CPhos Pd G4, CyJohnPhos Pd G4, DavePhos Pd G4, DPPF Pd G4, EPhos Pd G4, MorDalPhos Pd G4, neopentyl (tBu)2P Pd G4, PCy3 Pd G4, (tBu)2PMe Pd G4, (tBu)2PPh PdG4, 1,3,5,7-tetramethyl-6-phenyl-2,4,6-Trioxa-6-phosphaadamantane Pd G4, (R)-TolBINAP Pd G4, VPhos Pd G4, XantPhos Pd G4, N-XantPhos Pd G4, t-BuDavePhos Pd G4, XPhos Pd G2, RuPhos Pd G2, SPhos Pd G2, bis(triphenylphosphine)palladium(II) dichloride, tBuXPhos Pd G1, RuPhos Pd G1 methyl tert-butyl ether adduct, SPhos Pd G1 methyl tert-butyl ether adduct, 2'-(dimethylamino)-2-biphenyl-palladium(II) chloride dinorbornylphosphine complex, chloro(η2-P,C-tris(2,4-di-tert-butylphenyl)phosphite)(tricyclohexylphosphine)palladium(II), di-μ-chlorobis[5-chloro-2-[(4-chlorophenyl)(hydroxyimino-κN)methyl]phenyl-κC]palladium dimer, DavePhos Pd G2, (Ad-BippyPhos)2PdCl2, APhos Pd G2, sSPhos Pd G2, P(t-Bu)3Pd G3, BrettPhos Pd G1 methyl tert-butyl ether adduct, dichloro[2-(4,5-dihydro-2-oxazolyl)quinoline]palladium(II), salicylic acid semicarbazone palladium(II) chloride, XPhos Pd G1, bis[(dicyclohexyl)(4-dimethylaminophenyl)phosphine]palladium(II) chloride, bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II), di-μ-chlorobis[5-hydroxy-2-[1-(hydroxyimino-κN)ethyl]phenyl-κC]palladium(II) dimer, 2-(2'-di-tert-butylphosphino)biphenylacetic acid palladium(II) or 2-(dimethylaminomethyl)ferrocen-1-yl-palladium(II) chloride dinorbornylphosphine complex.

[0226] In some embodiments, the palladium catalyst or precatalyst is XPhos Pd G3.

[0227] In some embodiments, the base is an alkali metal alkoxide. In some embodiments, the base is sodium tert-butoxide.

[0228] In some embodiments, about 1 to about 1.5 equivalents of the compound of formula (1b) or its salt are used relative to 1 equivalent of the compound of formula (1c). In some embodiments, about 1.2 equivalents of the compound of formula (1b) or its salt are used relative to 1 equivalent of the compound of formula (1c).

[0229] In some embodiments, about 4 to about 6 equivalents of the base are used relative to 1 equivalent of the compound of formula (1c).

[0230] In some embodiments, about 0.0001 to about 0.1 equivalent of Buchwald catalyst or precatalyst is used relative to 1 equivalent of compound of formula (1c). In some embodiments, about 0.01 to about 0.05 equivalent of Buchwald catalyst or precatalyst is used relative to 1 equivalent of compound of formula (1c).

[0231] In some embodiments, the reaction of the compound of formula (1c) with the compound of formula (1b) or a salt thereof is carried out at a temperature of about 80° C. to about 100° C. In some embodiments, the reaction of the compound of formula (1c) with the compound of formula (1b) or a salt thereof is carried out at a temperature of about 90° C.

[0232] In some embodiments, the reaction of the compound of formula (1c) with the compound of formula (1b) or its salt is carried out in a solvent component. In some embodiments, the solvent component used for the reaction of the compound of formula (1c) with the compound of formula (1b) or its salt comprises a cyclic ether. In some embodiments, the solvent component used for the reaction of the compound of formula (1c) with the compound of formula (1b) or its salt comprises dioxane.

[0233] In some embodiments, the method further comprises reacting the compound of formula (1a) with an organic acid to form a salt of the compound of formula (1a).

[0234] In some embodiments, the organic acid is succinic acid.

[0235] In some embodiments, the salt of the compound of formula (1) is the hemisuccinate salt of the compound of formula (1a).

[0236] In some embodiments, the method further comprises reacting the compound of formula (1a) with succinic acid to form a hemisuccinate salt of the compound of formula (1a).

[0237] In some embodiments, about 2 to about 2.5 equivalents of succinic acid are used relative to 1 equivalent of the compound of formula (1a).

[0238] In some embodiments, the reaction of the compound of formula (1a) with succinic acid is carried out in a solvent component. In some embodiments, the solvent component for the reaction of the compound of formula (1a) with succinic acid comprises acetonitrile.

[0239] In some embodiments, the reaction of the compound of formula (1a) and succinic acid is carried out at a temperature of about 50°C to about 60°C.

[0240] In some embodiments, the method further comprises deprotecting the compound of formula (1a) or a salt thereof to form a compound of formula (I).

[0241] In some embodiments, the method further comprises deprotecting the compound of formula (1a) to form the compound of formula (I).

[0242] In some embodiments, the deprotection is accomplished by reacting the compound of formula (1a) with a strong acid. In some embodiments, the strong acid is hydrochloric acid.

[0243] In some embodiments, about 2 to about 3 equivalents of a strong acid are used relative to 1 equivalent of the compound of formula (1a).

[0244] In some embodiments, the deprotection of the compound of formula (1a) is carried out at a temperature of about 50° C. to about 70° C. In some embodiments, the deprotection of the compound of formula (1a) is carried out at a temperature of about 60° C.

[0245] In some embodiments, the deprotection of the compound of formula (1a) is carried out in a solvent component. In some embodiments, the solvent component for the deprotection of the compound of formula (1a) comprises a cyclic ether. In some embodiments, the solvent component for the deprotection of the compound of formula (1a) comprises tetrahydrofuran (THF).

[0246] In some embodiments, the compound of formula (1c) is prepared by a method comprising:

[0247] The compound of formula (1d):

[0248]

[0249] or a salt thereof is reacted with a halogenating agent to form a compound of formula (1c).

[0250] In some embodiments, the halogenating agent is a brominating agent.

[0251] In some embodiments, the halogenating agent is Cu(X 1 )2.

[0252] In some embodiments, the halogenating agent is CuBr2.

[0253] In some embodiments, about 1 to about 1.5 equivalents of the halogenating agent are used relative to 1 equivalent of the compound of formula (1d) or its salt. In some embodiments, about 1 to about 1.1 equivalents of the halogenating agent are used relative to 1 equivalent of the compound of formula (1d) or its salt.

[0254] In some embodiments, the reaction of the compound of formula (1d) or its salt with the halogenating agent is carried out at a temperature of about 0° C. to about 10° C. In some embodiments, the reaction of the compound of formula (1d) or its salt with the halogenating agent is carried out at a temperature of about 5° C., followed by warming to room temperature.

[0255] In some embodiments, the reaction of the compound of formula (1d) or its salt with the halogenating agent is carried out in a solvent component. In some embodiments, the solvent component for the reaction of the compound of formula (1d) or its salt with the halogenating agent comprises acetonitrile.

[0256] In some embodiments, the compound of formula (1d) or a salt thereof is prepared by a method comprising:

[0257] The compound of formula 1(e):

[0258]

[0259] Reaction with hydroxylamine hydrochloride and a base component to form a compound of formula (1d) or a salt thereof.

[0260] In some embodiments, the base component is a tertiary amine. In some embodiments, the tertiary amine is ethyl diisopropylamine.

[0261] In some embodiments, about 1 to about 2 equivalents of hydroxylamine hydrochloride are used relative to about 1 equivalent of the compound of formula (1e).

[0262] In some embodiments, the reaction of the compound of formula (1e) or its salt with hydroxylamine hydrochloride and a base component is carried out at a temperature of about 40° C. to about 60° C. In some embodiments, the reaction of the compound of formula (1e) or its salt with hydroxylamine hydrochloride and a base component is carried out at a temperature of about 50° C.

[0263] In some embodiments, the reaction of the compound of formula (1e) or its salt with hydroxylamine hydrochloride and a base component is carried out in a solvent component. In some embodiments, the solvent component for the reaction of the compound of formula (1e) or its salt with hydroxylamine hydrochloride and a base component comprises an alcohol. In some embodiments, the solvent component for the reaction of the compound of formula (1e) or its salt with hydroxylamine hydrochloride and a base component comprises an alcohol. In some embodiments, the solvent component for the reaction of the compound of formula (1e) or its salt with hydroxylamine hydrochloride and a base component comprises ethanol.

[0264] In some embodiments, the compound of formula (1e) is prepared by a method comprising:

[0265] The compound of formula (1f):

[0266]

[0267] Reaction with CH3CH2OC(O)-N=C=S to form a compound of formula (1e).

[0268] In some embodiments, about 1 to about 1.5 equivalents of CH3CH2OC(O)-N=C=S are used relative to the compound of formula (1f).

[0269] In some embodiments, the reaction of the compound of formula (1f) with CH3CH2OC(O)-N=C=S is carried out at a temperature of about 0°C to about 20°C, followed by warming to room temperature. In some embodiments, the reaction of the compound of formula (1f) with CH3CH2OC(O)-N=C=S is carried out at a temperature of about 10°C, followed by warming to room temperature.

[0270] In some embodiments, the reaction of the compound of formula (1f) with CH3CH2OC(O)-N=C=S is carried out in a solvent component. In some embodiments, the solvent component for the reaction of the compound of formula (1f) with CH3CH2OC(O)-N=C=S comprises a cyclic ether. In some embodiments, the solvent component for the reaction of the compound of formula (1f) with CH3CH2OC(O)-N=C=S comprises dioxane.

[0271] In some embodiments, the compound of formula (1f) is prepared by a method comprising:

[0272] The compound of formula (1h):

[0273]

[0274] or its salt and a compound of formula (1g):

[0275]

[0276] The reaction is carried out via a Buchwald coupling reaction to form a compound of formula (1f).

[0277] In some embodiments, the Buchwald coupling reaction comprises reacting a compound of formula (1h) or a salt thereof with a compound of formula (1g) in the presence of a Buchwald catalyst or precatalyst and a base.

[0278] In some embodiments, the Buchwald catalyst or precatalyst is a palladium catalyst. In some embodiments, the palladium catalyst or precatalyst is [(2-di-tert-butylphosphino-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl)] methanesulfonate palladium (II) (t-BuBrett Phos Pd G3), [tBuBrettPhos Pd(allyl)]OTf (Pd-175), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)] palladium (II) (XPhos-Pd-G2), [(4,5-bis(diphenylphosphino)-9,9-dimethylxanthene)-2-(2'-amino-1,1'-biphenyl)] methanesulfonate palladium (II) (XantPhos Pd G3), tBuBrettPhos Pd G3, SPhos Pd G3, A Pd G3, BrettPhos Pd G3, tBuXPhosPd G3, [(1,3,5,7-tetramethyl-6-phenyl-2,4,6-trioxa-6-phosphaadamantane)-2-(2'-amino-1,1'-biphenyl)]methanesulfonate palladium(II), JackiePhos Pd G3, CPhos Pd G3, RuPhos Pd G3, APhos Pd G3, RockPhos Pd G3, AdBrettPhos Pd G3, neopentyl(t-Bu)2P Pd G3, TrixiePhos Pd G3, N-XantPhos Pd G3, DTBPF-Pd-G3, DPPF Pd G3, DavePhos-Pd-G3, (t-Bu)2PhP Pd G3, rac-BINAP-Pd-G3, CyJohnPhos Pd G3, MorDalphos Pd G3, Josiphos SL-J009-1 Pd G3, P(Cy3)Pd G3, Me3(OMe)tBuXPhos-Pd-G3, 4MetBuXPhos Pd G3, (t-Bu)PhCPhos Pd G3, CyJohnPhosPd G3, methylsulfonyl[(tri-tert-butylphosphine)-2-(2-aminobiphenyl)]palladium(II), DTBPF-Pd-G3, P(o-tol)3PdG3, VPhos Pd G3, QPhos Pd G3, RuPhos Pd G4, SPhos Pd G4, BrettPhos Pd G4, XPhos PdG4, APhos Pd G4, rac-BINAP Pd G4, P(t-Bu)3Pd G4, (t-Bu)PhCPhos Pd G4, cataCXium PdG4, CPhos Pd G4, CyJohnPhos Pd G4, DavePhos Pd G4, DPPF Pd G4, EPhos Pd G4, MorDalPhos Pd G4, neopentyl (tBu)2P Pd G4, PCy3 Pd G4, (tBu)2PMe Pd G4, (tBu)2PPh PdG4, 1,3,5,7-tetramethyl-6-phenyl-2,4,6-Trioxa-6-phosphaadamantane Pd G4, (R)-TolBINAP Pd G4, VPhos Pd G4, XantPhos Pd G4, N-XantPhos Pd G4, t-BuDavePhos Pd G4, XPhos Pd G2, RuPhos Pd G2, SPhos Pd G2, bis(triphenylphosphine)palladium(II) dichloride, tBuXPhos Pd G1, RuPhos Pd G1 methyl tert-butyl ether adduct, SPhos Pd G1 methyl tert-butyl ether adduct, 2'-(dimethylamino)-2-biphenyl-palladium(II) chloride dinorbornylphosphine complex, chloro(η2-P,C-tris(2,4-di-tert-butylphenyl)phosphite)(tricyclohexylphosphine)palladium(II), di-μ-chlorobis[5-chloro-2-[(4-chlorophenyl)(hydroxyimino-κN)methyl]phenyl-κC]palladium dimer, DavePhos Pd G2, (Ad-BippyPhos)2PdCl2, APhos Pd G2, sSPhos Pd G2, P(t-Bu)3Pd G3, BrettPhos Pd G1 methyl tert-butyl ether adduct, dichloro[2-(4,5-dihydro-2-oxazolyl)quinoline]palladium(II), salicylic acid semicarbazone palladium(II) chloride, XPhos Pd G1, bis[(dicyclohexyl)(4-dimethylaminophenyl)phosphine]palladium(II) chloride, bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II), di-μ-chlorobis[5-hydroxy-2-[1-(hydroxyimino-κN)ethyl]phenyl-κC]palladium(II) dimer, 2-(2'-di-tert-butylphosphino)biphenylacetic acid palladium(II) or 2-(dimethylaminomethyl)ferrocen-1-yl-palladium(II) chloride dinorbornylphosphine complex.

[0279] In some embodiments, the compound of formula (1h) or a salt thereof is an HBr salt.

[0280] In some embodiments, the Buchwald catalyst or precatalyst present for the reaction of the compound of formula (1h) or its salt with the compound of formula (1g) is a palladium catalyst. In some embodiments, the Buchwald catalyst or precatalyst present for the reaction of the compound of formula (1h) or its salt with the compound of formula (1g) is (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl) [2-(2'-amino-1,1'-biphenyl)] methanesulfonate palladium (II) (XPhos PdG3).

[0281] In some embodiments, the base present for the reaction of the compound of formula (1h) or its salt with the compound of formula (1g) is an alkali metal phosphate. In some embodiments, the base present for the reaction of the compound of formula (1h) or its salt with the compound of formula (1g) is sodium phosphate.

[0282] In some embodiments, the reaction of the compound of formula (1h) or its salt with the compound of formula (1g) is carried out at a temperature of about 75° C. to about 95° C. In some embodiments, the reaction of the compound of formula (1h) or its salt with the compound of formula (1g) is carried out at a temperature of about 85° C.

[0283] In some embodiments, the reaction of the compound of formula (1h) or its salt with the compound of formula (1g) is carried out in a solvent component. In some embodiments, the solvent component used for the reaction of the compound of formula (1h) or its salt with the compound of formula (1g) comprises water and a cyclic ether. In some embodiments, the solvent component used for the reaction of the compound of formula (1h) or its salt with the compound of formula (1g) comprises water and dioxane.

[0284] In some embodiments, about 1 to about 1.5 equivalents of the compound of formula (1g) are used relative to 1 equivalent of the compound of formula (1h).

[0285] In some embodiments, about 2 to about 4 equivalents of the base are used relative to 1 equivalent of the compound of formula (1h).

[0286] In some embodiments, about 0.0001 to about 0.1 equivalent of Buchwald catalyst or precatalyst is used relative to 1 equivalent of compound of formula (1h). In some embodiments, about 0.001 to about 0.005 equivalent of Buchwald catalyst or precatalyst is used relative to 1 equivalent of compound of formula (1h).

[0287] In some embodiments, the compound of formula (1h) or a salt thereof is prepared by a method comprising:

[0288] The compound of formula (1i):

[0289]

[0290] or a salt thereof is reacted with an ethyl halide in the presence of a base to form a compound of formula (1h) or a salt thereof.

[0291] In some embodiments, the ethyl halide is ethyl iodide.

[0292] In some embodiments, about 1 to about 2 equivalents of ethyl halide are used relative to the compound of formula (1i) or a salt thereof.

[0293] In some embodiments, about 2 to about 3 equivalents of the base are used relative to the compound of formula (1i) or a salt thereof.

[0294] In some embodiments, the base present for the reaction of the compound of formula (1i) or its salt with the ethyl halide is a carbonate base. In some embodiments, the carbonate base is cesium carbonate. In some embodiments, the compound of formula (1i) or its salt is a HBr salt.

[0295] In some embodiments, the reaction of the compound of formula (1i) or its salt with ethyl halide is carried out at a temperature of about 55° C. to about 80° C. In some embodiments, the reaction of the compound of formula (1i) or its salt with ethyl halide is carried out at a temperature of about 65° C. to about 70° C.

[0296] In some embodiments, the reaction of the compound of formula (1i) or its salt with ethyl halide is carried out in a solvent component. In some embodiments, the solvent component for the reaction of the compound of formula (1i) or its salt with ethyl halide comprises acetonitrile.

[0297] In some embodiments, the compound of formula (1c) is prepared by a method comprising:

[0298] The compound of formula (2a):

[0299]

[0300] With the compound of formula (2b):

[0301]

[0302] In the presence of Suzuki catalyst and base, a compound of formula (1c) is formed, wherein X 1 It is a halogen group.

[0303] In some embodiments, X 1 For Br.

[0304] In some embodiments, about 1 to about 1.5 equivalents of the compound of formula (2b) are used relative to 1 equivalent of the compound of formula (2a).

[0305] In some embodiments, the Suzuki catalyst is a palladium catalyst. In some embodiments, the Suzuki catalyst is formed from a mixture of a phosphine ligand and a palladium (II) compound. In some embodiments, the Suzuki catalyst is formed from a mixture of CataCXium A and palladium acetate.

[0306] In some embodiments, the base present for the reaction of the compound of formula (2a) with the compound of formula (2b) is an alkali metal phosphate. In some embodiments, the base present for the reaction of the compound of formula (2a) with the compound of formula (2b) is sodium phosphate.

[0307] In some embodiments, the reaction of the compound of formula (2a) with the compound of formula (2b) is carried out at a temperature of about 40° C. to about 60° C. In some embodiments, the reaction of the compound of formula (2a) with the compound of formula (2b) is carried out at a temperature of about 50° C.

[0308] In some embodiments, the reaction of the compound of formula (2a) with the compound of formula (2b) is carried out in a solvent component. In some embodiments, the solvent component used for the reaction of the compound of formula (2a) with the compound of formula (2b) comprises a cyclic ether. In some embodiments, the solvent component used for the reaction of the compound of formula (2a) with the compound of formula (2b) comprises dioxane.

[0309] In some embodiments, the compound of formula (1b) or a salt thereof is prepared by a method comprising:

[0310] Reducing the compound of formula (3a):

[0311]

[0312] To form a compound of formula (1b) or a salt thereof.

[0313] In some embodiments, the reduction is accomplished by reacting a compound of formula (3a) with hydrogen in the presence of a palladium catalyst. In some embodiments, the reduction is accomplished by reacting a compound of formula (3a) with hydrogen in the presence of Pd(OH)2.

[0314] In some embodiments, the reduction of the compound of formula (3a) is carried out at room temperature.

[0315] In some embodiments, the reduction of the compound of formula (3a) is carried out in a solvent component. In some embodiments, the solvent component for the reduction of the compound of formula (3a) comprises an alcohol. In some embodiments, the solvent component for the reduction of the compound of formula (3a) comprises methanol.

[0316] In some embodiments, the compound of formula (3a) is prepared by a method comprising:

[0317] The compound of formula (3c):

[0318]

[0319] Reaction with a compound of formula (3b):

[0320]

[0321] Subsequent crystallization gives the compound of formula (3a).

[0322] In some embodiments, about 1 to about 2 equivalents of the compound of formula (3b) are used relative to 1 equivalent of the compound of formula (3c).

[0323] In some embodiments, the reaction of the compound of formula (3c) with the compound of formula (3b) is carried out in the presence of a coupling agent and a base. In some embodiments, the coupling agent present for the reaction of the compound of formula (3c) with the compound of formula (3b) is a borohydride. In some embodiments, the coupling agent present for the reaction of the compound of formula (3c) with the compound of formula (3b) is NaBH(OAc)2. In some embodiments, the base present for the reaction of the compound of formula (3c) with the compound of formula (3b) is a tertiary amine. In some embodiments, the base present for the reaction of the compound of formula (3c) with the compound of formula (3b) is diisopropylethylamine.

[0324] In some embodiments, the reaction of the compound of formula (3c) with the compound of formula (3b) is carried out at a temperature of about 10° C. to about 35° C. In some embodiments, the reaction of the compound of formula (3c) with the compound of formula (3b) is carried out at a temperature of about 20° C. to about 25° C.

[0325] In some embodiments, the reaction of the compound of formula (3c) with the compound of formula (3b) is carried out in a solvent component. In some embodiments, the solvent component for the reaction of the compound of formula (3c) with the compound of formula (3b) comprises a cyclic ether. In some embodiments, the solvent component for the reaction of the compound of formula (3c) with the compound of formula (3b) comprises tetrahydrofuran.

[0326] In some embodiments, crystallization is performed by dissolving the reaction product of the compound of formula (3c) and the compound of formula (3b) in a solvent component and then cooling the solution to form the compound of formula (3c). In some embodiments, the solvent component used for dissolution is ethyl acetate (EtOAc).

[0327] In some embodiments, the compound of formula (3c) is prepared by a method comprising:

[0328] The compound of formula (3d):

[0329]

[0330] or a salt thereof is reacted with methanesulfonyl chloride to form a compound of formula (3c).

[0331] In some embodiments, the reaction of the compound of formula (3d) with methanesulfonyl chloride is carried out in the presence of a base. In some embodiments, the base present for the reaction of the compound of formula (3d) with methanesulfonyl chloride is a tertiary amine. In some embodiments, the base present for the reaction of the compound of formula (3d) with methanesulfonyl chloride is triethylamine.

[0332] In some embodiments, about 1 to about 1.5 equivalents of methanesulfonyl chloride are used relative to 1 equivalent of the compound of formula (3d) or a salt thereof.

[0333] In some embodiments, the reaction of the compound of formula (3d) with methanesulfonyl chloride is carried out at room temperature.

[0334] In some embodiments, the reaction of the compound of formula (3d) with methanesulfonyl chloride is carried out in a solvent component. In some embodiments, the solvent component for the reaction of the compound of formula (3d) with methanesulfonyl chloride comprises dichloromethane.

[0335] In some embodiments, the present application also provides a compound selected from the following:

[0336]

[0337] or a salt thereof.

[0338] In some embodiments, the present application provides a hemisuccinate salt of a compound of formula (1a):

[0339]

[0340] It should be further understood that certain features of the present invention that are described in the context of separate embodiments for clarity may also be provided in combination in a single embodiment. Conversely, various features of the present invention that are described in the context of a single embodiment for brevity may also be provided separately or in any suitable subcombination.

[0341] As used herein, "halo" refers to F, Cl, Br, or I. In some embodiments, halo is F, Cl, or Br. In some embodiments, halo is F or Cl. In some embodiments, halo is F. In some embodiments, halo is Cl.

[0342] In some embodiments, the compound or its salt provided herein is separated substantially. "Substantially separated" means that the compound is separated at least partially or substantially from the environment in which the compound is formed or detected. Partial separation may include, for example, a composition rich in the compound provided herein. Substantially separation may include a composition containing at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, at least about 90% by weight, at least about 95% by weight, at least about 97% by weight or at least about 99% by weight of the compound or its salt provided herein. The method for separating compounds and their salts is a conventional method in the art.

[0343] The phrase "pharmaceutically acceptable" is used herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and are commensurate with a reasonable benefit / risk ratio.

[0344] The methods described herein can also be used to prepare pharmaceutically acceptable salts of compounds of formula (I). As used herein, the term "pharmaceutically acceptable salt" refers to a salt formed by adding a pharmaceutically acceptable acid or base to a compound disclosed herein. As used herein, the phrase "pharmaceutically acceptable" refers to a substance that is acceptable for use in pharmaceutical applications from a toxicological point of view and does not interact adversely with the active ingredient. Pharmaceutically acceptable salts (including monosalts and disalts) include, but are not limited to, those derived from organic and inorganic acids, such as, but not limited to, acetic acid, lactic acid, citric acid, cinnamic acid, tartaric acid, succinic acid, fumaric acid, maleic acid, malonic acid, mandelic acid, malic acid, oxalic acid, propionic acid, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, glycolic acid, pyruvic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, salicylic acid, benzoic acid, and similar known acceptable acids. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.

[0345] The reactions for preparing the compounds described herein can be carried out in suitable solvents, which can be easily selected by those skilled in the art of organic synthesis. Suitable solvents may not substantially react with starting materials (reactants), intermediates or products at the temperature at which the reaction is carried out (e.g., a temperature that can range from the freezing temperature of the solvent to the boiling temperature of the solvent). A given reaction can be carried out in one solvent or in a mixture of more than one solvent. Depending on the particular reaction step, a skilled person can select a suitable solvent for a particular reaction step.

[0346] The expression "ambient temperature" or "room temperature" or "rt" as used herein is understood in the art and generally refers to a temperature about the temperature of the room where the reaction is carried out (e.g., reaction temperature), for example a temperature of about 20°C to about 30°C.

[0347] The preparation of the compounds of the invention may involve the protection and deprotection of various chemical groups. Those skilled in the art can readily determine the need for protection and deprotection and the selection of appropriate protecting groups. The chemistry of protecting groups is described in, for example, Kocienski, Protecting Groups, (Thieme, 2007); Robertson, Protecting Group Chemistry, (Oxford University Press, 2000); Smith et al., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 6th edition (Wiley, 2007); Peturssion et al., "Protecting Groups in Carbohydrate Chemistry", J. Chem. Educ., 1997, 74 (11), 1297; and Wuts et al., Protective Groups in Organic Synthesis, 4th edition (Wiley, 2006).

[0348] The reaction can be monitored by any suitable method known in the art. For example, product formation can be monitored by spectroscopic means (e.g., nuclear magnetic resonance spectroscopy (e.g., 1 H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry) or by chromatographic methods (e.g., high performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LCMS) or thin layer chromatography (TLC)). Compounds can be purified by a variety of methods (including high performance liquid chromatography (HPLC) and normal phase silica chromatography) by those skilled in the art.

[0349] How to use

[0350] The solid forms and salts of the present disclosure can inhibit CDK2, and therefore can be used to treat diseases in which the underlying lesions are completely or partially mediated by CDK2. Such diseases include cancer and other diseases with proliferative disorders. In some embodiments, the present disclosure provides in vivo treatment of individuals or patients using the solid forms and salts of the present disclosure, so that the growth of cancerous tumors is inhibited. The solid forms and salts described herein can be used to inhibit the growth of cancerous tumors with aberrations that activate CDK2 kinase activity. These cancerous tumors include (but are not limited to) diseases (e.g., cancers) characterized by CCNE1 amplification or overexpression, such as ovarian cancer, uterine carcinosarcoma, and breast cancer, and diseases characterized by p27 inactivation, such as breast cancer and melanoma. Therefore, in some embodiments of the method, it has been previously determined that the patient has amplification of the cyclin E1 (CCNE1) gene and / or the expression level of CCNE1 in a biological sample obtained from a human subject is higher than the control expression level of CCNE1. Alternatively, the solid forms and salts described herein can be used in combination with other agents or standard cancer treatments as described below. In one embodiment, the present disclosure provides a method for inhibiting tumor cell growth in vitro. The method comprises contacting in vitro tumor cells with a solid form and a salt. In another embodiment, the present disclosure provides a method of inhibiting the growth of tumor cells having CCNE1 amplification and overexpression in an individual or patient. The method comprises administering to an individual or patient in need thereof a therapeutically effective amount of a solid form and a salt as described herein.

[0351] In some embodiments, provided herein is a method of inhibiting CDK2, the method comprising contacting the CDK2 with a solid form and salt as described herein. In some embodiments, provided herein is a method of inhibiting CDK2 in a patient, the method comprising administering to the patient a solid form and salt as described herein.

[0352] In some embodiments, provided herein is a method for treating cancer. The method comprises administering to a patient (in need thereof) a therapeutically effective amount of a solid form and salt as described herein. In another embodiment, the cancer is characterized by amplification or overexpression of CCNE1. In some embodiments, the cancer is ovarian cancer or breast cancer, characterized by amplification or overexpression of CCNE1.

[0353] In some embodiments, provided herein is a method of treating a disease or condition associated with CDK2 in a patient, the method comprising administering to the patient a therapeutically effective amount of a solid form and salt as described herein. In some embodiments, the disease or condition associated with CDK2 is associated with amplification of the cyclin E1 (CCNE1) gene and / or overexpression of CCNE1.

[0354] In some embodiments, the disease or condition associated with CDK2 is N-myc amplified neuroblastoma cells (see Molenaar et al., Proc Natl Acad Sci USA 106(31):12968-12973), K-Ras mutant lung cancer (see Hu, S. et al., Mol Cancer Ther, 2015.14(11):2576-85, and cancer with FBW7 mutation and CCNE1 overexpression (see Takada et al., Cancer Res, 2017.77(18):4881-4893).

[0355] In some embodiments, the disease or disorder associated with CDK2 is squamous cell carcinoma of the lung, adenocarcinoma of the lung, adenocarcinoma of the pancreas, invasive carcinoma of the breast, carcinosarcoma of the uterus, serous cystadenocarcinoma of the ovary, adenocarcinoma of the stomach, esophageal cancer, urothelial carcinoma of the bladder, mesothelioma, or sarcoma.

[0356] In some embodiments, the disease or disorder associated with CDK2 is lung adenocarcinoma, invasive breast carcinoma, uterine carcinosarcoma, ovarian serous cystadenocarcinoma, or gastric adenocarcinoma.

[0357] In some embodiments, the disease or disorder associated with CDK2 is adenocarcinoma, carcinoma, or cystadenocarcinoma.

[0358] In some embodiments, the disease or disorder associated with CDK2 is uterine cancer, ovarian cancer, gastric cancer, esophageal cancer, lung cancer, bladder cancer, pancreatic cancer, or breast cancer.

[0359] In some embodiments, the disease or disorder associated with CDK2 is cancer.

[0360] In some embodiments, the cancer is characterized by amplification or overexpression of CCNE1. In some embodiments, the cancer is ovarian cancer or breast cancer, characterized by amplification or overexpression of CCNE1.

[0361] In some embodiments, the breast cancer is chemotherapy or radiotherapy resistant breast cancer, endocrine resistant breast cancer, trastuzumab resistant breast cancer, or breast cancer showing primary or acquired resistance to CDK4 / 6 inhibition. In some embodiments, the breast cancer is advanced or metastatic breast cancer.

[0362] Examples of cancers that may be treated using the compounds of the present disclosure include, but are not limited to, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, fallopian tube cancer, carcinoma of the endometrium / endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, Disease), non-Hodgkin's lymphoma, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, chronic or acute leukemia (including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia), childhood solid tumors, lymphocytic lymphoma, bladder cancer, kidney or urethral cancer, renal pelvis cancer, central nervous system (CNS) neoplasms, primary CNS lymphoma, tumor angiogenesis, spinal axis tumors, brain stem gliomas, pituitary adenomas, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, environmentally induced cancers (including those induced by asbestos) and combinations of the cancers. The compounds of the present disclosure can also be used to treat metastatic cancers.

[0363] In some embodiments, cancers treatable using the compounds of the present disclosure include melanoma (e.g., metastatic malignant melanoma, BRAF and HSP90 inhibition-resistant melanoma), renal cancer (e.g., clear cell carcinoma), prostate cancer (e.g., hormone-refractory prostate adenocarcinoma), breast cancer, colon cancer, lung cancer (e.g., non-small cell lung cancer and small cell lung cancer), squamous cell head and neck cancer, urothelial carcinoma (e.g., bladder cancer), and high microsatellite instability (MSI) 高 ) cancer. In addition, the present disclosure includes refractory or recurrent malignancies whose growth can be inhibited using the compounds of the present disclosure.

[0364] In some embodiments, cancers that can be treated using the compounds of the present disclosure include, but are not limited to, solid tumors (e.g., prostate cancer, colon cancer, esophageal cancer, endometrial cancer, ovarian cancer, uterine cancer, kidney cancer, liver cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, head and neck cancer, thyroid cancer, glioblastoma, sarcoma, bladder cancer, etc.), blood cancers (e.g., lymphoma, leukemia such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), DLBCL, mantle cell lymphoma, non-Hodgkin lymphoma (including follicular lymphoma, including relapsed or refractory NHL and recurrent follicular lymphoma), Hodgkin lymphoma, or multiple myeloma), and combinations of the aforementioned cancers.

[0365] In some embodiments, cancers that may be treated using the compounds of the present disclosure include, but are not limited to, bile duct cancer, biliary tract cancer, triple negative breast cancer, rhabdomyosarcoma, small cell lung cancer, leiomyosarcoma, hepatocellular carcinoma, Ewing's sarcoma, brain cancer, brain tumor, astrocytoma, neuroblastoma, neurofibroma, basal cell carcinoma, chondrosarcoma, epithelioid sarcoma, eye cancer, fallopian tube cancer, gastrointestinal cancer, gastrointestinal stromal tumor, hairy cell leukemia, intestinal cancer, islet cell carcinoma, oral cancer, mouth cancer, pharyngeal cancer, laryngeal cancer, lip cancer, mesothelioma, neck cancer, nasal cancer, eye cancer, eye melanoma, pelvic cancer, rectal cancer, renal cell carcinoma, salivary gland cancer, sinus cancer, spinal cord cancer, tongue cancer, tubule cancer, urethral cancer, and ureteral cancer.

[0366] In some embodiments, the compounds of the present disclosure are useful for treating sickle cell disease and sickle cell anemia.

[0367] In some embodiments, diseases and indications that may be treated using the compounds of the present disclosure include, but are not limited to, hematological cancers, sarcomas, lung cancers, gastrointestinal cancers, genitourinary tract cancers, liver cancers, bone cancers, cancers of the nervous system, gynecological cancers, and skin cancers.

[0368] Exemplary hematological cancers include lymphomas and leukemias, such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, non-Hodgkin lymphoma (including relapsed or refractory NHL and relapsed follicular lymphoma), Hodgkin lymphoma, myeloproliferative disorders (e.g., primary myelofibrosis (PMF), polycythemia vera (PV), and essential thrombocythemia (ET)), myelodysplastic syndrome (MDS), T-cell acute lymphoblastic lymphoma (T-ALL), and multiple myeloma (MM).

[0369] Exemplary sarcomas include chondrosarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, myxoma, rhabdomyoma, rhabdomyosarcoma, fibroma, lipoma, hamartoma, and teratoma.

[0370] Exemplary lung cancers include non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), bronchogenic carcinoma (squamous cell carcinoma, undifferentiated small cell carcinoma, undifferentiated large cell carcinoma, adenocarcinoma), alveolar (bronchial) carcinoma, bronchial adenoma, cartilaginous hamartoma, and mesothelioma.

[0371] Exemplary gastrointestinal cancers include esophageal cancer (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), gastric cancer (carcinoma, lymphoma, leiomyosarcoma), pancreatic cancer (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor, vipoma), small intestine cancer (adenocarcinoma, lymphoma, carcinoid tumor, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large intestine cancer (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), and colorectal cancer.

[0372] Exemplary genitourinary tract cancers include renal cancer (adenocarcinoma, Wilm's tumor [Nephroblastoma]), bladder and urethral cancer (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate cancer (adenocarcinoma, sarcoma), and testicular cancer (seminoma, teratoma, embryonal carcinoma, teratoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenomatoid tumor, lipoma).

[0373] Exemplary liver cancers include hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma.

[0374] Exemplary bone cancers include, e.g., osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticular cell sarcoma), multiple myeloma, malignant giant cell tumor, chordoma, osteochondroma (osteocartilaginous exostosis), benign enchondroma, chondroblastoma, chondromyxoid fibroma, osteoid osteoma, and giant cell tumor.

[0375] Exemplary nervous system cancers include skull cancer (osteomas, hemangiomas, granulomas, xanthomas, osteitis deformans), meningeal cancer (meningioma, meningiosarcoma, glioma), brain cancer (astrocytoma, medulloblastoma, glioma, ependymoma, germ cell tumor (pinealoma), glioblastoma, glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), and spinal cord cancer (neurofibroma, meningioma, glioma, sarcoma), as well as neuroblastoma and Lhermitte-Duclos disease.

[0376] Exemplary gynecological cancers include uterine cancer (endometrial cancer), cervical cancer (cervical carcinoma, preneoplastic cervical dysplasia), ovarian cancer (ovarian cancer (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa theca cell tumor, Sertoli-Leydig cell tumor, dysgerminoma, malignant teratoma), vulvar cancer (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vaginal cancer (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), and fallopian tube cancer (carcinoma).

[0377] Exemplary skin cancers include melanoma, basal cell carcinoma, Merkel cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, hemangioma, dermatofibroma, and keloid. In some embodiments, diseases and indications that can be treated using the compounds of the present disclosure include, but are not limited to, sickle cell disease (e.g., sickle cell anemia), triple negative breast cancer (TNBC), myelodysplastic syndrome, testicular cancer, biliary tract cancer, esophageal cancer, and urothelial cancer.

[0378] It is believed that the solid forms and salts described herein may have a satisfactory pharmacological profile and promising biopharmaceutical properties, such as toxicological profiles, metabolic and pharmacokinetic properties, solubility and permeability. It should be understood that the determination of appropriate biopharmaceutical properties is within the knowledge of those skilled in the art, such as determining cytotoxicity in cells or inhibiting certain targets or pathways to determine potential toxicity.

[0379] The terms "individual," "patient," and "subject" are used interchangeably and refer to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, pigs, cows, sheep, horses, or primates, and most preferably humans.

[0380] The phrase "therapeutically effective amount" refers to that amount of an active compound or pharmaceutical agent that elicits the biological or medical response in a tissue, system, animal, individual or human that is being sought by the researcher, veterinarian, physician or other clinician.

[0381] As used herein, the terms "treating" or "treatment" refer to one or more of the following: (1) inhibiting a disease; e.g., inhibiting a disease, disorder or condition in a subject experiencing or displaying the pathology or symptoms of the disease, disorder or condition (i.e., preventing the pathology and / or symptoms from developing further); and (2) ameliorating a disease; e.g., ameliorating a disease, disorder or condition in a subject experiencing or displaying the pathology or symptoms of the disease, disorder or condition (i.e., reversing the pathology and / or symptoms), such as reducing the severity of the disease.

[0382] In some embodiments, the compounds of the invention are useful for preventing or reducing the risk of developing any of the diseases mentioned herein; for example, preventing or reducing the risk of developing a disease, disorder, or condition in an individual who may be susceptible to the disease, disorder, or condition but does not yet experience or display the signs or symptoms of the disease.

[0383] Combination therapy

[0384] I. Cancer Therapy

[0385] Cancer cell growth and survival can be affected by dysfunction in multiple signaling pathways. Therefore, it is useful to combine different enzyme / protein / receptor inhibitors that exhibit different preferences in the targets of the regulated activity to treat such disorders. Targeting more than one signaling pathway (or more than one biomolecule involved in a given signaling pathway) can reduce the likelihood of developing drug resistance in a cell population, and / or reduce the toxicity of the treatment.

[0386] One or more additional pharmaceutical agents (e.g., chemotherapeutic agents, anti-inflammatory agents, steroids, immunosuppressants, immune-oncology agents, metabolic enzyme inhibitors, chemokine receptor inhibitors, and phosphatase inhibitors) and targeted therapies (e.g., Bcr-Abl, Flt-3, EGFR, HER2, JAK, c-MET, VEGFR, PDGFR, c-Kit, IGF-1R, RAF, FAK, and CDK4 / 6 kinase inhibitors, such as those described in WO 2006 / 056399) can be used in combination with the compounds of the present disclosure for the treatment of CDK2-related diseases, disorders, or conditions. Other agents, such as therapeutic antibodies, can be used in combination with the compounds of the present disclosure for the treatment of CDK2-related diseases, disorders, or conditions. The one or more additional pharmaceutical agents can be administered to the patient simultaneously or sequentially.

[0387] In some embodiments, the solid forms and salts described herein are administered or used in combination with a BCL2 inhibitor or a CDK4 / 6 inhibitor.

[0388] Compounds as disclosed herein can be used in combination with one or more other enzyme / protein / receptor inhibitor therapies for the treatment of diseases, such as cancer and other diseases or conditions described herein. Examples of diseases and indications that can be treated using combination therapy include those diseases and indications described herein. Examples of cancer include solid tumors and non-solid tumors, such as liquid tumors and blood cancers. Examples of infections include viral infections, bacterial infections, fungal infections, or parasitic infections. For example, the compounds of the present disclosure can be combined with one or more inhibitors of the following kinases for the treatment of cancer: Akt1, Akt2, Akt3, BCL2, CDK4 / 6, TGF-βR, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IDH2, IGF-1R, IR-R, PDGFαR, PDGFβR, PI3K (α, β, γ, δ and multiple or selective), CSF1R, KIT, FLK-II , KDR / FLK-1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, PARP, Ron, Sea, TRKA, TRKB, TRKC, TAM kinases (Axl, Mer, Tyro3), FLT3, VEGFR / Flt2, Flt4, EphA1, EphA2, EphA3, EphB2, EphB4, Tie2, Src, Fyn, Lck, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK and B-Raf. In some embodiments, the compounds of the present disclosure can be combined with one or more of the following inhibitors for the treatment of cancer or infection. Non-limiting examples of inhibitors that can be combined with the compounds of the present disclosure for the treatment of cancer and infection include FGFR inhibitors (FGFR1, FGFR2, FGFR3, or FGFR4, such as pemigatinib (INCB54828), INCB62079), EGFR inhibitors (also known as ErB-1 or HER-1;(e.g., erlotinib, gefitinib, vandetanib, orsimertinib, cetuximab, necitumumab, or panitumumab), VEGFR inhibitors or pathway blockers (e.g., bevacizumab, pazopanib, sunitinib, sorafenib, axitinib, regorafenib, ponatinib, cabozantinib, vandetanib, ramucirumab, lenvatinib, ziv-aflibercept), PARP inhibitors (e.g., olaparib, rucaparib, vimicept), veliparib or niraparib), JAK inhibitors (JAK1 and / or JAK2 inhibitors, such as ruxolitinib or baricitinib; JAK1 inhibitors, such as itacitinib (INCB39110), INCB052793, or INCB054707), IDO inhibitors (such as epacadostat, NLG919, or BMS-98 6205, MK7162), LSD1 inhibitors (e.g., GSK2979552, INCB59872, and INCB60003), TDO inhibitors, PI3K-δ inhibitors (e.g., parsaclisib (INCB50465) or INCB50797), PI3K-γ inhibitors such as PI3K-γ selective inhibitors, Pim inhibitors (e.g., INCB53914), CSF1R inhibitors, TAM receptor tyrosine kinases (Tyro-3, Axl, and Mer;For example, INCB081776), adenosine receptor antagonists (e.g., A2a / A2b receptor antagonists), HPK1 inhibitors, chemokine receptor inhibitors (e.g., CCR2 or CCR5 inhibitors), SHP1 / 2 phosphatase inhibitors, histone deacetylase inhibitors (HDAC) such as HDAC8 inhibitors, angiogenesis inhibitors, interleukin receptor inhibitors, bromodomain and super-terminal family member inhibitors (e.g., bromodomain inhibitors or BET inhibitors such as INCB54329 and INCB57643), c-MET inhibitors (e.g., capmatinib), anti-CD19 antibodies (e.g., tafasitamab), ALK2 inhibitors (e.g., INCB00928); or combinations thereof. ;

[0389] In some embodiments, the solid forms and salts described herein are administered with PI3Kδ inhibitors. In some embodiments, the compounds or salts described herein are administered with JAK inhibitors. In some embodiments, the solid forms and salts described herein are administered with JAK1 or JAK2 inhibitors (e.g., baricitinib or ruxolitinib). In some embodiments, the solid forms and salts described herein are administered with JAK1 inhibitors. In some embodiments, the solid forms and salts described herein are administered with JAK1 inhibitors that are selectively superior to JAK2.

[0390] Example antibodies for use in combination therapy include, but are not limited to, trastuzumab (e.g., anti-HER2), ranibizumab (e.g., anti-VEGF-A), bevacizumab (AVASTIN TM , such as anti-VEGF), panitumumab (such as anti-EGFR), cetuximab (such as anti-EGFR), rituxan (anti-CD20), and antibodies against c-MET.

[0391] One or more of the following agents can be used in combination with the solid forms and salts described herein and are presented as a non-limiting list: cytostatics, cisplatin, doxorubicin, taxotere, paclitaxel, irinotecan, camptosar, topotecan, paclitaxel, docetaxel, epothilone, tamoxifen, 5-fluorouracil, methotrexate, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, IRESSA TM (gefitinib), TARCEVA TM (erlotinib), antibodies against EGFR, intron, ara-C, adriamycin, cytoxan, gemcitabine, uracil mustard, chlormethine, ifosfamide, melphalan, chlorambucil, pipobroman, triethylene melamine, triethylene thiophosphamide, busulfan, carmustine, lomustine, streptozocin, dacarbazine, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, oxaliplatin, leucovirin, ELOXATIN TM(oxaliplatin), pentostatin, vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, teniposide 17. alpha.-ethinylestradiol, diethylstilbestrol, testosterone, prednisone, fluoxymesterone, dromosterol propionate anolonepropionate, testolactone, megestrolacetate, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chlorotrianisene, hydroxyprogesterone oxyprogesterone, aminoglutethimide, estramustine, medroxyprogesterone acetate, leuprolide, flutamide, toremifene, goserelin, carboplatin, hydroxyurea, amsacrine, procarbazine, mitotane, mitoxantrone, levamisole, navelbene, anastrazole, letrazole, capecitabine, reloxafine, droloxafine, hexamethylmelamine, avastin, HERCEPTIN TM (trastuzumab), BEXXA R TM (tositumomab), VELCADE TM(bortezomib), ZEVALIN TM (ibritumomab tiuxetan), TRISENOX TM (arsenic trioxide), XELODA TM (capecitabine), vinorelbine, porfimer, ERBITUX TM (cetuximab), thiotepa, altretamine, melphalan, trastuzumab, letrozole, fulvestrant, exemestane, ifosfamide, rituximab, C225 (cetuximab), Campath (alemtuzumab), clofarabine, cladribine, aphidicolon, restuxan, sunitinib, dasatinib, tezacitabine, Sml1, fludarabine, pentostatin, triapine, didox, trimidox, amidox, 3-AP, and MDL-101,731.

[0392] Solid forms and salts described herein can be further used in combination with other methods for treating cancer, such as chemotherapy, irradiation therapy, tumor-targeted therapy, adjuvant therapy, immunotherapy or surgery. Examples of immunotherapy include cytokine therapy (e.g., interferon, GM-CSF, G-CSF, IL-2), CRS-207 immunotherapy, cancer vaccines, monoclonal antibodies, bispecific or multispecific antibodies, antibody drug conjugates, adoptive T cell transfer, Toll receptor agonists, RIG-I agonists, oncolytic virus therapy and immunomodulatory small molecules, including thalidomide or JAK1 / 2 inhibitors, PI3Kδ inhibitors, etc. The compound can be administered in combination with one or more anticancer drugs (e.g., chemotherapeutic agents). Examples of chemotherapeutic agents include any of the following: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, hexamethylmelamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bevacizumab, bexarotene, baricitinib, bleomycin, bortezomib, intravenous busulfan, oral busulfan, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, actinomycin D, dalteparin sodium sodium), dasatinib, daunomycin, decitabine, denileukin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, drostanolone propionate, eculizumab, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylatemesylate, interferon α2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, meclorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine, nofetumomab, oxaliplatin, paclitaxel, pamidronate, panitumumab, pegaspargase, pegfilgrastim, pemetrexed disodium), pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib, sorafenib, streptozotocin, sunitinib, sunitinib maleate, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinostat, and zoledronate.

[0393] Additional examples of chemotherapeutic agents include proteasome inhibitors (eg, bortezomib), thalidomide, revlimid, and DNA damaging agents, such as melphalan, doxorubicin, cyclophosphamide, vincristine, etoposide, carmustine, and the like.

[0394] Example steroids include corticosteroids, such as dexamethasone or prednisone.

[0395] Example Bcr-Abl inhibitors include imatinib mesylate (GLEEVAC TM ), nilotinib, dasatinib, bosutinib and ponatinib and pharmaceutically acceptable salts. Other suitable examples of Bcr-Abl inhibitors include compounds of the genus and species disclosed in U.S. Pat. No. 5,521,184, WO 04 / 005281 and U.S. Pat. No. 60 / 578,491 and pharmaceutically acceptable salts thereof.

[0396] Suitable example Flt-3 inhibitors include midostaurin, lestaurtinib, linifanib, sunitinib, sunitinib maleate, sorafenib, quizartinib, crenolanib, pacritinib, tandutinib, PLX3397 and ASP2215 and pharmaceutically acceptable salts thereof. Other suitable example Flt-3 inhibitors include compounds disclosed in WO 03 / 037347, WO 03 / 099771 and WO 04 / 046120 and pharmaceutically acceptable salts thereof.

[0397] Suitable example RAF inhibitors include dabrafenib, sorafenib and vemurafenib and pharmaceutically acceptable salts thereof. Other suitable example RAF inhibitors include compounds disclosed in WO 00 / 09495 and WO 05 / 028444 and pharmaceutically acceptable salts thereof.

[0398] Suitable example FAK inhibitors include VS-4718, VS-5095, VS-6062, VS-6063, BI853520 and GSK2256098 and pharmaceutically acceptable salts thereof. Other suitable example FAK inhibitors include compounds disclosed in WO 04 / 080980, WO 04 / 056786, WO 03 / 024967, WO 01 / 064655, WO 00 / 053595 and WO 01 / 014402 and pharmaceutically acceptable salts thereof.

[0399] Suitable examples of CDK4 / 6 inhibitors include palbociclib, ribociclib, trilaciclib, lerociclib and abemaciclib and pharmaceutically acceptable salts thereof. Other suitable examples of CDK4 / 6 inhibitors include compounds disclosed in WO 09 / 085185, WO 12 / 129344, WO 11 / 101409, WO 03 / 062236, WO 10 / 075074 and WO 12 / 061156 and pharmaceutically acceptable salts thereof.

[0400] In some embodiments, the solid forms and salts described herein can be used in combination with one or more other kinase inhibitors, including imatinib, particularly for treating patients who are resistant to imatinib or other kinase inhibitors.

[0401] In some embodiments, the solid forms and salts described herein can be used in combination with chemotherapeutic agents in cancer treatment, and can improve the treatment response compared to the response to a single chemotherapeutic agent without exacerbating its toxic effects. In some embodiments, the solid forms and salts described herein can be used in combination with chemotherapeutic agents provided herein. For example, the additional pharmaceutical agents used in the treatment of multiple myeloma may include, but are not limited to, melphalan, melphalan plus prednisone [MP], doxorubicin, dexamethasone, and Velcade (bortezomib). Other additional agents used in the treatment of multiple myeloma include Bcr-Abl, Flt-3, RAF, and FAK kinase inhibitors. In some embodiments, the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulator. Examples of alkylating agents include cyclophosphamide (CY), melphalan (MEL), and bendamustine. In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (DEX). In some embodiments, the immunomodulator is lenalidomide (LEN) or pomalidomide (POM).Additive or synergistic effects of combining the CDK2 inhibitors of the present disclosure with additional agents are desirable outcomes.

[0402] The agents may be combined with the solid forms and salts described herein in a single or sequential dosage form, or the agents may be administered simultaneously or sequentially as separate dosage forms.

[0403] The solid forms and salts described herein can be used in combination with one or more other inhibitors or one or more therapies for treating infections. Examples of infections include viral infections, bacterial infections, fungal infections, or parasitic infections.

[0404] In some embodiments, a corticosteroid (eg, dexamethasone) is administered to a patient in combination with the solid forms and salts described herein, wherein the dexamethasone is administered intermittently rather than continuously.

[0405] The solid forms and salts described herein can be combined with another immunogenic agent, such as cancer cells, purified tumor antigens (including recombinant proteins, peptides and carbohydrate molecules), cells and cells transfected with genes encoding immunostimulatory cytokines. Non-limiting examples of tumor vaccines that can be used include peptides of melanoma antigens, such as gp100, MAGE antigens, Trp-2, MARTI and / or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF.

[0406] The solid forms and salts described herein can be used in combination with vaccination regimens for the treatment of cancer. In some embodiments, tumor cells are transduced to express GM-CSF. In some embodiments, tumor vaccines include proteins from viruses associated with human cancers, such as human papillomavirus (HPV), hepatitis viruses (HBV and HCV), and Kaposi's herpes sarcoma virus (KHSV). In some embodiments, the compounds of the present disclosure can be used in combination with tumor-specific antigens (e.g., heat shock proteins isolated from tumor tissue itself). In some embodiments, the solid forms and salts described herein can be combined with dendritic cell immunity to activate a potent anti-tumor response.

[0407] The solid forms and salts described herein can be used in combination with bispecific macrocyclic peptides that target effector cells expressing Fcα or Fcγ receptors to tumor cells. The solid forms and salts described herein can also be combined with macrocyclic peptides that activate host immune responses.

[0408] In some other embodiments, the solid forms and salts described herein can be administered to patients before, during and / or after bone marrow transplantation or stem cell transplantation in combination with other therapeutic agents. The solid forms and salts described herein can be used in combination with bone marrow transplantation for the treatment of tumors of various hematopoietic origin.

[0409] The solid forms and salts described herein can be used in combination with vaccines to stimulate immune responses to pathogens, toxins, and self-antigens. Examples of pathogens for which such treatment methods may be particularly useful include pathogens for which there are currently no effective vaccines or pathogens for which conventional vaccines are not fully effective. These pathogens include, but are not limited to, HIV, hepatitis (A, B, and C), influenza, herpes, Giardia, malaria, Leishmania, Staphylococcus aureus, Pseudomonas Aeruginosa.

[0410] Viruses causing infections treatable by the methods of the present disclosure include, but are not limited to, human papillomavirus, influenza, hepatitis A, B, C, or D virus, adenovirus, poxvirus, herpes simplex virus, human cytomegalovirus, severe acute respiratory syndrome virus, Ebola virus, measles virus, herpes virus (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein Barr virus), flavivirus, echovirus, rhinovirus, coxsackie virus, coronavirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, polio virus, rabies virus, JC virus, and arboviral encephalitis virus.

[0411] Pathogenic bacteria causing infections treatable by the methods of the present disclosure include, but are not limited to, chlamydia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci and gonococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme's disease bacteria.

[0412] Pathogenic fungi that can be treated by the methods of the present disclosure include, but are not limited to, Candida (Candida albicans, Candida krusei, Candida glabrata, Candida tropicalis, etc.), Cryptococcus neoformans, Aspergillus (Aspergillus fumigatus, Aspergillus niger, etc.), Genus Mucorales (Mucorales mucor, Mucorales absidia, Mucorales rhizophus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis, etc. immitis and Histoplasma capsulatum.

[0413] Pathogenic parasites that cause infections that can be treated by the methods of the present disclosure include, but are not limited to, Entamoeba histolytica, Balantidium coli, Naegleria fowleri, Acanthamoeba sp., Giardia lamblia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, and Nippostrongylus brasiliensis.

[0414] When more than one pharmaceutical agent is administered to a patient, they may be administered simultaneously, separately, sequentially, or in combination (eg, for more than two agents).

[0415] Methods for safe and effective administration of most of these chemotherapeutic agents are known to those skilled in the art. In addition, their administration is described in standard literature. For example, the administration of many chemotherapeutic agents is described in "Physicians' Desk Reference" (PDR, e.g., 1996 edition, Medical Economics Company, Montvale, NJ), the disclosure of which is incorporated herein by reference as if set forth in its entirety.

[0416] II. Immune Checkpoint Therapy

[0417] The solid form and salt described herein can be used in combination with one or more immune checkpoint inhibitors for treating diseases, such as cancer or infection. Exemplary immune checkpoint inhibitors include inhibitors for immune checkpoint molecules, such as CBL-B, CD20, CD28, CD40, CD70, CD122, CD96, CD73, CD47, CDK2, GITR, CSF1R, JAK, PI3Kδ, PI3Kγ, TAM, arginase, HPK1, CD137 (also known as 4-1BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, TLR (TLR7 / 8), TIGIT, CD112R, VISTA, PD-1, PD-L1 and PD-L2. In some embodiments, the immune checkpoint molecule is a stimulatory checkpoint molecule selected from the following: CD27, CD28, CD40, ICOS, OX40, GITR and CD137. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from the following: A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, TIGIT and VISTA. In some embodiments, the solid forms and salts described herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors and TGFRβ inhibitors.

[0418] In some embodiments, the solid forms and salts described herein may be used in combination with one or more agonists of immune checkpoint molecules, such as OX40, CD27, GITR, and CD137 (also known as 4-1BB).

[0419] In some embodiments, the immune checkpoint molecule inhibitor is an anti-PD1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody.

[0420] In some embodiments, the immune checkpoint molecule inhibitor is an inhibitor of PD-1 or PD-L1, such as an anti-PD-1 or anti-PD-L1 monoclonal antibody. In some embodiments, the anti-PD-1 or anti-PD-L1 antibody is nivolumab, pembrolizumab, atezolizumab, durval umab, avelumab, cemiplimab, atezolizumab, avelumab, tislelizumab, spartalizumab, or mab)(PDR001), cetrelimab(JNJ-63723283), toripalimab(JS001), camrelizumab(SHR-1210), sintilimab(IBI308), AB122(GLS-010), AMP-224, AMP-514 / MEDI-0680, BMS936559, JTX-4014, BGB-108, SHR-1210, MEDI4736, FAZ053, BCD-100, KN035, CS1001, BAT1306, LZM009, AK105, HLX10, SHR-1316, CBT- 502(TQB2450), A167(KL-A167), STI-A101(ZKAB001), CK-301, BGB-A333, MSB-2311, HLX20, TSR-042 or LY3300054. In some embodiments, the inhibitor of PD-1 or PD-L1 is an inhibitor disclosed in U.S. Pat. Nos. 7,488,802, 7,943,743, 8,008,449, 8,168,757, 8,217,149, WO03042402, WO 2008156712, WO 2010089411, WO 2010036959, WO 2011066342, WO2011159877, WO 2011082400, or WO 2011161699, each of which is herein incorporated by reference in its entirety.

[0421] In some embodiments, the antibody is an anti-PD-1 antibody, such as an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 antibody is nivolumab, pembrolizumab, cemiprilimab, spartuzumab, carrelizumab, setrelimumab, terelizumab, sintilimab, AB122, AMP-224, JTX-4014, BGB-108, BCD-100, BAT1306, LZM009, AK105, HLX10 or TSR-042. In some embodiments, the anti-PD-1 antibody is nivolumab, pembrolizumab, cemiprilimab, spartuzumab, carrelizumab, setrelimumab, terelizumab or sintilimab. In some embodiments, the anti-PD-1 antibody is pembrolizumab. In some embodiments, the anti-PD-1 antibody is nivolumab. In some embodiments, the anti-PD-1 antibody is cemiplizumab. In some embodiments, the anti-PD-1 antibody is spazumab. In some embodiments, the anti-PD-1 antibody is camrelizumab. In some embodiments, the anti-PD-1 antibody is selelimumab. In some embodiments, the anti-PD-1 antibody is terelizumab. In some embodiments, the anti-PD-1 antibody is sintilimab. In some embodiments, the anti-PD-1 antibody is AB122. In some embodiments, the anti-PD-1 antibody is AMP-224. In some embodiments, the anti-PD-1 antibody is JTX-4014. In some embodiments, the anti-PD-1 antibody is BGB-108. In some embodiments, the anti-PD-1 antibody is BCD-100. In some embodiments, the anti-PD-1 antibody is BAT1306. In some embodiments, the anti-PD-1 antibody is LZM009. In some embodiments, the anti-PD-1 antibody is AK105. In some embodiments, the anti-PD-1 antibody is HLX10. In some embodiments, the anti-PD-1 antibody is TSR-042. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab. In some embodiments, the anti-PD-1 monoclonal antibody is MGA012. In some embodiments, the anti-PD1 antibody is SHR-1210. Other anticancer agents include antibody therapeutics, such as 4-1BB (e.g., urelumab, utomilumab). In some embodiments, the immune checkpoint molecule inhibitor is a PD-L1 inhibitor, such as an anti-PD-L1 monoclonal antibody.In some embodiments, the anti-PD-L1 monoclonal antibody is atezolizumab, avelumab, durvalumab, tisarezumab, BMS-935559, MEDI4736, atezolizumab (MPDL3280A; also known as RG7446), avelumab (MSB0010718C), FAZ053, KN035, CS1001, SHR-1316, CBT-502, A167, STI-A101, CK-301, BGB-A333, MSB-2311, HLX20, or LY3300054. In some embodiments, the anti-PD-L1 antibody is atezolizumab, avelumab, durvalumab, or tisarezumab. In some embodiments, the anti-PD-L1 antibody is atezolizumab. In some embodiments, the anti-PD-L1 antibody is avelumab. In some embodiments, the anti-PD-L1 antibody is durvalumab. In some embodiments, the anti-PD-L1 antibody is tisarezumab. In some embodiments, the anti-PD-L1 antibody is BMS-935559. In some embodiments, the anti-PD-L1 antibody is MEDI4736. In some embodiments, the anti-PD-L1 antibody is FAZ053. In some embodiments, the anti-PD-L1 antibody is KN035. In some embodiments, the anti-PD-L1 antibody is CS1001. In some embodiments, the anti-PD-L1 antibody is SHR-1316. In some embodiments, the anti-PD-L1 antibody is CBT-502. In some embodiments, the anti-PD-L1 antibody is A167. In some embodiments, the anti-PD-L1 antibody is STI-A101. In some embodiments, the anti-PD-L1 antibody is CK-301. In some embodiments, the anti-PD-L1 antibody is BGB-A333. In some embodiments, the anti-PD-L1 antibody is MSB-2311. In some embodiments, the anti-PD-L1 antibody is HLX20. In some embodiments, the anti-PD-L1 antibody is LY3300054.

[0422] In some embodiments, the immune checkpoint molecule inhibitor is a small molecule or a pharmaceutically acceptable salt thereof that is bound to PD-L1. In some embodiments, the immune checkpoint molecule inhibitor is a small molecule or a pharmaceutically acceptable salt thereof that is bound to PD-L1 and internalized by PD-L1. In some embodiments, the immune checkpoint molecule inhibitor is a compound or a pharmaceutically acceptable salt thereof selected from US2018 / 0179201, US2018 / 0179197, US2018 / 0179179, US 2018 / 0179202, US2018 / 0177784, US2018 / 0177870, the U.S. No. 16 / 369,654 (filed on March 29, 2019) and the U.S. No. 62 / 688,164, each of which is incorporated herein by reference in its entirety.

[0423] In some embodiments, the immune checkpoint molecule inhibitor is an inhibitor of KIR, TIGIT, LAIR1, CD160, 2B4 and TGFRβ.

[0424] In some embodiments, the inhibitor is MCLA-145.

[0425] In some embodiments, the immune checkpoint molecule inhibitor is a CTLA-4 inhibitor, such as an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab, tremelimumab, AGEN1884 or CP-675,206.

[0426] In some embodiments, the immune checkpoint molecule inhibitor is a LAG3 inhibitor, such as an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016, LAG525, INCAGN2385, or eftilagimod alpha (IMP321).

[0427] In some embodiments, the immune checkpoint molecule inhibitor is a CD73 inhibitor. In some embodiments, the CD73 inhibitor is oleclumab.

[0428] In some embodiments, the immune checkpoint molecule inhibitor is a TIGIT inhibitor. In some embodiments, the TIGIT inhibitor is OMP-31M32.

[0429] In some embodiments, the immune checkpoint molecule inhibitor is a VISTA inhibitor. In some embodiments, the VISTA inhibitor is JNJ-61610588 or CA-170.

[0430] In some embodiments, the immune checkpoint molecule inhibitor is a B7-H3 inhibitor. In some embodiments, the B7-H3 inhibitor is enoblituzumab, MGD009 or 8H9.

[0431] In some embodiments, the immune checkpoint molecule inhibitor is a KIR inhibitor. In some embodiments, the KIR inhibitor is lirilumab or IPH4102.

[0432] In some embodiments, the immune checkpoint molecule inhibitor is an A2aR inhibitor. In some embodiments, the A2aR inhibitor is CPI-444.

[0433] In some embodiments, the immune checkpoint molecule inhibitor is a TGF-β inhibitor. In some embodiments, the TGF-β inhibitor is trabedersen, galusertinib, or M7824.

[0434] In some embodiments, the immune checkpoint molecule inhibitor is a PI3K-γ inhibitor. In some embodiments, the PI3K-γ inhibitor is IPI-549.

[0435] In some embodiments, the immune checkpoint molecule inhibitor is a CD47 inhibitor. In some embodiments, the CD47 inhibitor is Hu5F9-G4 or TTI-621.

[0436] In some embodiments, the immune checkpoint molecule inhibitor is a CD73 inhibitor. In some embodiments, the CD73 inhibitor is MEDI9447.

[0437] In some embodiments, the immune checkpoint molecule inhibitor is a CD70 inhibitor. In some embodiments, the CD70 inhibitor is cusatuzumab or BMS-936561.

[0438] In some embodiments, the immune checkpoint molecule inhibitor is a TIM3 inhibitor, such as an anti-TIM3 antibody. In some embodiments, the anti-TIM3 antibody is INCAGN2390, MBG453 or TSR-022.

[0439] In some embodiments, the immune checkpoint molecule inhibitor is a CD20 inhibitor, such as an anti-CD20 antibody. In some embodiments, the anti-CD20 antibody is obinutuzumab or rituximab.

[0440] In some embodiments, the agonist of an immune checkpoint molecule is an agonist of OX40, CD27, CD28, GITR, ICOS, CD40, TLR7 / 8, and CD137 (also known as 4-1BB).

[0441] In some embodiments, the CD137 agonist is Urelumab. In some embodiments, the CD137 agonist is Urelumab.

[0442] In some embodiments, the agonist of the immune checkpoint molecule is a GITR inhibitor. In some embodiments, the GITR agonist is TRX518, MK-4166, INCAGN1876, MK-1248, AMG228, BMS-986156, GWN323, MEDI1873 or MEDI6469. In some embodiments, the agonist of the immune checkpoint molecule is an OX40 agonist, such as an OX40 agonist antibody or an OX40L fusion protein. In some embodiments, the anti-OX40 antibody is INCAGN01949, MEDI0562 (tavolimab), MOXR-0916, PF-04518600, GSK3174998, BMS-986178 or 9B12. In some embodiments, the OX40L fusion protein is MEDI6383.

[0443] In some embodiments, the agonist of the immune checkpoint molecule is a CD40 agonist. In some embodiments, the CD40 agonist is CP-870893, ADC-1013, CDX-1140, SEA-CD40, RO7009789, JNJ-64457107, APX-005M or Chi Lob 7 / 4.

[0444] In some embodiments, the agonist of the immune checkpoint molecule is an ICOS agonist. In some embodiments, the ICOS agonist is GSK-3359609, JTX-2011 or MEDI-570.

[0445] In some embodiments, the agonist of the immune checkpoint molecule is a CD28 agonist. In some embodiments, the CD28 agonist is theralizumab.

[0446] In some embodiments, the agonist of the immune checkpoint molecule is a CD27 agonist. In some embodiments, the CD27 agonist is varlilumab.

[0447] In some embodiments, the agonist of the immune checkpoint molecule is a TLR7 / 8 agonist. In some embodiments, the TLR7 / 8 agonist is MEDI9197.

[0448] The solid forms and salts described herein can be used in combination with bispecific antibodies. In some embodiments, one domain of the bispecific antibody targets PD-1, PD-L1, CTLA-4, GITR, OX40, TIM3, LAG3, CD137, ICOS, CD3 or TGFβ receptor. In some embodiments, the bispecific antibody binds to PD-1 and PD-L1. In some embodiments, the bispecific antibody that binds to PD-1 and PD-L1 is MCLA-136. In some embodiments, the bispecific antibody binds to PD-L1 and CTLA-4. In some embodiments, the bispecific antibody that binds to PD-L1 and CTLA-4 is AK104.

[0449] In some embodiments, the solid forms and salts described herein can be used in combination with one or more metabolic enzyme inhibitors. In some embodiments, the metabolic enzyme inhibitor is an inhibitor of IDO1, TDO or arginase. Examples of IDO1 inhibitors include epasistat, NLG919, BMS-986205, PF-06840003, IOM2983, RG-70099 and LY338196.

[0450] As provided throughout, other compounds, inhibitors, agents, etc. can be combined with the compounds of the present invention in a single or sequential dosage form, or they can be administered simultaneously or sequentially as separate dosage forms.

[0451] Drug preparations and dosage forms

[0452] When used as a drug, the solid forms and salts described herein can be administered in the form of a pharmaceutical composition. These compositions can be prepared in a manner well known in the medical field and can be administered by a variety of routes, depending on whether local or systemic treatment is desired and the area to be treated. Administration can be topical (including transdermal, epidermal, ocular and to mucous membranes, including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by a nebulizer; intratracheal or intranasal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial (e.g., intrathecal or intraventricular) administration. Parenteral administration can be in the form of a single bolus dose, or can be implemented, for example, by a continuous infusion pump. Pharmaceutical compositions and preparations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powdered or oily bases, thickeners, etc. may be necessary or desired.

[0453] The present disclosure also includes pharmaceutical compositions containing solid forms and salts described herein as active ingredients in combination with one or more pharmaceutically acceptable carriers (excipients). In some embodiments, the composition is suitable for topical application. When preparing the composition of the present disclosure, the active ingredient is usually mixed with an excipient, diluted with an excipient or encapsulated in such a carrier in the form of, for example, a capsule, a sachet, paper or other container. When an excipient is used as a diluent, it can be a solid, semisolid or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Therefore, the composition can be in the following forms: tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (in solid form or in a liquid medium), ointments containing, for example, up to 10% by weight of active compounds, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.

[0454] In preparing the formulation, the active compound may be milled to provide an appropriate particle size prior to combining with other ingredients. If the active compound is substantially insoluble, it may be milled to a particle size of less than 200 mesh. If the active compound is substantially soluble in water, the particle size may be adjusted by milling to provide a substantially uniform distribution in the formulation, for example, about 40 mesh.

[0455] The solid forms and salts described herein can be milled using known milling procedures (e.g., wet milling) to obtain particle sizes suitable for tablet formulations and other formulation types. Fine powder (nanoparticulate) formulations of the disclosed compounds can be prepared by methods known in the art, for example, see International Application No. WO 2002 / 000196.

[0456] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup and methylcellulose. The formulation may additionally include: lubricants, such as talc, magnesium stearate and mineral oil; wetting agents; emulsifiers and suspending agents; preservatives, such as methyl hydroxybenzoate and propyl hydroxybenzoate; sweeteners; and flavoring agents. The compositions of the present disclosure may be formulated so as to provide rapid, sustained or delayed release of the active ingredient after administration to a patient by employing procedures known in the art.

[0457] The composition can be formulated in unit dosage form, each dose containing about 5 to about 1000 mg (1 g) or more, for example, about 100 to about 500 mg of active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

[0458] In some embodiments, the compositions of the present disclosure contain about 5 to about 50 mg of active ingredient. Those of ordinary skill in the art will appreciate that this includes compositions containing about 5 to about 10 mg, about 10 to about 15 mg, about 15 to about 20 mg, about 20 to about 25 mg, about 25 to about 30 mg, about 30 to about 35 mg, about 35 to about 40 mg, about 40 to about 45 mg, or about 45 to about 50 mg of active ingredient.

[0459] In some embodiments, the compositions of the present disclosure contain about 50 to about 500 mg of active ingredient. Those of ordinary skill in the art will appreciate that this includes compositions containing about 50 to about 100 mg, about 100 to about 150 mg, about 150 to about 200 mg, about 200 to about 250 mg, about 250 to about 300 mg, about 350 to about 400 mg, or about 450 to about 500 mg of active ingredient.

[0460] In some embodiments, the compositions of the present disclosure contain about 500 to about 1000 mg of active ingredient. Those of ordinary skill in the art will appreciate that this includes compositions containing about 500 to about 550 mg, about 550 to about 600 mg, about 600 to about 650 mg, about 650 to about 700 mg, about 700 to about 750 mg, about 750 to about 800 mg, about 800 to about 850 mg, about 850 to about 900 mg, about 900 to about 950 mg, or about 950 to about 1000 mg of active ingredient.

[0461] Similar dosages of the compounds described herein may be used in the methods and uses of the present disclosure.

[0462] The active compound can be effective within a wide dosage range and is generally administered in a pharmaceutically effective amount. However, it should be understood that the amount of compound actually administered will generally be determined by a physician based on relevant circumstances, including the condition to be treated, the selected route of administration, the actual compound administered, the age, weight and response of the individual patient, the severity of the patient's symptoms, etc.

[0463] In order to prepare a solid composition (e.g., tablet), the main active ingredient is mixed with a pharmaceutical excipient to form a solid preformulated composition containing a homogeneous mixture of the solid form and salt described herein. When these preformulated compositions are referred to as homogeneous, the active ingredient is generally evenly dispersed throughout the composition so that the composition can be easily subdivided into equally effective unit dosage forms, such as tablets, pills, and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above, containing, for example, about 0.1 to about 1000 mg of the active ingredient of the present disclosure.

[0464] Tablets or pills of the present disclosure may be coated or otherwise compounded to provide a dosage form with a lasting effect advantage. For example, the tablet or pill may include an inner dosage component and an outer dosage component, the latter being in the form of a coating on the former. The two components may be separated by an enteric layer that is used to resist disintegration in the stomach and allow the inner component to pass intact into the duodenum or to delay release. A variety of materials may be used for such enteric layers or coatings, including a variety of polymeric acids and mixtures of polymeric acids with materials such as shellac, cetyl alcohol, and cellulose acetate.

[0465] Liquid forms in which the compounds and compositions of the present disclosure may be incorporated for oral or injection administration include aqueous solutions, suitably flavored syrups, aqueous or oily suspensions and emulsions flavored with edible oils (e.g., cottonseed oil, sesame oil, coconut oil, or peanut oil), as well as elixirs and similar pharmaceutical vehicles.

[0466] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents or mixtures thereof, and powders. Liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described above. In some embodiments, the composition is administered by oral or nasal respiratory route to obtain local or systemic effects. The composition can be atomized by using an inert gas. The atomized solution can be breathed directly from the atomizing device or the atomizing device can be attached to a mask, curtain, or intermittent positive pressure breathing machine. Solutions, suspensions, or powder compositions can be administered orally or nasally from a device that delivers the formulation in an appropriate manner.

[0467] The topical preparation may contain one or more conventional carriers. In some embodiments, the ointment may contain water and one or more hydrophobic carriers selected from, for example, liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white vaseline, etc. The carrier composition of the cream may be based on a combination of water with glycerol and one or more other components (e.g., glycerol monostearate, PEG-glycerol monostearate, and cetyl stearyl alcohol). The gel may be prepared using isopropyl alcohol and water, suitably in combination with other components (e.g., glycerol, hydroxyethyl cellulose, etc.). In some embodiments, the topical preparation contains at least about 0.1wt%, at least about 0.25wt%, at least about 0.5wt%, at least about 1wt%, at least about 2wt%, or at least about 5wt% of the compound of the present disclosure. The topical preparation may be suitably packaged in, for example, a 100g tube, which optionally has instructions for treating selected indications (e.g., psoriasis or other skin disorders).

[0468] The amount of active ingredient or composition administered to a patient will vary depending on the drug being administered, the purpose of administration (e.g., prevention or treatment), the patient's state, the mode of administration, etc. In therapeutic applications, the composition can be administered to a patient already suffering from the disease in an amount sufficient to cure or at least partially prevent the symptoms of the disease and its complications. The effective dose will depend on the disease condition being treated and the judgment of the attending clinician based on factors such as the severity of the disease, the patient's age, weight, and general condition.

[0469] The composition administered to the patient may be in the form of a pharmaceutical composition as described above. These compositions may be sterilized by conventional sterilization techniques, or may be aseptically filtered. The aqueous solution may be packaged for use as is, or lyophilized, and the lyophilized preparation may be combined with a sterile aqueous carrier prior to administration. The pH of the compound formulation will generally be between 3 and 11, more preferably 5 to 9 and most preferably 7 to 8. It should be understood that the use of some of the above-mentioned excipients, carriers or stabilizers will form a pharmaceutical salt.

[0470] The therapeutic dose of the solid forms and salts described herein may vary according to, for example, the specific use of the treatment being performed, the mode of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The ratio or concentration of the compounds disclosed herein in the pharmaceutical composition may vary according to a variety of factors, including dosage, chemical properties (e.g., hydrophobicity), and route of administration. For example, the solid forms and salts described herein may be provided in a physiologically buffered aqueous solution containing about 0.1% to about 10% w / v of the compound for parenteral administration. Some typical dosage ranges are from about 1 μg / kg body weight / day to about 1 g / kg body weight / day. In some embodiments, the dosage range is from about 0.01 mg / kg body weight / day to about 100 mg / kg body weight / day. The dosage may depend on, for example, the following variables: the type and degree of progression of the disease or condition, the overall health status of a particular patient, the relative biological efficacy of the selected compound, the formulation of the excipient, and its route of administration. The effective dose may be extrapolated from a dose-response curve derived from an in vitro or animal model test system.

[0471] The compositions of the present disclosure may also include one or more additional pharmaceutical agents, such as chemotherapeutic agents, steroids, anti-inflammatory compounds, or immunosuppressants, examples of which are listed herein.

[0472] Pill Box

[0473] The present disclosure also includes a pharmaceutical kit that can be used, for example, to treat or prevent a CDK2-related disease or condition (e.g., cancer, inflammatory disease, cardiovascular disease, or neurodegenerative disease), comprising one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a solid form and salt as described herein. As will be apparent to those skilled in the art, such kits may also include one or more of various conventional pharmaceutical kit components, such as containers containing one or more pharmaceutically acceptable carriers, additional containers, etc., when necessary. Instructions (as inserts or as labels) indicating the amount of the components to be administered, guidelines for administration, and / or guidelines for mixing the components may also be included in the kit.

[0474] Biomarkers and pharmacodynamic markers

[0475] The present disclosure also provides predictive markers (e.g., biomarkers and pharmacodynamic markers, such as gene copy number, gene sequence, expression level, or phosphorylation level) to identify those human subjects who have, are suspected of having, or are at risk of a disease or condition associated with CDK2 and for whom administration of a CDK2 inhibitor (as used herein, "CDK2 inhibitor" refers to the solid form and salt described herein) is likely to be effective. The present disclosure also provides pharmacodynamic markers (e.g., phosphorylation levels) to identify those human subjects who have, are suspected of having, or are at risk of a disease or condition associated with CDK2 and who respond to a CDK2 inhibitor. The uses of CCNE1, p16, and Rb S780 are further described in U.S. Patent Publication No. 2020 / 0316064), the drawings and disclosures of which are incorporated herein by reference in their entirety.

[0476] The method is based at least in part on the discovery that the functional status of cyclin-dependent kinase inhibitor 2A ("CDKN2A"; also known as "p16") is a biomarker for predicting the sensitivity of G1 / S-specific cyclin-E1- ("CCNE1-") amplified cells to CDK2 targeted therapies suitable for patient stratification. In addition, the present disclosure is based at least in part on the discovery that in CCNE1 amplified cell lines, the phosphorylation level of human retinoblastoma-related protein ("Rb") at the serine corresponding to amino acid position 780 of SEQ ID NO:3 is a pharmacodynamic marker of CDK2 activity and is suitable for measuring CDK2 enzyme activity in cell assays or preclinical and clinical applications, such as monitoring the progress of treatment with CDK2 inhibitors or responsiveness to the treatment.

[0477] CCNE1 and p16

[0478] CCNE1 and p16 have been identified in the Examples as a gene combination that can be used to predict responsiveness (eg, disease improvement as evidenced by disease remission / regression) to a CDK2 inhibitor in a subject suffering from a disease or disorder associated with CDK2.

[0479] p16 (also known as cyclin-dependent kinase inhibitor 2A, cyclin-dependent kinase 4 inhibitor A, multiple tumor suppressor gene 1, and p16-INK4a) acts as a negative regulator of normal cell proliferation by interacting with CDK4 and CDK6. p16 is encoded by the cyclin-dependent kinase inhibitor 2A ("CDKN2A") gene (GenBank accession number NM_000077). The cytogenetic location of the CDKN2A gene is 9p21.3, which is the short (p) arm of chromosome 9 at position 21.3. The molecular location of the CDKN2A gene is base pairs 21,967,752 to 21,995,043 on chromosome 9 (Homo sapiens annotation release 109, GRCh38.p12). It is believed that genetic and epigenetic abnormalities in the gene encoding p16 lead to escape from aging and cancer formation (Okamoto et al., 1994, PNAS 91 (23): 11045-9). Non-limiting examples of genetic abnormalities in the gene encoding p16 are described in Table A below. The amino acid sequence of human p16 is provided below (GenBank Accession No. NP_000068 / UniProtKB Accession No. P42771):

[0480]

[0481] CCNE1 is a cell cycle factor that is essential for controlling the cell cycle during the G1 / S transition (Ohtsubo et al., 1995, Mol. Cell. Biol. 15: 2612-2624). CCNE1 acts as a regulatory subunit of CDK2, interacting with CDK2 to form a serine / threonine kinase holoenzyme complex. The CCNE1 subunit of this holoenzyme complex provides the substrate specificity of the complex (Honda et al., 2005, EMBO 24: 452-463). CCNE1 is encoded by the cyclin E1 ("CCNE1") gene (GenBank Accession No. NM_001238). The amino acid sequence of human CCNE1 is provided below (GenBank Accession No. NP_001229 / UniProtKB Accession No. P24864):

[0482]

[0483] The Examples demonstrate that CDK2 knockdown inhibits proliferation of CCNE1 amplified cell lines, but not CCNE1 non-amplified cell lines. In contrast, the Examples show that CDK4 / 6 inhibition inhibits proliferation of CCNE1 non-amplified cell lines, but not CCNE1 amplified cell lines. The Examples further demonstrate that in CCNE1 amplified cells treated with CDK2 inhibitors, the presence of a normal (e.g., non-mutated or non-deleted) p16 gene is necessary to observe inhibition of cell proliferation. Therefore, CCNE1 and p16 together are a combination biomarker: cells that respond to CDK2 inhibitor treatment show amplification of the CCNE1 gene and / or a CCNE1 expression level that is higher than the control expression level of CCNE1, and have a nucleotide sequence (e.g., a gene or mRNA) encoding a p16 protein (e.g., a p16 protein comprising the amino acid sequence of SEQ ID NO: 1) and / or the presence of p16 protein, while control cells that do not respond to CDK2 inhibitor treatment do not have amplification of the CCNE1 gene and / or a CCNE1 expression level that is higher than the control expression level of CCNE1, and often have a mutated or deleted gene encoding the p16 protein and / or lack expression of the p16 protein.

[0484] Thus, the present disclosure provides a method of treating a human subject having, suspected of having, or at risk of having a disease or condition associated with CDK2, the method comprising administering a CDK2 inhibitor to the human subject, wherein the human subject has previously been determined to: (i) (a) have a nucleotide sequence encoding a p16 protein comprising the amino acid sequence of SEQ ID NO: 1, (b) have a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and / or deletions, and / or (c) express p16 protein, and (ii) (a) have an amplification of the CCNE1 gene and / or (b) have an expression level of CCNE1 above a control expression level of CCNE1 in a biological sample obtained from the human subject. In certain embodiments, the prediction methods described herein predict that a subject will respond to treatment with a CDK2 inhibitor with an accuracy of at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or 100%. For example, in some embodiments, if the prediction methods described herein are applied to 10 subjects who have, are suspected of having, or are at risk of having a disease or condition associated with CDK2, and 8 of those 10 subjects are predicted to respond to treatment with a CDK2 inhibitor based on the prediction methods described herein, and 7 of those 8 subjects do respond to treatment with a CDK2 inhibitor, then the prediction methods have an accuracy of 87.5% (7 divided by 8). A subject is considered to respond to a CDK2 inhibitor if the subject shows any improvement in the disease state (as evidenced by, for example, a reduction or alleviation of symptoms, disease remission / regression, etc.).

[0485] In some embodiments, the subject suffers from a disease or condition associated with CDK2. In some embodiments, it has been previously determined that a human subject: (i) (a) has a nucleotide sequence encoding a p16 protein comprising an amino acid sequence of SEQ ID NO: 1 and / or (b) has a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and / or deletions, and (ii) has an amplification of the CCNE1 gene in a biological sample obtained from the human subject. In some embodiments, the CDKN2A gene encodes a protein comprising an amino acid sequence of SEQ ID NO: 1. In specific embodiments, the CDKN2A gene encodes a protein comprising an amino acid sequence of SEQ ID NO: 1.

[0486] In a specific embodiment, the one or more inactivating nucleic acid substitutions and / or deletions in the CDKN2A gene are as described in Table A. In a specific embodiment, the one or more inactivating nucleic acid substitutions and / or deletions in the CDKN2A gene are as described in Yarbrough et al., Journal of the National Cancer Institute, 91(18):1569-1574, 1999; Liggett and Sidransky, Biology of Neoplasia, Journal of Oncology, 16(3):1197-1206, 1998; and Cairns et al., Nature Genetics, 11:210-212, 1995, each of which is incorporated herein by reference in its entirety.

[0487] Table A. CDKN2A gene substitutions, deletions and modifications

[0488]

[0489]

[0490]

[0491] The present disclosure also provides a method for treating a human subject having, suspected of having, or at risk of having a disease or condition associated with CDK2, the method comprising: (i) identifying in a biological sample obtained from the human subject: (a) a nucleotide sequence encoding a p16 protein comprising an amino acid sequence of SEQ ID NO: 1, (b) a CDKN2A gene lacking one or more inactivating nucleic acid substitutions, and / or (c) the presence of a p16 protein; (ii) identifying in a biological sample obtained from the human subject: (a) amplification of a CCNE1 gene and / or (b) a CCNE1 expression level higher than a control expression level of CCNE1; and (iii) administering a CDK2 inhibitor to the human subject. In some embodiments, the subject has a disease or condition associated with CDK2. In some embodiments, the subject is suspected of having a disease or condition associated with CDK2 or is at risk of having the disease or condition. In some embodiments, the method comprises: (i) identifying in a biological sample obtained from a human subject: (a) a nucleotide sequence encoding a p16 protein comprising the amino acid sequence of SEQ ID NO: 1, (b) a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and / or deletions, and / or (c) the presence of a p16 protein; (ii) identifying in a biological sample obtained from a human subject: (a) amplification of a CCNE1 gene; and (iii) administering a CDK2 inhibitor to the human subject.

[0492] The present disclosure also provides a method for predicting the response of a human subject having, suspected of having, or at risk of having a disease or condition associated with CDK2 to a CDK2 inhibitor, the method comprising: (i) determining in a biological sample obtained from the human subject: (a) the nucleotide sequence of a CDKN2A gene, (b) the presence of a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and / or deletions, and / or (c) the presence of a p16 protein; and (ii) determining in a biological sample obtained from the human subject: (a) the copy number of a CCNE1 gene and / or (b) the expression level of CCNE1, wherein (1) (a) the presence of a CDKN2A gene encoding a p16 protein comprising the amino acid sequence of SEQ ID NO: 1, (b) the presence of a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and / or deletions, and / or (c) the presence of a p16 protein, and (2) (a) amplification of the CCNE1 gene and / or (b) an expression level of CCNE1 above a control expression level of CCNE1 predicts that the human subject will respond to a CDK2 inhibitor. In some embodiments, the subject suffers from a disease or condition associated with CDK2. In some embodiments, the subject is suspected of suffering from a disease or condition associated with CDK2 or is at risk of suffering from the disease or condition. In some embodiments, the method comprises: (i) determining in a biological sample obtained from a human subject: (a) the nucleotide sequence of the CDKN2A gene and / or (b) the presence of a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and / or deletions; and (ii) determining in a biological sample obtained from a human subject: (a) the copy number of the CCNE1 gene, wherein (1) (a) the presence of a CDKN2A gene encoding a p16 protein comprising an amino acid sequence of SEQ ID NO: 1 and / or (b) the presence of a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and / or deletions, and (2) (a) amplification of the CCNE1 gene predicts that the human subject will respond to a CDK2 inhibitor.

[0493] In specific embodiments, (i) determining (a) the nucleotide sequence of a CDKN2A gene, (b) the presence of a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and / or deletions, and / or (c) the presence of a p16 protein is performed prior to administering a CDK2 inhibitor to a human subject (e.g., at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 2 weeks, at least 3 weeks, or at least 4 weeks, or 6 hours to 16 hours, 6 hours to 20 hours, or 6 hours to 24 hours, 2 days to 3 days, 2 days to 4 days, 2 days to 5 days, 2 days to 6 days, 2 days to 7 days, 1 week to 2 weeks, 1 week to 3 weeks, or 1 week to 4 weeks prior). In specific embodiments, (ii) determining the copy number of (a) the CCNE1 gene and / or (b) the expression level of CCNE1 in a biological sample obtained from a human subject is performed before administering a CDK2 inhibitor to the human subject (e.g., at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 2 weeks, at least 3 weeks, or at least 4 weeks, or 6 hours to 16 hours, 6 hours to 20 hours, or 6 hours to 24 hours, 2 days to 3 days, 2 days to 4 days, 2 days to 5 days, 2 days to 6 days, 2 days to 7 days, 1 week to 2 weeks, 1 week to 3 weeks, or 1 week to 4 weeks before).

[0494] Amplification of the CCNE1 gene and / or an expression level of CCNE1 above a control expression level of CCNE1, combined with the presence of a CDKN2A gene encoding a p16 protein comprising the amino acid sequence of SEQ ID NO: 1, the presence of a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and / or deletions, and / or the presence of a p16 protein (e.g., a p16 protein comprising the amino acid sequence of SEQ ID NO: 1), indicates / predicts that a human subject having, suspected of having, or at risk of having a disease or condition associated with CDK2 will respond to a CDK2 inhibitor.

[0495] In some embodiments, the CCNE1 gene is amplified to a gene copy number of 3 to 25. In specific embodiments, the CCNE1 gene is amplified to a gene copy number of at least 3. In specific embodiments, the CCNE1 gene is amplified to a gene copy number of at least 5. In specific embodiments, the CCNE1 gene is amplified to a gene copy number of at least 7. In specific embodiments, the CCNE1 gene is amplified to a gene copy number of at least 10. In specific embodiments, the CCNE1 gene is amplified to a gene copy number of at least 12. In specific embodiments, the CCNE1 gene is amplified to a gene copy number of at least 14. In specific embodiments, the CCNE1 gene is amplified to a gene copy number of at least 21.

[0496] In a specific embodiment, the expression level of CCNE1 is the level of CCNE1 mRNA. In a specific embodiment, the expression level of CCNE1 is the level of CCNE1 protein.

[0497] In some embodiments of the aforementioned methods, the control expression level of CCNE1 is a pre-established cutoff value. In some embodiments of the aforementioned methods, the control expression level of CCNE1 is the expression level of CCNE1 in one or more samples obtained from one or more subjects who did not respond to CDK2 inhibitor treatment.

[0498] In some embodiments of the aforementioned methods, the expression level of CCNE1 is the expression level of CCNE1 mRNA. In some embodiments of the aforementioned methods, the expression level of CCNE1 is the expression level of CCNE1 protein. In some embodiments where the expression level of CCNE1 is the expression level of CCNE1 mRNA, the expression level of CCNE1 is measured by RNA sequencing, quantitative polymerase chain reaction (PCR), in situ hybridization, nucleic acid array or RNA sequencing. In some embodiments where the expression level of CCNE1 is the expression level of CCNE1 protein, the expression level of CCNE1 is measured by western blot, enzyme-linked immunosorbent assay or immunohistochemical staining.

[0499] Rb S780

[0500] The present disclosure also provides a method for evaluating the CDKN2A gene and the CCNE1 gene, the method comprising determining in one or more biological samples obtained from a human subject suffering from a disease or condition associated with CDK2 (i) the presence of (a) a nucleotide sequence of the CDKN2A gene or (b) a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and / or deletions, and (ii) the copy number of the CCNE1 gene.

[0501] The present disclosure also provides a method for evaluating the response of a human subject suffering from, suspected of suffering from, or at risk of suffering from a disease or condition associated with CDK2 to a CDK2 inhibitor, the method comprising: (a) administering a CDK2 inhibitor to the human subject, wherein the human subject has previously been determined to have an amplification of the CCNE1 gene and / or an expression level of CCNE1 that is higher than a control expression level of CCNE1; (b) after the administration of step (a), measuring the phosphorylation level of the retinoblastoma (Rb) protein at the serine corresponding to amino acid position 780 of SEQ ID NO: 3 in a biological sample obtained from the subject, wherein a decrease in the phosphorylation level of Rb at the serine corresponding to amino acid position 780 of SEQ ID NO: 3 compared to a control level of Rb phosphorylation at the serine corresponding to amino acid position 780 of SEQ ID NO: 3 indicates that the human subject is responsive to the CDK2 inhibitor. In some embodiments, the subject suffers from a disease or condition associated with CDK2. In some embodiments, the subject is suspected of suffering from a disease or condition associated with CDK2 or is at risk of suffering from the disease or condition. In some embodiments, the biological sample comprises a blood sample or a tumor biopsy sample.

[0502] Phosphorylation of Rb at the serine corresponding to amino acid position 780 of SEQ ID NO:3 (referred to herein as "Ser780" or "S780") has been identified in the Examples as a pharmacodynamic marker that can be used to assess responsiveness to a CDK2 inhibitor (e.g., inhibition by CDK2) in a human subject having a disease or disorder with CCNE1 amplification.

[0503] Rb is a regulator of the cell cycle and acts as a tumor suppressor. Rb is activated by phosphorylation at Ser780 and Ser795 by cyclin D-CDK4 / 6 and phosphorylation at Ser807 and Ser811 by cyclin E / CDK2. Rb is encoded by RB transcriptional co-repressor 1 ("RB1") gene (GenBank accession number NM_000321). The amino acid sequence of human Rb is provided below (GenBank accession number NP_000312 / UniProtKB accession number P06400) (S780 is bold and underlined):

[0504]

[0505] As described above, the examples demonstrate that CDK2 knockdown inhibits proliferation of CCNE1 amplified cell lines, but does not inhibit proliferation of CCNE1 non-amplified cell lines. The examples further demonstrate that CDK2 knockdown or inhibition blocks phosphorylation of Rb at S780 in CCNE1 amplified cell lines, but does not block in CCNE1 non-amplified cell lines. Therefore, phosphorylation of Rb at the serine corresponding to amino acid position 780 of SEQ ID NO:3 is a pharmacodynamic marker for evaluating the response of CCNE1 amplified cancer cells or patients with a disease or condition with CCNE1 amplification to CDK2 inhibition. Therefore, the present invention provides a method for using the phosphorylation level of Rb at the serine corresponding to amino acid position 780 of SEQ ID NO:3 as a marker indicating the response of the human subject to a CDK2 inhibitor in a human subject suffering from, suspected of suffering from, or at risk of suffering from a disease or condition associated with CDK2. The human subject has an increased CCNE1 expression level.

[0506] Therefore, the present disclosure provides a method for measuring the amount of a protein in a sample, the method comprising: (a) providing a biological sample obtained from a human subject suffering from a disease or condition associated with CDK2; and (b) measuring the phosphorylation level of Rb protein in the biological sample at the serine corresponding to amino acid position 780 of SEQ ID NO: 3. In some embodiments, the biological sample comprises a blood sample or a tumor biopsy sample. In a specific embodiment, provided herein is a method for evaluating a human subject having, suspected of having, or at risk of having a disease or condition associated with CDK2 for a response to a CDK2 inhibitor, the method comprising: (a) administering a CDK2 inhibitor to the human subject, wherein the human subject has previously been determined to have an amplification of the CCNE1 gene and / or a CCNE1 expression level above a control expression level of CCNE1; and (b) after the administration of step (a), measuring the phosphorylation level of Rb at the serine corresponding to amino acid position 780 of SEQ ID NO: 3 in a biological sample obtained from the human subject, wherein a decrease in the phosphorylation level of Rb at the serine corresponding to amino acid position 780 of SEQ ID NO: 3 as compared to a control level of Rb phosphorylation at the serine corresponding to amino acid position 780 of SEQ ID NO: 3 indicates that the human subject is responsive to the CDK2 inhibitor. In specific embodiments, the human subject has a disease or condition associated with CDK2.

[0507] A reduced level of Rb phosphorylation at serine corresponding to amino acid position 780 of SEQ ID NO: 3, compared to a control level of Rb phosphorylation at serine corresponding to amino acid position 780 of SEQ ID NO: 3, combined with an amplification of the CCNE1 gene and / or an expression level of CCNE1 above a control expression level of CCNE1, indicates that the human subject having, suspected of having, or at risk of having a disease or condition associated with CDK2 is responsive to a CDK2 inhibitor. For example, in a subject having an amplification of the CCNE1 gene and / or an expression level of CCNE1 above a control expression level of CCNE1, a biological sample obtained from the subject having a low (e.g., reduced compared to a control) or undetectable level of Rb phosphorylation at serine corresponding to amino acid position 780 of SEQ ID NO: 3 following treatment with a CDK2 inhibitor indicates that the subject is responsive to a CDK2 inhibitor.

[0508] A biological sample obtained from the subject having a reduced level of Rb phosphorylation at the serine corresponding to amino acid position 780 of SEQ ID NO:3 (compared to a control level of Rb phosphorylation at the serine corresponding to amino acid position 780 of SEQ ID NO:3) after administration of the CDK2 inhibitor to the subject, in combination with (i) CCNE1 gene amplification and / or a CCNE1 expression level above a control expression level of CCNE1, and (ii) the presence of a CDKN2A gene encoding a p16 protein comprising the amino acid sequence of SEQ ID NO:1, the presence of a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and / or deletions, and / or the presence of a p16 protein (e.g., a p16 protein comprising the amino acid sequence of SEQ ID NO:1), indicates that the human subject having, suspected of having, or at risk of having a disease or condition associated with CDK2 is responsive to the CDK2 inhibitor. For example, in a human subject having (i) amplification of the CCNE1 gene and / or a CCNE1 expression level that is higher than a control expression level of CCNE1 and (ii) the presence of a CDKN2A gene encoding a p16 protein comprising the amino acid sequence of SEQ ID NO:1, the presence of a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and / or deletions, and / or the presence of a p16 protein (e.g., a p16 protein comprising the amino acid sequence of SEQ ID NO:1), after administration of a CDK2 inhibitor to the human subject, a biological sample obtained from the subject having a low (e.g., decreased compared to a control) or undetectable level of Rb phosphorylation at serine corresponding to amino acid position 780 of SEQ ID NO:3 indicates that the human subject is responsive to the CDK2 inhibitor.

[0509] In some embodiments, the CCNE1 gene is amplified to a gene copy number of 3 to 25. In a specific embodiment, the CCNE1 gene is amplified to a gene copy number of at least 3. In a specific embodiment, the CCNE1 gene is amplified to a gene copy number of at least 5. In a specific embodiment, the CCNE1 gene is amplified to a gene copy number of at least 7. In a specific embodiment, the CCNE1 gene is amplified to a gene copy number of at least 10. In a specific embodiment, the CCNE1 gene is amplified to a gene copy number of at least 12. In a specific embodiment, the CCNE1 gene is amplified to a gene copy number of at least 14. In a specific embodiment, the CCNE1 gene is amplified to a gene copy number of at least 21. In a specific embodiment, the expression level of CCNE1 is the level of CCNE1 mRNA. In a specific embodiment, the expression level of CCNE1 is the level of CCNE1 protein.

[0510] Comparison

[0511] As described above, methods related to biomarkers and pharmacodynamic markers may involve measuring one or more markers (e.g., biomarkers or pharmacodynamic markers, such as amplification of the CCNE1 gene, expression level of CCNE1, presence of a CDKN2A gene encoding a p16 protein comprising the amino acid sequence of SEQ ID NO: 1, presence of a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and / or deletions, presence of a p16 protein (e.g., a p16 protein comprising the amino acid sequence of SEQ ID NO: 1), and phosphorylation of Rb at serine corresponding to amino acid position 780 of SEQ ID NO: 3) in a biological sample from a human subject suffering from, suspected of suffering from, or at risk of suffering from a disease or condition associated with CDK2. In a specific embodiment, the human subject suffers from a disease or condition associated with CDK2. In a specific embodiment, the human subject is suspected of suffering from or at risk of suffering from a disease or condition associated with CDK2. In certain aspects, the level of one or more biomarkers (e.g., amplification (e.g., for CCNE1 gene), expression level (e.g., for CCNE1 or p16 protein), or phosphorylation level (e.g., for Rb)) compared to a control level of the one or more biomarkers predicts / indicates a human subject's response to a treatment comprising a CDK2 inhibitor. In certain embodiments, when (i) the CCNE1 gene is amplified and / or the expression level of CCNE1 is higher than the control expression level of CCNE1, and (ii) there is a CDKN2A gene encoding a p16 protein comprising the amino acid sequence of SEQ ID NO: 1, there is a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and / or deletions, and / or there is a p16 protein (e.g., a p16 protein comprising the amino acid sequence of SEQ ID NO: 1), the human subject is identified as likely to respond to a CDK2 inhibitor. In other embodiments, the human subject is identified as responsive to a CDK2 inhibitor when (i) the CCNE1 gene is amplified and / or the expression level of CCNE1 is higher than a control expression level of CCNE1, and (ii) after administration of a CDK2 inhibitor to the human subject, in a biological sample from the human subject, the level of Rb phosphorylation at the serine corresponding to amino acid position 780 of SEQ ID NO:3 is lower than a control level of Rb phosphorylation at the serine corresponding to amino acid position 780 of SEQ ID NO:3.In another embodiment, the human subject is identified as responsive to a CDK2 inhibitor when (i) the CCNE1 gene is amplified and / or the expression level of CCNE1 is higher than a control expression level of CCNE1, (ii) a CDKN2A gene encoding a p16 protein comprising the amino acid sequence of SEQ ID NO: 1 is present, a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and / or deletions is present, and / or a p16 protein (e.g., a p16 protein comprising the amino acid sequence of SEQ ID NO: 1) is present, and (iii) after administration of a CDK2 inhibitor to the human subject, in a biological sample from the human subject, the level of Rb phosphorylation at the serine corresponding to amino acid position 780 of SEQ ID NO: 3 is lower than a control level of Rb phosphorylation at the serine corresponding to amino acid position 780 of SEQ ID NO: 3. In this context, the term "control" includes samples (from the same tissue type) obtained from human subjects known to be non-responsive to CDK2 inhibitors. The term "control" also includes samples (from the same tissue type) that were previously obtained from human subjects known to be unresponsive to CDK2 inhibitors and used as references for subsequent comparisons with test samples taken from human subjects whose treatment responsiveness is to be predicted. A "control" level (e.g., gene copy number, expression level, or phosphorylation level) of a particular biomarker (e.g., CCNE1, p16, or Rb phosphorylation) in a particular cell type or tissue can be established in advance by analyzing the biomarker level (e.g., expression level or phosphorylation level) in one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, or 40 or more) human subjects who do not respond to CDK2 inhibitor treatment. This pre-established reference value (which may be the average or median level (e.g., gene copy number, expression level, or phosphorylation level) taken from multiple human subjects who do not respond to therapy) can then be used as a "control" level of a biomarker (e.g., CCNE1, p16, or Rb phosphorylation) in comparisons with test samples. In such a comparison, if the CCNE1 gene is amplified and / or the expression level of CCNE is higher than a pre-established reference, and there is a CDKN2A gene encoding a p16 protein comprising the amino acid sequence of SEQ ID NO:1, there is a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and / or deletions, and / or there is a p16 protein (e.g., a p16 protein comprising the amino acid sequence of SEQ ID NO:1), then the human subject is expected to respond to a CDK2 inhibitor.In another such comparison, if (i) the CCNE1 gene is amplified and / or the expression level of CCNE is higher than a pre-established reference, and (ii) after administration of the CDK2 inhibitor to the human subject, the level of Rb phosphorylation at the serine corresponding to amino acid position 780 of SEQ ID NO:3 is lower than a pre-established reference, then the human subject is expected to respond to the CDK2 inhibitor. In another such comparison, if (i) the CCNE1 gene is amplified and / or the expression level of CCNE is higher than a pre-established reference, (ii) there is a CDKN2A gene encoding a p16 protein comprising the amino acid sequence of SEQ ID NO:1, there is a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and / or deletions, and / or there is a p16 protein (e.g., a p16 protein comprising the amino acid sequence of SEQ ID NO:1), and (iii) after administration of the CDK2 inhibitor to the human subject, the level of Rb phosphorylation at the serine corresponding to amino acid position 780 of SEQ ID NO:3 is lower than a pre-established reference, then the human subject is indicated to respond to the CDK2 inhibitor.

[0512] A "control" level of a particular biomarker in a particular cell type or tissue may alternatively be pre-established by analysis of the biomarker level in one or more human subjects who respond to treatment with a CDK2 inhibitor. This pre-established reference value (which may be an average or median level (e.g., expression level or phosphorylation level) taken from multiple human subjects who respond to therapy) can then be used as a "control" level (e.g., expression level or phosphorylation level) in comparison with a test sample. In such a comparison, if the level of the analyzed biomarker (e.g., the number of copies of the CCNE1 gene, the expression level of CCNE1, the expression level of p16, or the level of Rb phosphorylation at serine corresponding to amino acid position 780 of SEQ ID NO: 3) is equal to the pre-established reference or is comparable thereto (e.g., at least 85% but less than 115%), it indicates that the human subject is responsive to a CDK2 inhibitor.

[0513] In certain embodiments, "control" is a pre-established cutoff value. The cutoff value is generally the level of a biomarker (e.g., copy number, expression level, or phosphorylation level), and being higher or lower than the level is considered to be predictive of the responsiveness of a human subject to the therapy of interest. Therefore, according to the methods and compositions described herein, a reference level (e.g., CCNE1 gene copy number, CCNE1 expression, p16 expression, or a reference level of Rb phosphorylation at serine at amino acid position 780 corresponding to SEQ ID NO: 3) is identified as a cutoff value, and being higher or lower than the cutoff value predicts responsiveness to a CDK2 inhibitor. The determined cutoff value used in the methods described herein can be compared with, for example, a published concentration range, but can be individualized for the method used and the patient population.

[0514] In some embodiments, the expression level of CCNE1 is increased compared to the expression level of CCNE1 in a control. For example, the expression level of CCNE1 analyzed can be at least 1.5 times, at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times, at least 20 times, at least 25 times, at least 50 times, at least 75 times, or at least 100 times, or at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 75% or at least 80% higher than the expression level of CCNE1 in a control. 0%, at least 80%, at least 90%, at least 100%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, at least 1,000%, at least 1,500%, at least 2,000%, at least 2,500%, at least 3,000%, at least 3,500%, at least 4,000%, at least 4,500% or at least 5,000%.

[0515] If the p16 protein is detectable by any assay known in the art or described herein (e.g., Western blot, immunohistochemistry, fluorescence activated cell sorting, and enzyme-linked immunosorbent assay), the protein is present. In some embodiments, the p16 protein is present at an expression level within at least 5%, at least 10%, at least 20%, or at least 30% of the p16 expression level in a healthy control.

[0516] In some embodiments, the level of Rb phosphorylation at the serine corresponding to amino acid position 780 of SEQ ID NO: 3 analyzed is reduced compared to the level of Rb phosphorylation at the serine corresponding to amino acid position 780 of SEQ ID NO: 3 in a control. For example, the level of Rb phosphorylation at the serine corresponding to amino acid position 780 of SEQ ID NO: 3 analyzed may be at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 20-fold, at least 25-fold, at least 50-fold, at least 75-fold, or at least 100-fold, or at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% lower than the level of Rb phosphorylation at the serine corresponding to amino acid position 780 of SEQ ID NO: 3 in a control.

[0517] Biological samples

[0518] Suitable biological samples for the methods described herein include any sample containing blood or tumor cells obtained from or derived from a human subject in need of treatment. For example, a biological sample may contain tumor cells from a biopsy of a patient with a solid tumor. A tumor biopsy can be obtained by a variety of means known in the art. Alternatively, a blood sample can be obtained from a patient with a blood cancer.

[0519] The biological sample can be obtained from a human subject having, suspected of having, or at risk of having a disease or disorder associated with CDK2. In some embodiments, the disease or disorder associated with CDK2 is cancer (eg, those cancers described above).

[0520] Methods for obtaining and / or storing samples in which the activity or integrity of molecules (e.g., nucleic acids or proteins) in the sample is maintained are well known to those skilled in the art. For example, the biological sample may be further contacted with one or more additional agents such as buffers and / or inhibitors, including one or more of nuclease, protease, and phosphatase inhibitors, which maintain the molecules in the sample or minimize their changes.

[0521] Evaluation of biomarkers and pharmacodynamic markers

[0522] The expression level of CCNE1 or p16 can be detected, for example, as RNA expression of a target gene (i.e., a gene encoding CCNE1 or p16). That is, the expression level (amount) of CCNE1 or p16 can be determined by detecting and / or measuring the mRNA expression level of a gene encoding CCNE1. Alternatively, the expression level of CCNE1 or p16 can be detected, for example, as protein expression of a target gene (i.e., a gene encoding CCNE1 or p16). That is, the expression level (amount) of CCNE1 or p16 can be determined by detecting and / or measuring the protein expression level of a gene encoding CCNE1 or p16.

[0523] In some embodiments, the expression level of CCNE1 or p16 is determined by measuring RNA levels. A variety of suitable methods can be used to detect and / or measure the mRNA expression level of a gene. For example, Northern blot or dot blot analysis, reverse transcriptase-PCR (RT-PCR; e.g., quantitative RT-PCR), in situ hybridization (e.g., quantitative in situ hybridization), nucleic acid arrays (e.g., oligonucleotide arrays or gene chips), and RNA sequencing analysis can be used to determine mRNA expression. Details of such methods are described below and in, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Volumes 1, 2, and 3, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York, USA, November 1989; Gibson et al. (1999) Genome Res., 6(10):995-1001; and Zhang et al. (2005) Environ. Sci. Technol., 39(8):2777-2785; U.S. Publication No. 2004086915; European Patent No. 0543942; and U.S. Patent No. 7,101,663; Kukurba et al. (2015) Cold Spring Harbor Protocols., 2015(11):951-69; the disclosures of each of which are incorporated herein by reference in their entirety.

[0524] In one example, the presence or amount of one or more discrete mRNA populations in a biological sample can be determined by isolating total mRNA from the biological sample (e.g., see Sambrook et al. (supra) and U.S. Patent No. 6,812,341), and subjecting the separated mRNA to agarose gel electrophoresis to separate the mRNA by size. The size-separated mRNA is then transferred (e.g., by diffusion) to a solid support such as a nitrocellulose membrane. The presence or amount of one or more mRNA populations in the biological sample can then be determined using one or more detectably labeled polynucleotide probes complementary to the mRNA sequence of interest, which bind to their corresponding mRNA populations and thereby enable detection of the mRNA populations. Detectable labels include, for example, fluorescence (e.g., umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride, allophycocyanin, or phycoerythrin), luminescence (e.g., europium, terbium, Qdot supplied by Quantum Dot Corporation, Palo Alto, CA). TM nanoparticles), radioactivity (e.g. 125 I. 131 I. 35 S. 32 P. 33 P or 3 H) and enzyme (horseradish peroxidase, alkaline phosphatase, β-galactosidase or acetylcholinesterase) labeling.

[0525] In some embodiments, the expression level of CCNE1 or p16 is determined by measuring protein levels. A variety of suitable methods can be used to detect and / or measure the protein expression level of the target gene. For example, Western blot, enzyme-linked immunosorbent assay ("ELISA"), fluorescence activated cell sorting, or immunohistochemical analysis (e.g., using CCNE1-specific or p16-specific antibodies, respectively) can be used to determine CCNE1 or p16 protein expression. Details of such methods are described below and, for example, in Sambrook et al. (supra).

[0526] In one example, the presence or amount of one or more discrete protein populations (e.g., CCNE1 or p16) in a biological sample can be determined by Western blot analysis, for example, by isolating total protein from the biological sample (e.g., see Sambrook et al. (supra)), and subjecting the separated proteins to agarose gel electrophoresis to separate the proteins by size. The size-separated proteins are then transferred (e.g., by diffusion) to a solid support, such as a nitrocellulose membrane. The presence or amount of one or more protein populations in the biological sample can then be determined using one or more antibody probes (e.g., a first antibody specific for the protein of interest (e.g., CCNE1 or p16), and a second antibody specific for the first antibody with a detectable label), which binds to the corresponding protein population and thereby enables detection of the corresponding protein population. Detectable labels suitable for Western blot analysis are known in the art.

[0527] Methods for detecting or measuring gene expression (e.g., mRNA or protein expression) can optionally be implemented in a format that allows for rapid preparation, processing, and analysis of multiple samples. This can be performed, for example, in a multi-well assay plate (e.g., 96-well or 386-well) or array (e.g., a nucleic acid chip or a protein chip). Stock solutions of various reagents can be provided manually or automatically, and subsequent sample preparation (e.g., RT-PCR, labeling, or cell fixation), pipetting, dilution, mixing, distribution, washing, incubation (e.g., hybridization), sample readout, data collection (optical data), and / or analysis (computer-assisted image analysis) can be automated using commercially available analysis software, robotics, and detection instruments capable of detecting signals generated from the assay. Examples of such detectors include, but are not limited to, spectrophotometers, photometers, fluorometers, and devices for measuring radioisotope decay. Exemplary cell-based high-throughput assays (e.g., detecting the presence or level of a target protein in a cell) can utilize VTI HCS Reader or HCS Reader Technology (Cellomics Inc., Pittsburg, PA).

[0528] In some embodiments, the presence of a CDKN2A gene encoding a p16 protein comprising the amino acid sequence of SEQ ID NO: 1 and / or the presence of a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and / or deletions is determined by evaluating the DNA sequence of the CDKN2A gene (e.g., genomic DNA or cDNA) or by evaluating the RNA sequence of the CDKN2A gene (e.g., RNA, such as mRNA). Methods for performing nucleic acid sequencing analysis are known in the art and are described above. Non-limiting examples of inactivating nucleic acid substitutions and / or deletions that prevent the CDKN2A gene from encoding a protein comprising the amino acid sequence of SEQ ID NO: 1 are described in Table A above. In a specific embodiment, the one or more inactivating nucleic acid substitutions and / or deletions in the CDKN2A gene are as described in Yarbrough et al., Journal of the National Cancer Institute, 91(18):1569-1574, 1999; Liggett and Sidransky, Biology of Neoplasia, Journal of Oncology, 16(3):1197-1206, 1998, and Cairns et al., Nature Genetics, 11:210-212, 1995, each of which is incorporated herein by reference in its entirety.

[0529] In some embodiments, the expression level of a gene or the presence of a gene lacking one or more inactivating nucleic acid substitutions or deletions is determined by evaluating the copy number variation (CNV) of the gene. The CNV of a gene (e.g., CCNE1 gene and / or CDKN2A gene) can be determined / identified by a variety of suitable methods. For example, fluorescence in situ hybridization (FISH), multiple ligation-dependent probe amplification (MLPA), array comparative genomic hybridization (aCGH), single nucleotide polymorphism (SNP) arrays, and next generation sequencing (NGS) techniques can be used to determine CNV.

[0530] In one example, the copy number variation of one or more discrete genes in a biological sample can be determined by MLPA, for example, by extracting a DNA sample from the biological sample (e.g., see Sambrook et al. (supra) and U.S. Pat. No. 6,812,341), and amplifying a DNA sequence of interest (e.g., CCNE1 or CDKN2A) using a mixture of MLPA probes. Each MLPA probe consists of two oligonucleotides that hybridize to be adjacent to a target DNA sequence (e.g., CCNE1 or CDKN2A) so as to be connected to a single probe. The connected probes are amplified via PCR using a fluorescently labeled PCR primer so that the amplified product can be visualized during fragment separation by capillary electrophoresis. The presence, absence, or amplification of one or more genes of interest in a biological sample is calculated by measuring the fluorescence of the PCR source, quantifying the amount of the normalized PCR product, and comparing it to a control DNA sample.

[0531] The level of Rb phosphorylation at the serine at amino acid position 780 corresponding to SEQ ID NO: 3 can be detected by a variety of suitable methods. For example, Western blot, ELISA, fluorescence activated cell sorting or immunohistochemical analysis can be used to determine the phosphorylation state. The details of such methods are described below and in, for example, Sambrook et al. (supra).

[0532] As with the methods of detecting or measuring gene expression (above), methods for detecting or measuring Rb phosphorylation levels at the serine corresponding to amino acid position 780 of SEQ ID NO:3 can optionally be performed in a format that allows for rapid preparation, processing, and analysis of multiple samples.

[0533] Implementation

[0534] 1. A solid form of a compound of formula (I):

[0535]

[0536] The form is Form I.

[0537] 2. The solid form of embodiment 1, which is non-solvated.

[0538] 3. The solid form of embodiment 1, which is crystalline.

[0539] 4. The solid form of embodiment 1, wherein the form has at least one XRPD peak, expressed as 2-θ (±0.2°), selected from the group consisting of 7.3, 10.5, 12.8, 14.5, 15.2, 16.4, 20.3, 21.3, 21.6, and 27.0.

[0540] 5. The solid form of embodiment 1, wherein the form has at least two XRPD peaks, expressed as 2-θ (±0.2°), selected from 7.3, 10.5, 12.8, 14.5, 15.2, 16.4, 20.3, 21.3, 21.6, and 27.0.

[0541] 6. A solid form as described in embodiment 1, wherein the form has at least three XRPD peaks, expressed as 2-θ (±0.2°), selected from 7.3, 10.5, 12.8, 14.5, 15.2, 16.4, 20.3, 21.3, 21.6 and 27.0.

[0542] 7. The solid form of embodiment 1, wherein the form has at least four XRPD peaks, expressed as 2-θ (±0.2°), selected from 7.3, 10.5, 12.8, 14.5, 15.2, 16.4, 20.3, 21.3, 21.6, and 27.0.

[0543] 8. The solid form of embodiment 1, wherein the form has at least five XRPD peaks, expressed as 2-θ (±0.2°), selected from 7.3, 10.5, 12.8, 14.5, 15.2, 16.4, 20.3, 21.3, 21.6, and 27.0.

[0544] 9. The solid form of embodiment 1, wherein the form has at least ten XRPD peaks, expressed as 2-θ (±0.2°), selected from 7.3, 10.5, 12.8, 14.5, 15.2, 16.4, 20.3, 21.3, 21.6, and 27.0.

[0545] 10. A solid form as described in any one of embodiments 1-9, wherein the form has substantially Figure 1 XRPD pattern shown in .

[0546] 11. The solid form of any one of embodiments 1-9, having an endothermic peak with an onset temperature (±3°C) of 191.7°C and a maximum value of 193.6°C.

[0547] 12. A solid form as described in any one of embodiments 1-9, wherein the form has substantially Figure 2 DSC thermogram shown in .

[0548] 13. A solid form as described in any one of embodiments 1-12, wherein the form has substantially Figure 3 TGA thermogram shown in .

[0549] 14. A salt of a compound of formula (I):

[0550]

[0551] The salt is selected from:

[0552] A monomaleate salt of the compound of formula (I);

[0553] The dibenzenesulfonate salt of the compound of formula (I);

[0554] The monomethanesulfonate salt of the compound of formula (I);

[0555] The xylenesulfonate salt of the compound of formula (I);

[0556] The monohydrochloride salt of the compound of formula (I); and

[0557] The dihydrochloride salt of the compound of formula (I).

[0558] 15. The salt according to embodiment 14, which is a monomaleate salt of the compound of formula (I).

[0559] 16. The salt according to embodiment 15, which is crystalline.

[0560] 17. The salt of embodiment 15 or 16, wherein the salt has at least one XRPD peak, expressed as 2-θ (±0.2°), selected from the group consisting of 10.4, 11.6, 12.0, 14.1, 15.1, 17.2, 18.1, 19.1, 21.3, 21.9, 22.9, 24.2, and 25.9.

[0561] 18. The salt of embodiment 15 or 16, wherein the salt has at least two XRPD peaks, expressed as 2-θ (±0.2°), selected from 10.4, 11.6, 12.0, 14.1, 15.1, 17.2, 18.1, 19.1, 21.3, 21.9, 22.9, 24.2, and 25.9.

[0562] 19. The salt of embodiment 15 or 16, wherein the salt has at least three XRPD peaks, expressed as 2-θ (±0.2°), selected from 10.4, 11.6, 12.0, 14.1, 15.1, 17.2, 18.1, 19.1, 21.3, 21.9, 22.9, 24.2, and 25.9.

[0563] 20. The salt of embodiment 15 or 16, wherein the salt has at least four XRPD peaks, expressed as 2-θ (±0.2°), selected from 10.4, 11.6, 12.0, 14.1, 15.1, 17.2, 18.1, 19.1, 21.3, 21.9, 22.9, 24.2, and 25.9.

[0564] 21. The salt of embodiment 15 or 16, wherein the salt has at least five XRPD peaks, expressed as 2-θ (±0.2°), selected from 10.4, 11.6, 12.0, 14.1, 15.1, 17.2, 18.1, 19.1, 21.3, 21.9, 22.9, 24.2, and 25.9.

[0565] 22. The salt of embodiment 15 or 16, wherein the salt has at least ten XRPD peaks, expressed as 2-θ (±0.2°), selected from 10.4, 11.6, 12.0, 14.1, 15.1, 17.2, 18.1, 19.1, 21.3, 21.9, 22.9, 24.2, and 25.9.

[0566] 23. A salt as described in embodiment 15 or 16, wherein the salt has substantially Figure 4 XRPD pattern shown in .

[0567] 24. The salt of any one of embodiments 15-23, which has an endothermic peak with an onset temperature (±3°C) of 180.4°C and a maximum temperature (±3°C) of 181.8°C.

[0568] 25. A salt as described in any one of embodiments 15-23, wherein the salt has substantially Figure 5 DSC thermogram shown in .

[0569] 26. A salt as described in any one of embodiments 15-25, wherein the salt has substantially Figure 6 TGA thermogram shown in .

[0570] 27. The salt according to embodiment 14, which is a dibenzenesulfonate salt of the compound of formula (I).

[0571] 28. The salt according to embodiment 27, which is crystalline.

[0572] 29. The salt of embodiment 27 or 28, wherein the salt has at least one XRPD peak, expressed as 2-θ (±0.2°), selected from 6.3, 9.9, 12.1, 12.6, 15.9, 17.4, 18.7, 19.0, 19.6 and 25.1.

[0573] 30. The salt of embodiment 27 or 28, wherein the salt has at least two XRPD peaks expressed as 2-θ (±0.2°) selected from 6.3, 9.9, 12.1, 12.6, 15.9, 17.4, 18.7, 19.0, 19.6 and 25.1.

[0574] 31. The salt of embodiment 27 or 28, wherein the salt has at least three XRPD peaks, expressed as 2-θ (±0.2°), selected from 6.3, 9.9, 12.1, 12.6, 15.9, 17.4, 18.7, 19.0, 19.6, and 25.1.

[0575] 32. The salt of embodiment 27 or 28, wherein the salt has at least four XRPD peaks, expressed as 2-θ (±0.2°), selected from 6.3, 9.9, 12.1, 12.6, 15.9, 17.4, 18.7, 19.0, 19.6, and 25.1.

[0576] 33. The salt of embodiment 27 or 28, wherein the salt has at least five XRPD peaks, expressed as 2-θ (±0.2°), selected from 6.3, 9.9, 12.1, 12.6, 15.9, 17.4, 18.7, 19.0, 19.6, and 25.1.

[0577] 34. The salt of embodiment 27 or 28, wherein the salt has at least ten XRPD peaks, expressed as 2-θ (±0.2°), selected from 6.3, 9.9, 12.1, 12.6, 15.9, 17.4, 18.7, 19.0, 19.6, and 25.1.

[0578] 35. The salt of embodiment 27 or 28, wherein the salt has substantially Figure 7 XRPD pattern shown in .

[0579] 36. The salt of any one of embodiments 27-35, which has an endothermic peak with an onset temperature (±3°C) of 160.4°C and a maximum temperature (±3°C) of 163.4°C.

[0580] 37. A salt as described in any one of embodiments 27-35, wherein the salt has substantially Figure 8 DSC thermogram shown in .

[0581] 38. A salt as described in any one of embodiments 27-37, wherein the salt has substantially Fig. 9 TGA thermogram shown in .

[0582] 39. The salt according to embodiment 14, which is the monomethanesulfonate salt of the compound of formula (I).

[0583] 40. The salt of embodiment 39, which is crystalline.

[0584] 41. The salt of embodiment 39 or 40, wherein the salt has at least one XRPD peak, expressed as 2-θ (±0.2°), selected from 4.8, 7.0, 11.9, 14.1, 14.9, 17.7, 18.9, 20.2, 22.1, and 26.1.

[0585] 42. The salt of embodiment 39 or 40, wherein the salt has at least two XRPD peaks expressed as 2-θ (±0.2°) selected from 4.8, 7.0, 11.9, 14.1, 14.9, 17.7, 18.9, 20.2, 22.1 and 26.1.

[0586] 43. The salt of embodiment 39 or 40, wherein the salt has at least three XRPD peaks, expressed as 2-θ (±0.2°), selected from 4.8, 7.0, 11.9, 14.1, 14.9, 17.7, 18.9, 20.2, 22.1 and 26.1.

[0587] 44. The salt of embodiment 39 or 40, wherein the salt has at least four XRPD peaks, expressed as 2-θ (±0.2°), selected from 4.8, 7.0, 11.9, 14.1, 14.9, 17.7, 18.9, 20.2, 22.1 and 26.1.

[0588] 45. The salt of embodiment 39 or 40, wherein the salt has at least five XRPD peaks, expressed as 2-θ (±0.2°), selected from 4.8, 7.0, 11.9, 14.1, 14.9, 17.7, 18.9, 20.2, 22.1 and 26.1.

[0589] 46. ​​The salt of embodiment 39 or 40, wherein the salt has at least ten XRPD peaks, expressed as 2-θ (±0.2°), selected from 4.8, 7.0, 11.9, 14.1, 14.9, 17.7, 18.9, 20.2, 22.1, and 26.1.

[0590] 47. The salt of embodiment 39 or 40, wherein the salt has substantially Fig.10 XRPD pattern shown in .

[0591] 48. The salt of any one of embodiments 39-47, which has a first endothermic peak with a maximum temperature (±3°C) of 61.1°C and a second endothermic peak with an onset temperature (±3°C) of 134.4°C and a maximum temperature (±3°C) of 150.1°C.

[0592] 49. A salt as described in any one of embodiments 39-47, wherein the salt has substantially Fig.11 DSC thermogram shown in .

[0593] 50. A salt as described in any one of embodiments 39-49, wherein the salt has substantially Fig.12 TGA thermogram shown in .

[0594] 51. The salt according to embodiment 14, which is a ditoluenesulfonate salt of the compound of formula (I).

[0595] 52. The salt of embodiment 51, which is crystalline.

[0596] 53. The salt of embodiment 51 or 52, wherein the salt has at least one XRPD peak, expressed as 2-θ (±0.2°), selected from 5.7, 7.8, 8.1, 9.3, 13.7, 13.9, 16.2, 18.8 and 20.6.

[0597] 54. The salt of embodiment 51 or 52, wherein the salt has at least two XRPD peaks expressed as 2-θ (±0.2°) selected from 5.7, 7.8, 8.1, 9.3, 13.7, 13.9, 16.2, 18.8 and 20.6.

[0598] 55. The salt of embodiment 51 or 52, wherein the salt has at least three XRPD peaks, expressed as 2-θ (±0.2°), selected from 65.7, 7.8, 8.1, 9.3, 13.7, 13.9, 16.2, 18.8, and 20.6.

[0599] 56. The salt of embodiment 51 or 52, wherein the salt has at least four XRPD peaks, expressed as 2-θ (±0.2°), selected from 5.7, 7.8, 8.1, 9.3, 13.7, 13.9, 16.2, 18.8 and 20.6.

[0600] 57. The salt of embodiment 51 or 52, wherein the salt has at least five XRPD peaks, expressed as 2-θ (±0.2°), selected from 5.7, 7.8, 8.1, 9.3, 13.7, 13.9, 16.2, 18.8 and 20.6.

[0601] 58. The salt of embodiment 51 or 52, wherein the salt has at least eight XRPD peaks, expressed as 2-θ (±0.2°), selected from 5.7, 7.8, 8.1, 9.3, 13.7, 13.9, 16.2, 18.8, and 20.6.

[0602] 59. The salt of embodiment 51 or 52, wherein the salt has substantially Fig.13 XRPD pattern shown in .

[0603] 60. The salt of any one of embodiments 51-59, which has an exothermic peak with an onset temperature (±3°C) of 99.6°C and a maximum temperature (±3°C) of 110.5°C, and an endothermic peak with an onset temperature (±3°C) of 216.1°C and a maximum temperature (±3°C) of 218.7°C.

[0604] 61. A salt as described in any one of embodiments 51-59, wherein the salt has substantially Fig.14 DSC thermogram shown in .

[0605] 62. A salt as described in any one of embodiments 51-61, wherein the salt has substantially Fig.15 TGA thermogram shown in .

[0606] 63. The salt according to embodiment 14, which is the monohydrochloride salt of the compound of formula (I).

[0607] 64. The salt of embodiment 63, which is crystalline.

[0608] 65. The salt of embodiment 63 or 64, wherein the salt has at least one XRPD peak, expressed as 2-θ (±0.2°), selected from 5.7, 8.5, 11.3, 14.1, 15.0, 18.4, 19.3, 20.5, 21.8, 22.8 and 25.7.

[0609] 66. The salt of embodiment 63 or 64, wherein the salt has at least two XRPD peaks, expressed as 2-θ (±0.2°), selected from 5.7, 8.5, 11.3, 14.1, 15.0, 18.4, 19.3, 20.5, 21.8, 22.8 and 25.7.

[0610] 67. The salt of embodiment 63 or 64, wherein the salt has at least three XRPD peaks, expressed as 2-θ (±0.2°), selected from 5.7, 8.5, 11.3, 14.1, 15.0, 18.4, 19.3, 20.5, 21.8, 22.8 and 25.7.

[0611] 68. The salt of embodiment 63 or 64, wherein the salt has at least four XRPD peaks, expressed as 2-θ (±0.2°), selected from 5.7, 8.5, 11.3, 14.1, 15.0, 18.4, 19.3, 20.5, 21.8, 22.8 and 25.7.

[0612] 69. The salt of embodiment 63 or 64, wherein the salt has at least five XRPD peaks, expressed as 2-θ (±0.2°), selected from 5.7, 8.5, 11.3, 14.1, 15.0, 18.4, 19.3, 20.5, 21.8, 22.8 and 25.7.

[0613] 70. The salt of embodiment 63 or 64, wherein the salt has at least ten XRPD peaks, expressed as 2-θ (±0.2°), selected from 5.7, 8.5, 11.3, 14.1, 15.0, 18.4, 19.3, 20.5, 21.8, 22.8, and 25.7.

[0614] 71. The salt of embodiment 63 or 64, wherein the salt has substantially Fig.16 XRPD pattern shown in .

[0615] 72. The salt of any one of embodiments 63-71, which has an endothermic peak with an onset temperature (±3°C) of 196.0°C and a maximum temperature (±3°C) of 212.2°C.

[0616] 73. A salt as described in any one of embodiments 63-71, wherein the salt has substantially Fig.17 DSC thermogram shown in .

[0617] 74. The salt of any one of embodiments 63-73, wherein the salt has substantially Fig.18 TGA thermogram shown in .

[0618] 75. The salt according to embodiment 14, which is the dihydrochloride salt of the compound of formula (I).

[0619] 76. The salt of embodiment 75, which is crystalline.

[0620] 77. The salt of embodiment 75 or 76, wherein the salt has at least one XRPD peak expressed as 2-θ (±0.2°) selected from 9.9, 10.7, 12.3, 13.0, 14.0, 15.2, 19.9, 21.8, 22.3 and 24.8.

[0621] 78. The salt of embodiment 75 or 76, wherein the salt has at least two XRPD peaks expressed as 2-θ (±0.2°) selected from 9.9, 10.7, 12.3, 13.0, 14.0, 15.2, 19.9, 21.8, 22.3 and 24.8.

[0622] 79. The salt of embodiment 75 or 76, wherein the salt has at least three XRPD peaks, expressed as 2-θ (±0.2°), selected from 9.9, 10.7, 12.3, 13.0, 14.0, 15.2, 19.9, 21.8, 22.3 and 24.8.

[0623] 80. The salt of embodiment 75 or 76, wherein the salt has at least four XRPD peaks expressed as 2-θ (±0.2°) selected from 9.9, 10.7, 12.3, 13.0, 14.0, 15.2, 19.9, 21.8, 22.3 and 24.8.

[0624] 81. The salt of embodiment 75 or 76, wherein the salt has at least five XRPD peaks, expressed as 2-θ (±0.2°), selected from 9.9, 10.7, 12.3, 13.0, 14.0, 15.2, 19.9, 21.8, 22.3, and 24.8.

[0625] 82. The salt of embodiment 75 or 76, wherein the salt has at least ten XRPD peaks, expressed as 2-θ (±0.2°), selected from 9.9, 10.7, 12.3, 13.0, 14.0, 15.2, 19.9, 21.8, 22.3, and 24.8.

[0626] 83. The salt of embodiment 75 or 76, wherein the salt has substantially Fig.19 XRPD pattern shown in .

[0627] 84. The salt of any one of embodiments 75-83, which has an endothermic peak with an onset temperature (±3°C) of 182.1°C and a maximum temperature (±3°C) of 206.4°C.

[0628] 85. A salt as described in any one of embodiments 75-83, wherein the salt has substantially Fig. 20 DSC thermogram shown in .

[0629] 86. A salt as described in any one of embodiments 75-85, wherein the salt has substantially Fig.21 TGA thermogram shown in .

[0630] 87. A pharmaceutical composition comprising the solid form of any one of embodiments 1-13 or the salt of any one of embodiments 14-86 and a pharmaceutically acceptable carrier.

[0631] 88. A method of inhibiting CDK2, the method comprising contacting the CDK2 with the solid form of any one of embodiments 1-13 or the salt of any one of embodiments 14-86.

[0632] 89. A method of inhibiting CDK2 in a patient, the method comprising administering to the patient the solid form of any one of embodiments 1-13 or the salt of any one of embodiments 14-86.

[0633] 90. A method of treating a disease or condition associated with CDK2 in a patient, the method comprising administering to the patient a therapeutically effective amount of a solid form of any one of embodiments 1-13 or a salt of any one of embodiments 14-86.

[0634] 91. The method of embodiment 90, wherein the disease or condition is associated with amplification of the cyclin E1 (CCNE1) gene and / or overexpression of CCNE1.

[0635] 92. A method of treating a human subject having a disease or condition associated with cyclin dependent kinase 2 (CDK2), the method comprising administering to the human subject a solid form of any one of embodiments 1-13 or a salt of any one of embodiments 14-86, wherein the human subject has previously been determined to:

[0636] (i)

[0637] (a) having a nucleotide sequence encoding a p16 protein comprising the amino acid sequence of SEQ ID NO: 1; and / or

[0638] (b) having a cyclin-dependent kinase inhibitor 2A (CDKN2A) gene lacking one or more inactivating nucleic acid substitutions and / or deletions;

[0639] (ii)

[0640] (a) having an amplification of the cyclin E1 (CCNE1) gene; and / or

[0641] (b) having an expression level of CCNE1 higher than a control expression level of CCNE1 in a biological sample obtained from the human subject.

[0642] 93. A method of treating a human subject having a disease or condition associated with cyclin dependent kinase 2 (CDK2), the method comprising:

[0643] (i) identifying in a biological sample obtained from said human subject:

[0644] (a) a nucleotide sequence encoding a p16 protein comprising the amino acid sequence of SEQ ID NO: 1; and / or

[0645] (b) a cyclin-dependent kinase inhibitor 2A (CDKN2A) gene lacking one or more inactivating nucleic acid substitutions;

[0646] (ii) identifying in a biological sample obtained from said human subject:

[0647] (a) amplification of the cyclin E1 (CCNE1) gene; and / or

[0648] (b) an expression level of CCNE1 that is greater than a control expression level of CCNE1; and

[0649] (iii) administering to the human subject the solid form of any one of embodiments 1-13 or the salt of any one of embodiments 14-86.

[0650] 94. The method of embodiment 93, comprising:

[0651] (i) identifying in a biological sample obtained from said human subject:

[0652] (a) a nucleotide sequence encoding a p16 protein comprising the amino acid sequence of SEQ ID NO: 1; and / or

[0653] (b) a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and / or deletions;

[0654] (ii) identifying in a biological sample obtained from said human subject:

[0655] (a) amplification of CCNE1 gene; and

[0656] (iii) administering the compound or the salt to the human subject.

[0657] 95. A method of evaluating a human subject having a disease or condition associated with cyclin dependent kinase 2 (CDK2) for response to a solid form of any one of embodiments 1-13 or a salt of any one of embodiments 14-86, the method comprising:

[0658] (a) administering the compound or the salt to the human subject, wherein the human subject has previously been determined to have an amplification of the Cyclin E1 (CCNE1) gene and / or an expression level of CCNE1 that is higher than a control expression level of CCNE1;

[0659] (b) measuring the phosphorylation level of retinoblastoma (Rb) protein at serine corresponding to amino acid position 780 of SEQ ID NO: 3 in a biological sample obtained from the subject after said administering of step (a),

[0660] wherein a decrease in the level of Rb phosphorylation at serine corresponding to amino acid position 780 of SEQ ID NO:3 as compared to a control level of Rb phosphorylation at serine corresponding to amino acid position 780 of SEQ ID NO:3 indicates that the human subject is responsive to the compound or the salt.

[0661] 96. The method of embodiment 95, wherein the disease or condition is cancer.

[0662] 97. A method of preparing a solid form of any one of embodiments 1-13, the method comprising cooling a solution of the compound of formula (I) in a solvent component comprising ethanol and water.

[0663] 98. The method of embodiment 97, wherein the solvent component comprises 6% water and 94% ethanol.

[0664] 99. A method as described in embodiment 97 or 98, wherein the solution is cooled to a temperature of 0°C ± 3°C.

[0665] 100. The method of any one of embodiments 97-99, wherein the solution is prepared by heating a slurry of the compound of formula (I) in the solvent component prior to the cooling.

[0666] 101. A method for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof; a solid form of any one of embodiments 1-13; or a salt of any one of embodiments 14-86, the method comprising:

[0667] The compound of formula (1c):

[0668]

[0669] With the compound of formula (1b):

[0670]

[0671] or a salt thereof via a Buchwald coupling reaction to form a compound of formula (1a):

[0672]

[0673] Where X 1 It is a halogen group.

[0674] 102. The method according to embodiment 101, wherein X 1 For Br.

[0675] 103. The method of embodiment 101 or 102, wherein the compound of formula (1b) or its salt is an HCl salt.

[0676] 104. The method of any one of embodiments 101-103, wherein the Buchwald coupling reaction comprises reacting the compound of formula (1c) with the compound of formula (1b) or a salt thereof in the presence of a Buchwald catalyst or precatalyst and a base.

[0677] 105. The method of embodiment 104, wherein the Buchwald catalyst or the precatalyst is a palladium catalyst.

[0678] 106. A method as described in embodiment 104, wherein the palladium catalyst is [(2-di-tert-butylphosphino-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl)]methanesulfonate palladium (II) (t-BuBrett Phos Pd G3) or [tBuBrettPhos Pd(allyl)]OTf (Pd-175).

[0679] 107. The method of any one of embodiments 104-106, wherein the base is an alkali metal alkoxide.

[0680] 108. The method of any one of embodiments 104-106, wherein the base is sodium tert-butoxide.

[0681] 109. The method of any one of embodiments 101-108, further comprising deprotecting the compound of formula (1a) to form the compound of formula (I).

[0682] 110. The method according to embodiment 109, wherein the deprotection is accomplished by reacting the compound of formula (1a) with a strong acid.

[0683] 111. A method as described in embodiment 110, wherein the strong acid is hydrochloric acid.

[0684] 112. The method of any one of embodiments 101-111, wherein the compound of formula (1c) is prepared by a method comprising:

[0685] The compound of formula (1d):

[0686]

[0687] or a salt thereof is reacted with a halogenating agent to form the compound of formula (1c).

[0688] 113. A method as described in embodiment 112, wherein the halogenating agent is a brominating agent.

[0689] 114. A method as described in embodiment 112, wherein the halogenating agent is Cu(X 1 )2.

[0690] 115. A method as described in embodiment 112, wherein the halogenating agent is CuBr2.

[0691] 116. The method of any one of embodiments 112-115, wherein the compound of formula (1d) or a salt thereof is prepared by a method comprising:

[0692] The compound of formula 1(e):

[0693]

[0694] The mixture is reacted with hydroxylamine hydrochloride and a base component to form the compound of formula (1d) or a salt thereof.

[0695] 117. A method as described in embodiment 116, wherein the base component is a tertiary amine.

[0696] 118. A method as described in embodiment 117, wherein the tertiary amine is ethyldiisopropylamine.

[0697] 119. The method of any one of embodiments 116-118, wherein the compound of formula (1e) is prepared by a method comprising:

[0698] The compound of formula (1f):

[0699]

[0700] Reaction with CH3CH2OC(O)-N=C=S to form the compound of formula (1e).

[0701] 120. The method of embodiment 119, wherein the compound of formula (1f) is prepared by a method comprising:

[0702] The compound of formula (1h):

[0703]

[0704] or its salt and a compound of formula (1g):

[0705]

[0706] The reaction is carried out via a Buchwald coupling reaction to form the compound of formula (1f).

[0707] 121. The method of embodiment 120, wherein the compound of formula (1h) or a salt thereof is an HBr salt.

[0708] 122. The method of embodiment 120 or 121, wherein the Buchwald coupling reaction comprises reacting the compound of formula (1h) or a salt thereof with the compound of formula (1g) in the presence of a Buchwald catalyst or a precatalyst and a base.

[0709] 123. The method of embodiment 122, wherein the Buchwald catalyst or the precatalyst present for the reaction of the compound of formula (1h) or its salt with the compound of formula (1g) is a palladium catalyst.

[0710] 124. A method as described in embodiment 122, wherein the Buchwald catalyst present for the reaction of the compound of formula (1h) or its salt with the compound of formula (1g) is (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]methanesulfonate palladium(II) (XPhos Pd G3).

[0711] 125. The method of any one of embodiments 122-124, wherein the base present for the reaction of the compound of formula (1h) or a salt thereof with the compound of formula (1g) is an alkali metal phosphate.

[0712] 126. The method of any one of embodiments 122-124, wherein the base present for the reaction of the compound of formula (1h) or a salt thereof with the compound of formula (1g) is sodium phosphate.

[0713] 127. The method of any one of embodiments 120-126, wherein the compound of formula (1h) or a salt thereof is prepared by a method comprising:

[0714] The compound of formula (1i):

[0715]

[0716] or a salt thereof is reacted with an ethyl halide in the presence of a base to form the compound of formula (1h) or a salt thereof.

[0717] 128. The method of embodiment 127, wherein the ethyl halide is ethyl iodide.

[0718] 129. The method of embodiment 127 or 128, wherein the base present for the reaction of the compound of formula (1i) or its salt with the ethyl halide is a carbonate base.

[0719] 130. The method of embodiment 129, wherein the carbonate base is cesium carbonate.

[0720] 131. The method of any one of embodiments 127-130, wherein the compound of formula (1i) or a salt thereof is an HBr salt.

[0721] 132. The method of any one of embodiments 101-111, wherein the compound of formula (1c) is prepared by a method comprising:

[0722] The compound of formula (2a):

[0723]

[0724] With the compound of formula (2b):

[0725]

[0726] In the presence of a Suzuki catalyst and a base, the compound of formula (1c) is formed, wherein X 1 It is a halogen group.

[0727] 133. The method according to embodiment 132, wherein X 1 For Br.

[0728] 134. A method as described in embodiment 132 or 133, wherein the Suzuki catalyst is a palladium catalyst.

[0729] 135. The method of embodiment 132 or 133, wherein the Suzuki catalyst is formed from a mixture of a phosphine ligand and a palladium (II) compound.

[0730] 136. A method as described in embodiment 132 or 133, wherein the Suzuki catalyst is formed from a mixture of CataCXium A and palladium acetate.

[0731] 137. The method of any one of embodiments 132-136, wherein the base present for the reaction of the compound of formula (2a) and the compound of formula (2b) is an alkali metal phosphate.

[0732] 138. The method of any one of embodiments 132-136, wherein the base present for the reaction of the compound of formula (2a) and the compound of formula (2b) is sodium phosphate.

[0733] 139. The method of any one of embodiments 132-138, wherein the compound of formula (1b) or a salt thereof is prepared by a method comprising:

[0734] Reducing the compound of formula (3a):

[0735]

[0736] To form the compound of formula (1b) or a salt thereof.

[0737] 140. The method of embodiment 139, wherein the reduction is accomplished by reacting the compound of formula (3a) with hydrogen in the presence of a palladium catalyst.

[0738] 141. The method of any one of embodiments 139-140, wherein the compound of formula (3a) is prepared by a method comprising:

[0739] The compound of formula (3c):

[0740]

[0741] Reaction with a compound of formula (3b):

[0742]

[0743] Then crystallization is carried out to obtain the compound of formula (3a).

[0744] 142. The method of embodiment 141, wherein the compound of formula (3c) is prepared by a method comprising:

[0745] The compound of formula (3d):

[0746]

[0747] or a salt thereof is reacted with methanesulfonyl chloride to form a compound of formula (3c).

[0748] 143. A compound selected from:

[0749]

[0750] or a salt thereof.

[0751] The present invention will be described in more detail by means of specific examples. The following examples are provided for illustrative purposes and are not intended to limit the present invention in any way. Those skilled in the art will readily recognize multiple non-critical parameters that may be changed or modified to produce substantially the same result.

[0752] Example

[0753] The following provides experimental procedures for compounds, solid forms and salts of the present disclosure. Preparative LC-MS purification of some of the prepared compounds was implemented on a Waters mass directional fractionation system. The basic equipment settings, protocols and control software for operating these systems have been described in detail in the literature. See, for example, "Two-Pump at-ColumnDilution Configuration for Preparative LC-MS", K. Blom, J. Combi. Chem., 4, 295 (2002); "Optimizing Preparative LC-MS Configurations and Methods for ParallelSynthesis" Purification", K. Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi. Chem., 5, 670 (2003); and "Preparative LC-MS Purification: Improved CompoundSpecific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Combi. Chem., 6, 874-883 (2004). The isolated compounds were usually subjected to analytical liquid chromatography mass spectrometry (LCMS) under the following conditions for purity check: Instrument: Agilent 1100 series, LC / MSD; Column: Waters Sunfire TM C 18 5 μm particle size, 2.1 x 5.0 mm; buffer: mobile phase A: water with 0.025% TFA and mobile phase B: acetonitrile; gradient 2% to 80% B in 3 minutes, flow rate 2.0 ml / min.

[0754] As also indicated in the Examples, some of the prepared compounds were separated on a preparative scale by reverse phase high performance liquid chromatography (RP-HPLC) with MS detection or flash chromatography (silica gel). Typical preparative reverse phase high performance liquid chromatography (RP-HPLC) column conditions were as follows:

[0755] pH = 2 Purification: Waters Sunfire TM C 18 5 μm particle size, 19x100 mm column, eluted with mobile phase A: water containing 0.1% TFA (trifluoroacetic acid) and mobile phase B: acetonitrile; flow rate was 30 ml / min, and the separation gradient of each compound was optimized using the compound-specific method optimization scheme as described in the literature (see "Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)). Typically, the flow rate used for a 30x100 mm column is 60 ml / min.

[0756] pH = 10 Purification: Waters XBridge C 18 5 μm particle size, 19x100 mm column, eluted with mobile phase A: water containing 0.15% NH4OH and mobile phase B: acetonitrile; flow rate was 30 ml / min, and the separation gradient of each compound was optimized using the compound-specific method optimization scheme as described in the literature (see "Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)). Typically, the flow rate used for the 30x100 mm column is 60 ml / min.

[0757] Example 1

[0758] Synthesis of 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I))

[0759]

[0760] Intermediate (8). 3-Ethoxy-4-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)pyridin-2-amine

[0761]

[0762] 4-Bromo-3-ethoxypyridin-2-amine (4) (prepared according to Example 4) (1.998 kg, 9.205 mol, 1 eq) and 1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (2.94 kg, 11.0 mol, 1.2 eq) were charged to a 50 L reactor containing a solution of potassium phosphate (5.9 kg, 27.6 mmol, 3 eq) in water (10 L, 5 v). The slurry was diluted with dioxane (20 L, 10 v) and degassed via nitrogen bubbling for 50 min. Catalyst XPhos Pd G2 (21.7 g, 27.6 mmol, 0.003 eq) was charged and degassing was continued for 15 min, followed by a temperature increase of 2.5 hours at 85 °C until complete by HPLC analysis. The reaction mixture is cooled to room temperature, and the organic layer is separated and washed with brine (6L, 3v). The water layer is merged and extracted with ethyl acetate (10L, 5v). The organic layer is merged, filtered through a diatomaceous earth plug, and concentrated to about 6L (3v). The concentrated mixture is diluted with MTBE (18L, 9v), and warmed at 50 ° C to form a clear solution. Heptane (18L, 9v) is slowly loaded over about 10min, and the solution is cooled to 1 ° C over 2 hours. The slurry is filtered, washed with heptane (4L, 2v), and dried on the filter to obtain 8 (2.033kg, 80% yield,> 99% purity) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ8.38(s,1H),8.00(s,1H),7.65(d,J=8.0Hz,1H),6.79(d,J=8.0Hz,1H),5.77(s,2H),5.62(dd,J=8.0,4. C 14 H 20 N4O2,(MW 276.34),LCMS(EI)m / e 277.13(M + +H).

[0763] Intermediates (9)

[0764]

[0765] The slurry of 8 (1.0kg, 3.62mol, 1eq) in dioxane (5L, 5v) is cooled to 10 ° C, and carbon isothiocyanate O-ethyl ester (512mL, 4.34mol, 1.2eq) is loaded once. The addition causes a slight exotherm from 9.1 ° C to 21.7 ° C, and the reactant is stirred at room temperature for 16 hours, at which point the reaction is considered complete according to HPLC. The reactant is quenched by adding saline (2.5L, 2.5v) and water (1L, 1v) and each layer is separated. The aqueous layer is extracted with ethyl acetate (2.5L, 2.5v), and the organic layer is combined and concentrated to dryness. Crude 9 (assuming 1.475kg, quantitative) is directly used in the next reaction as a viscous orange oil. 1 H NMR (400MHz, DMSO) δ11.56(s,1H),11.43(s,1H),8.52(s,1H),8.17(d,J=5. 1Hz,1H),8.13(s,1H),7.63(d,J=5.1Hz,1H),5.65(q,J=5.9Hz,1H),4.24(q, J=7.1Hz,2H),3.89(q,J=7.0Hz,2H),3.48(dq,J=9.6,7.0Hz,1H),3.25(dq,J =9.6,7.0Hz,1H),1.64(d,J=6.0Hz,3H),1.29(m,6H),1.06(t,J=7.0Hz,3H). C 18 H 25 N5O4S, (calculated value M+H: 408.1700), LCMS (EI) m / e 408.3 (M + +H).

[0766] Intermediate (10). 8-Ethoxy-7-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

[0767]

[0768] Hünig's base (790mL, 4.53mol, 1.25eq) is loaded into a slurry of hydroxylamine hydrochloride (377g, 5.43mol, 1.5eq) in ethanol (3L, 2v). A bleach scrubber is installed to capture hydrogen sulfide gas emissions. 9 (1.475kg, 3.62mol, 1eq) in ethanol (4L, 2.7v) is slowly loaded over 1 hour, and the pipeline is flushed with ethanol (400mL, 0.3v). With the addition, gas emission starts immediately with a slight exotherm (final temperature 28°C). The reaction mixture is warmed to 50°C, and a homogeneous solution is obtained. After 3 hours at 50°C, the reaction is considered complete according to HPLC, and a sticky solid product is precipitated. Water (2.2L, 1.5v) is loaded to dissolve the product, and any sulfur-containing byproducts are precipitated. The reaction mixture was filtered and the solids were washed with ethanol / water (2:1, 700 mL, 0.5 v). The filtrate was concentrated to remove ethanol (approximately 7 L), leaving a slurry of 10 in water. The solids were dissolved in dichloromethane (7.3 L, 5 v) and 30% ammonium hydroxide (2.9 L, 2 v) was loaded. The layers were separated and the aqueous layer was extracted with dichloromethane (700 mL, 0.5 v). The organics were washed twice with 15% ammonium hydroxide (1.5 L, 1 v) and the aqueous layer was back-extracted with dichloromethane (700 mL, 0.5 v). The combined organic layers were washed with brine (3 L, 2 v) and the aqueous layer was extracted with dichloromethane (700 mL, 0.5 v). The combined organics were concentrated to approximately 4-5 v (removing approximately 7 L) and isopropyl acetate (6.3 L, 4.3 v) was loaded. The remaining dichloromethane (about 3 L) was removed in vacuo, and the slurry was transferred to a 22 L round-bottom flask containing isopropyl acetate (1 L, 0.7 v). The slurry was diluted with heptane (3.7 L, 2.5 v) and stirred at 80 ° C for 1 hour, then slowly cooled to room temperature overnight. The slurry was filtered, washed with isopropyl acetate / heptane (2: 1, 700 mL, 0.5 v) and dried in a vacuum oven at 40 ° C to give 10 (920 g, 80% yield) as a white solid. 1 H NMR (400MHz, DMSO) δ8.47(s,1H),8.27(d,J=7.0Hz,1H),8.12(s,1H),7.17(d,J=7.0Hz,1H),5.99(s,2H),5.62(q,J=5.9Hz,1H),4.56(q,J =7.1Hz, 2H), 3.47 (dq, J = 9.6, 7.0Hz, 1H), 3.26 (dq, J = 9.6, 7.1Hz, 1H), 1.64 (d, J = 5.9Hz, 3H), 1.35 (t, J = 7.0Hz, 3H), 1.06 (t, J = 7.0Hz, 3H). C 15 H20 N6O2, (calculated value M+H: 317.1721), LCMS (EI) m / e 317.1 (M + +H).

[0769] Intermediate (11). 2-Bromo-8-ethoxy-7-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridine

[0770]

[0771] Copper (II) bromide (449 g, 2.0 mol, 1.05 eq) was charged to an ambient slurry of 10 (605 g, 1.9 mol, 1 eq) in acetonitrile (9 L, 15 v) to produce a dark solution. The reaction mixture was cooled to 5 °C and tert-butyl nitrite (607 mL, 4.6 mol, 2.4 eq) was added in one go. The reaction mixture was slowly warmed to room temperature overnight (the ice bath was allowed to melt to warm more slowly). After 16 hours, the reaction was complete by HPLC and quenched by the addition of 15% ammonium hydroxide (5 L, 8 v). Acetonitrile (about 6-8 L) was removed in vacuo and the mixture was diluted with dichloromethane (3 L, 5 v). The layers were separated and the aqueous portion was extracted with dichloromethane (0.5 L, 1 v). The organics were washed with 15% ammonium hydroxide (1.8 L, 3 v) and the aqueous layer was extracted with dichloromethane (0.5 L, 1 v). The turbid organic layer was washed twice with brine (1.2L, 2v), and each aqueous layer was extracted with dichloromethane (0.5L, 1v). The organic layer was slurried together with SiliaMetS thiol (150g, 0.25x wt) at room temperature for 1 hour, then filtered through a small diatomaceous earth bed and washed with dichloromethane (3x0.5L, 1v). The filtrate was concentrated to 1.2-1.5L (about 2-2.5v) in a vacuum, and the resulting slurries were heated under reflux and diluted with heptane (3L, 5v). The slurries were heated at 40 ° C for 1 hour, then cooled to room temperature and aged for 30min. The slurries were filtered and washed with heptane / DCM (2: 1, 1.4L, 2v). The solid was dried at 40 ° C in a vacuum oven to obtain 11 (536g, 74%) as a white solid. 1H NMR (400MHz, DMSO) δ8.68(d,J=7.1Hz,1H),8.58(s,1H),8.21(s,1H),7.58(d,J=7.1Hz,1H),5.65(q,J=5.9Hz,1H),4.65(q,J=7.0Hz ,2H),3.48(dq,J=9.6,7.0Hz,1H),3.27(dq,J=9.6,7.0Hz,1H),1.65(d,J=6.0Hz,3H),1.40(t,J=7.0Hz,3H),1.07(t,J=7.0Hz,3H). C 15 H 18 BrN5O2, (calculated value M+H: 380.0717), LCMS (EI) m / e 380.0717 (M + +H).

[0772] Intermediate (12). 8-Ethoxy-7-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

[0773]

[0774] A solution of 11 (1.5 kg, 3.9 mol, 1 eq), 3 (1.08 kg, 4.7 mol, 1.2 eq) (prepared according to Example 3), sodium tert-butoxide (1.9 kg, 19.7 mol, 5 eq) and t-BuBrettPhos Pd G3 (101 g, 118 mmol, 0.03 eq) in dioxane was degassed with nitrogen bubbling for 1 hour. The slurry was heated to 90 ° C to form a homogeneous solution and stirred at the temperature for 2 hours until the analysis by HPLC was complete. The reaction mixture was cooled to room temperature and quenched by adding water (7.5 L, 5 v). The layers were separated and the aqueous layer was extracted twice with ethyl acetate (15 L and 7.5 L, 10 v and 5 v). The combined organic layers were treated with a solution of N-acetylcysteine ​​(690 g) and potassium phosphate (990 g) in water (7.5 L) at 60 ° C for 3 hours. The washing solution of palladium removal is cooled to room temperature, and each layer is separated. The water layer is extracted twice with ethyl acetate (7.5L, 5v), and organic matter is concentrated to about 20L (13v) in a vacuum and is slurried together with carbon C-941 (300g, 0.20wt) and SiliMetS mercaptan (300g, 0.20wt) at room temperature and is no more than 8 hours. The slurries are filtered through a diatomaceous earth pad and rinsed with ethyl acetate (7.5L, 5v). The filtrate is concentrated to obtain a crude oily substance (assuming quantitative) of 12, which is directly used in the next step.1 H NMR (600MHz, DMSO-d6) δ8.48(s,1H),8.33(d,J=6.0Hz,1H),8.13(s,1H),7.18(d,J=12.0H z,1H),6.76(d,J=6.0Hz,1H),5.62(q,J=6.0Hz,1H),4.55(q,J=6.0Hz,2H),3.88(m,1H),3. 47(m,1H),3.26(m,2H),3.12(m,3H),2.87(s,3H),2.18(m,1H),1.85(m,1H),1.76(m,1H),1 .64(d,J=6.0Hz,3H),1.36(t,J=6.0Hz,3H),1.06(t,J=6.0Hz,3H),0.93(d,J=6.0Hz,3H); C 22 H 33 N7O4S,(MW 491.61),LCMS(EI)m / e 492.2(M + +H).

[0775] Compound of formula (I): 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

[0776]

[0777] 1N hydrochloric acid (9L, 9.0mol, 2.3eq) was added to a solution of 12 (1.9kg, 3.9mol, 1eq) (or 12 hemisuccinate) in THF (14L, 7v), and the solution was warmed at 60°C for 2 hours until completion by HPLC. The reaction mixture was cooled to room temperature and neutralized with 16% sodium hydroxide (2L, 9.3mol). The reaction mixture was extracted twice with ethyl acetate (14L and 8L, 7v and 4v), and the combined organic layer was stirred with activated carbon C-941 (600g, 0.32wt) and SiliaMetS thiol (600g, 0.32wt) for 16 hours. The slurry was filtered through a diatomaceous earth pad and washed with ethyl acetate (7.5L, 5v). The filtrate was concentrated to about 7.5L (5v) and the slurry was diluted with heptane (4.5L, 3v), stirred at room temperature for 30min, and then cooled to 0°C. The solid was filtered and washed with ethyl acetate / heptane (5:3, 1.5 L, 1 v). The solid was dried on the filter to give the crude compound of formula (I) (1.312 kg, 80% yield).

[0778] The crude compound of formula (I) (1.4 kg, 3.3 mol) was slurried in 6% water / ethanol (7 L, 5 v), and the slurry was warmed under reflux to obtain a clear solution. The mixture was slowly cooled to 0 ° C and filtered, rinsed with ethanol (500 mL, 0.35 v). The solid was vacuum dried at 45 ° C for 3 days to obtain the compound of formula (I) (1.163 kg, 83% yield) as a white solid. 1 HNMR(500MHz,DMSO-d6)δ13.10(s,1H),8.33(s,1H),8.31(d,J=10.0Hz,1H),8.12(s,1H) ,7.17(d,J=10.0Hz,1H),6.73(d,J=10.0Hz,1H),4.54(dd,J=15.0,10.0Hz,2H),3.88(m,1 H), 3.26 (m, 1H), 3.12 (m, 3H), 2.87 (s, 3H), 2.19 (m, 1H), 1.85 (m, 1H), 1.76 (m, 1H), 1.36 (t, J = 10.0 Hz, 3H), 0.93 (d, J = 5.0 Hz, 3H); C18H25N7O3S, (calculated value M+H: 420.1812), LCMS (EI) m / e 420.1818 (M++H).

[0779] Example 2

[0780] Synthesis of 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I))

[0781]

[0782] Intermediate (11). 2-Bromo-8-ethoxy-7-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridine (alternative synthesis)

[0783]

[0784] Pd(OAc)2(7.35g, 0.5mol%) and CataCXium A (25.8g, 1.1mol%) were loaded into degassed dioxane (0.84L) under nitrogen, and the mixture was evacuated and refilled three times with nitrogen. The mixture was stirred at room temperature under nitrogen for no more than 20min. 7 (prepared according to Example 4) (2.10kg), cesium carbonate (4.26kg, 2eq), 1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (2.05kg, 1.2eq), dioxane (a total of 9.7L, 5vol, including dioxane for in-situ catalyst formation) and water (5.3L, 2.5vol) were loaded into a separate reactor. Next, the mixture was purged with nitrogen for no more than 30min. Thereafter, the catalyst prepared above was added to the mixture. The combined mixture was purged with nitrogen for 5 min. The mixture was then heated to 50 ° C for no more than 10 hours. The reaction was monitored by HPLC until completion. Next, water (15.8 L, 7.5 v) was slowly charged via an addition funnel. The resulting slurry was slowly cooled to room temperature and further cooled to 0 ° C and stirred for no more than 30 min. The slurry was filtered and the solid was washed with water (3.2 L). The solid was dried at no more than 50 ° C to obtain 2.49 kg of 11.

[0785] Crude 11 (4.61 kg) was mixed with THF (18.4 L, 4 v, based on the weight of the isolated solid) and stirred at 50°C to give a clear solution. Heptane (36.8 L, 8 v) was then charged at 50°C. The resulting slurry was slowly cooled to 15°C-30°C, and then further cooled to 0°C. The slurry was filtered, and the solid was washed with heptane (4.6 L) and dried at no more than 50°C to obtain 4.91 kg (84%) of 11 with a purity of >99A%. 1 H NMR (400MHz, DMSO-d6) δ8.67(d,J=8.0Hz,1H),8.58(s,1H),8.21(s,1H),7.58(d,J=8.0Hz,1H),5.65(dd,J=12.0,8.0Hz,1H), C 15 H 18 BrN5O2,(MW 380.25),LCMS(EI)m / e380.0,382.0(M + +H).

[0786] Intermediate (12). 8-Ethoxy-7-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

[0787]

[0788] 11 (4.1kg, 1.0eq), 3 (2.71kg, 1.1eq) (prepared according to Example 3) and NaOtBu (3.63kg, 3.5eq) are combined in 2-MeTHF (10v). The solution is degassed and Pd-175 (8.41g, 0.001eq) is loaded. The solution is further degassed and heated to 70°C until completed by HPLC. Next, the reactant is cooled to room temperature and quenched by adding saline (4v). Organic matter is then washed with saline (3v). The rough 12 in 2-MeTHF is concentrated to about 10v, and is directly used in the next reaction (assuming quantitative).

[0789] Alternative synthesis of intermediate 12 in the form of the hemisuccinate salt

[0790] Alternatively, 11 (10 g, 1.0 eq), 3 (6.62 g, 1.1 eq) and NaOtBu (8.85 g, 3.5 eq) were combined in 2-MeTHF (10 v). The solution was degassed and Pd-175 (21 mg, 0.001 eq) was loaded. The solution was further degassed and heated to 70 ° C until it was completed by HPLC. The reactants were then cooled to room temperature and quenched by adding ammonium chloride (aqueous solution, 20 wt %, 6 v). The organic matter was then washed with brine (6 v). The crude 12 in 2-MeTHF was concentrated to about 5 v and azeotropically dried by constant distillation with 2-MeTHF until KF <1.5%. Acetonitrile (5 v) was loaded, followed by succinic acid (2.3 g, 0.75 eq) at 55 ° C. The resulting slurry was aged for 1 h at 55 ° C and cooled to room temperature overnight. Filtration and subsequent washing with acetonitrile / 2-MeTHF (1:1, 2v) gave 12 hemisuccinate salt (13.8 g, 95% yield) as a white solid. 1H NMR (400 MHz, DMSO) δ 12.18 (s, 1H), 8.48 (s, 1H), 8.33 (d, J = 7.0 Hz, 1H), 8.13 (s, 1H), 7.18 (d, J = 7.0 Hz, 1H), 6.75 (d, J = 8.6 Hz, 1H), 5.62 (q, J = 5.9 Hz, 1H), 4.55 (q, J = 7.1 Hz, 2H), 3.88 (dp, J = 10.8, 3.8 Hz, 1H), 3.47 (dq, J = 9.6 ,7.0Hz,1H),3.25(dt,J=9.8,6.9Hz,2H),3.13(m,3H),2.86(s,3H),2.42(s,2H),2.18(tt,J=7.7,4.3Hz,1H),1.90-1.71(m,1H),1.64(d,J=6.0Hz,3H),1.36(t,J=7.1Hz,3H),1.06(t,J=7.0Hz,3H),0.93(d,J=6.9Hz,3H). C22H33N7O4S,(calculated value M+H:492.2387), LCMS(EI)m / e492.2389(M + +H).

[0791] Compound of formula (I): 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (crude)

[0792]

[0793] A clean inert gas-filled reactor was charged with 12 (or 12 hemisuccinate) in 2-MeTHF, followed by 1N HCl aqueous solution (32.3 L, 3 eq). The mixture was heated to 70 ± 5 ° C, while the reaction mixture was concentrated to remove acetaldehyde until the reaction was complete as indicated by HPLC. After completion, the reactants were cooled to 15 ° C-30 ° C, and the aqueous layer containing the product was removed. The organic layer was extracted twice with 1N HCl (2x5.3 L, a total of 2 v), and the combined aqueous layer was diluted with 2-MeTHF (45 L). The reaction mixture was neutralized to a pH of about 8-9 by adding 5N sodium hydroxide (8.4 L). The organic layer containing the product was separated, and the aqueous layer was extracted with 2-MeTHF (10.6 L, 2 v). The combined organic layers were treated with carbon C-941 (530 g, 20% w / w) and SiliaMetS imidazole (530 g, 20% w / w) at 40°C for no more than 12 hours. The mixture was cooled to 15°C-30°C and filtered through diatomaceous earth. The collected solid was washed with 2-MeTHF (21.2 L). The filtrate containing the product was washed twice with water (7.95 L). The organic layer was concentrated and 2-Me THF was charged at NMT 50°C to remove residual water. The reaction mixture was then diluted with heptane (10 v) and the temperature was maintained at>45°C. After aging for about 30 min at 50°C, the reaction mixture was cooled to 15°C-30°C and filtered. The product was washed with heptane (10.6 L, 2 v) and dried at no more than 50°C to obtain a crude compound of formula (I).

[0794] Solid form of the compound of formula (I). 8-ethoxy-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine (Formula (I))

[0795]

[0796] Prepare a 10% ethanol aqueous solution (42 L) in a clean inert gas filled reactor. Next, load the crude compound of formula (I) (4.2 kg) from the previous step, and heat the contents of the reactor to 50°C-80°C until a solution is observed. Allow the solution to cool to 47°C-57°C, and add C-941 activated carbon (420 g) and SiliaMetS imidazole (420 g). Stir the mixture for no more than 12 hours. Allow the mixture to cool to 35°C-50°C, and filter through diatomaceous earth. Then finely filter the filtrate into a clean inert gas filled reactor. Load finely filtered ethanol and distill to remove water from the solution until the Karl Fisher analysis meets the criteria specified in the batch record. Allow the mixture to cool to -5°C-5°C. Wash the solid with cold ethanol (4.2 L) and dry in a vacuum oven at no more than 50°C.

[0797] Example 3

[0798] Synthesis of (3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-amine hydrochloride (3)

[0799]

[0800] Intermediate (1). 3-Methyl-1-(methylsulfonyl)piperidin-4-one

[0801]

[0802] Under nitrogen, 3-methylpiperidin-4-one hydrochloride (106.2g, 710mmol), DCM (708mL) and mesyl chloride (60.4mL, 781mmol) were added to 3 liters of 3-necked round-bottom flasks with mechanical stirrer and thermocouple. The reaction mixture was stirred, and it became a solution in a few minutes. Triethylamine (218mL, 1562mmol) was slowly added via a feed funnel over 30min. Stirring was continued overnight (12 hours) at room temperature. The suspended solid was filtered out as waste, and the solid was rinsed in three portions with DCM (300mL). The filtrate was then washed with a 0.5N HCl aqueous solution to remove TEA residues. The DCM layer was further washed with a saline solution (60mL). The DCM layer was then concentrated to dryness under reduced pressure on a rotary evaporator to be a light yellow solid (132g, 97% yield). The resulting crude product, 3-methyl-1-(methylsulfonyl)piperidin-4-one (1,132.1 g, 691 mmol, 97% yield), was used in the next reaction without further purification. 1HNMR (400MHz, DMSO) δ3.85-3.74(m,2H),3.21(td,J=11.9,3.8Hz,1H),2.98(s,3H),2.88(t,J=11.5 Hz, 1H), 2.78-2.67 (m, 1H), 2.70-2.59 (m, 1H), 2.34 (dt, J = 14.7, 3.6Hz, 1H), 0.95 (d, J = 6.6Hz, 3H). 7H 13 NO3S, (calculated value M+H: 192.0689), LCMS (EI) m / e 192.1 (M + +H).

[0803] Intermediate (2). (3R,4S)-3-Methyl-1-(methylsulfonyl)-N-((S)-1-phenylethyl)piperidin-4-amine

[0804]

[0805] (S) -1- phenyl ethyl -1- amine (134mL, 1.5eq) and DIPEA (145mL, 1.2eq) were loaded into a solution of 1 (132.4g, 1eq) in THF (1324mL, 10v). Sodium triacetoxyborohydride (STAB; 220g, 1.5eq) was added portion by portion while maintaining 20-25°C (delayed exotherm can be observed). The reaction mixture was stirred for 1h until completed by HPLC, and then quenched by slowly adding methanol (132mL, 1v). The mixture was concentrated to a minimum volume and diluted with dichloromethane (1324mL, 10v). The organic matter was washed twice with saturated sodium bicarbonate (6v and 4v), then washed with brine (2v), and then concentrated to near dryness. The crude was diluted with EtOAc (4v), and concentrated to a minimum volume to remove residual DCM. The crude solid was then slurried in EtOAc (4 v) and warmed at 70 ° C to form a homogeneous mixture. The reaction mixture was cooled to 60 ° C and seeded with 2, cooled to 50 ° C, and aged for crystal growth for 6 hours, then slowly cooled to 0 ° C. The solid was filtered, washed with EtOAc (1 v) and dried to give 2 (115 g, 56.3% yield, 94:0.5:5:5 dr) as a white solid.

[0806] The diastereomeric mixture of 2 (115g, 1eq, 94:0.5:5:5dr) was heated under reflux in EtOAc (693mL, 6v) to obtain a solution that was clarified to almost clarified. The solution was cooled at 60°C and seeded because no automatic seeding was observed. The mixture was aged at 50-60°C for 5 hours to obtain a viscous slurry and continued to slowly cool to room temperature. The solid was separated by filtration, washed with EtOAc (1v), and dried in a vacuum oven to obtain 2 (92.4g, 80% yield, 99.27:0:0.73:0dr) as a white solid. Crystallization was repeated until the desired dr was obtained (usually recrystallized twice). 1 H NMR(400MHz,DMSO)δ7.39-7.32(m,2H),7.35-7.26(m,2H),7.25-7.16(m,1H ),3.77(q,J=6.6Hz,1H),3.37-3.27(m,1H),3.18(ddd,J=11.7,4.5,1.8Hz, 1H),2.75(s,3H),2.70-2.59(m,2H),2.37(dt,J=9.1,4.5Hz,1H),1.99(q,J =4.8, 4.0Hz, 2H), 1.45 (m, 2H), 1.23 (d, J = 6.6Hz, 3H), 0.94 (d, J = 6.9Hz, 3H). C 15 H 24 N2O2S, (calculated value M+H: 297.1631), LCMS (EI) m / e 297.2 (M + +H).

[0807] Intermediate (3). (3R,4S)-3-Methyl-1-(methylsulfonyl)piperidin-4-amine hydrochloride

[0808]

[0809] Pd(OH)2 (2.4 g, 20% wt) and HCl (3N in MeOH; 11.6 mL, 1 eq) were loaded into a solution of 2 (10.31 g, 1 eq) in methanol (200 mL, 20 v). The reaction mixture was degassed and subjected to H2 (60 psi) for 24 hours. Pd(OH)2 (0.73 g, 20% wt) was reloaded, and the mixture was subjected to H2 for another 6 hours, at which point it was complete by HPLC analysis. The reaction mixture was filtered through diatomaceous earth, washed with methanol (3x60 mL, 6 v) and concentrated to dryness in vacuo. The crude solid was wet-milled in heptane (40 mL, 4 v) at 60 ° C for 6 hours. The slurry was cooled to room temperature, filtered, and washed with heptane (20 mL, 2 v) to give 3 (7.5 g, 94% yield) in the form of the HCl salt. 1 H NMR (400MHz, DMSO) δ8.38-8.33(s,3H),3.49-3.39(m,1H),3.33-3.24(m,2H),3.02(dd,J=12.1,3 .3Hz,1H),2.98-2.89(m,1H),2.87(s,3H),2.24-2.14(m,1H),1.83(m,2H),0.97(d,J=7.0Hz,3H). 7H 16 N2O2S, (calculated value M+H: 193.1005), LCMS (EI) m / e 193.1 (M + +H).

[0810] Example 4

[0811] Synthesis of 2,7-dibromo-8-ethoxy-[1,2,4]triazolo[1,5-a]pyridine (7)

[0812]

[0813] Intermediate (4). 4-Bromo-3-ethoxypyridin-2-amine

[0814]

[0815] 2-amino-4-bromopyridine-3-ol hydrobromide (245.0 g, 871 mmol), cesium carbonate (568 g, 1743 mmol) and acetonitrile (2000-2500 mL, 711 mmol) were combined in a 5L round-bottom flask equipped with a mechanical stirrer and a reflux condenser under a nitrogen atmosphere. The mixture was stirred for 15 minutes, and iodoethane (105 mL, 1307 mmol) was added. The reaction mixture was heated at 65-70 ° C for 18 hours, and the reaction mixture was analyzed by HPLC and completed. The reaction mixture was cooled and stirred at room temperature for 30 min. The resulting reaction slurry was filtered through diatomite to remove salts, and the filter cake was washed with dichloromethane. The filtrate containing the product was concentrated to dryness, and 500 mL of dichloromethane was added. Additional cesium carbonate was precipitated and removed by filtration. The filtrate was concentrated, and a 750 g Biotage column was used to undergo a silica plug using a gradient of ethyl acetate / dichloromethane from 0 to 25%. The clean fractions were combined and concentrated on a rotary evaporator.

[0816] The resulting solid was slurried in 1.25 to 1.5 volumes of heptane and heated to 98° C. The mixture was then cooled to 0° C. The solid was filtered and washed with ice-cold heptane. The solid was dried by drawing air through the filter cake. 4-bromo-3-ethoxypyridin-2-amine (4) was obtained in a yield of 70%-75%. 1 H NMR (400 MHz, DMSO) δ7.53 (d, J = 5.4 Hz, 1H), 6.73 (d, J = 5.3 Hz, 1H), 6.13 (s, 2H), 3.91 (q, J = 7.0 Hz, 2H), 1.35 (t, J = 7.0 Hz, 3H). C7H9BrN2O, (calculated value M+H: 216.9971), LCMS (EI) m / e 216.9 (M + +H).

[0817] Intermediates (5)

[0818]

[0819] To a solution of 4 (44.7 g, 1 eq) in DCM (400 mL, 9 v) was added ethoxycarbonyl isothiocyanate (26.7 mL, 1.1 eq) while maintaining the temperature at 20° C. The reaction mixture was stirred for 16 hours until complete by HPLC and then concentrated to dryness to give 5 (71.7 g, quantitative) and used directly in the next reaction. 11 H 14 BrN3O3S (calculated value M+H: 348.0012), LCMS (EI) m / e 348.1 (M + +H).

[0820] Intermediate (6). 7-Bromo-8-ethoxy-[1,2,4]triazolo[1,5-a]pyridin-2-amine

[0821]

[0822] To a slurry of hydroxylamine hydrochloride (42.9 g, 3 eq) in methanol (300 mL, 4 v) was added Huniger's base (N, N-diisopropylethylamine) (71.9 mL, 2 eq), and the mixture was stirred at room temperature for 50 min. The reaction mixture was then added to a separate flask containing 5 (71.7 g, 1 eq) in ethanol (300 mL, 4 v) and warmed under reflux for 2 hours until completed by HPLC. The reaction mixture was cooled to room temperature and concentrated to about 1.5 v. The resulting slurry was cooled to 0 ° C and quenched by adding ammonium hydroxide (28%, 57.3 mL, 2 eq) and then diluted with water (120 mL, 2 v). The slurry was stirred for 15 min, filtered, and washed with water (2x100 mL) and dried to give 6 (48.8 g, 92% yield). 1 H NMR (400MHz, DMSO) δ8.25 (d, J = 7.0 Hz, 1H), 7.03 (d, J = 7.0 Hz, 1H), 6.16 (s, 2H), 4.55 (q, J = 7.0 Hz, 2H), 1.32 (t, J = 7.1 Hz, 3H). C8H 10 BrN4O, (calculated value M+H: 257.0032), LCMS (EI) m / e 257.0 (M + +H).

[0823] Intermediate (7). 2,7-Dibromo-8-ethoxy-[1,2,4]triazolo[1,5-a]pyridine

[0824]

[0825] t-BuONO (144.3 g, 1399 mmol) was added dropwise to a mixture of 6 (150 g, 583 mmol) and CuBr2 (134 g, 600 mmol) in acetonitrile (1500 mL) at 0 ° C over 30 minutes. The resulting mixture was stirred at 0 ° C for 2 hours, then stirred at room temperature for 2 hours (TLC indicated that all starting materials were consumed). The reaction mixture was concentrated under reduced pressure. DCM (3L) was added to the residue and stirred for half an hour. The mixture was then passed through a silica gel pad (300 g) and eluted with DCM until the product was not detected by TLC. The collected fractions were evaporated to obtain the desired product (137 g). Charcoal (45 g, about 100 mesh particle size) was added to the product (137 g) in EtOAc (1500 mL), and the resulting suspension was stirred at room temperature for 2 hours. The mixture was filtered through a diatomaceous earth pad and washed with EtOAc (1500 mL). The filtrate was concentrated under reduced pressure. Hexane (500 mL) was added to the residue (125 g) and stirred. The solid was recovered by filtration and washed with hexane (500 mL). The filter cake was air-dried to give 7 (111 g) as a light beige solid. 1 H NMR (400 MHz, DMSO) δ 8.65 (d, J = 7.2 Hz, 1H), 7.47 (d, J = 7.2 Hz, 1H), 4.65 (q, J = 7.0 Hz, 2H), 1.37 (t, J = 7.0 Hz, 3H). C8H7Br2N3O, (calculated value M+H: 319.9029), LCMS (EI) m / e 319.9 (M + +H).

[0826] Example 5

[0827] Solid-state characterization of formula (I)

[0828] X-ray powder diffraction (XRPD)

[0829] X-ray powder diffraction (XRPD) was obtained from a Bruker D8 Advance ECO X-ray powder diffractometer (XRPD). The general experimental procedure for XRPD is as follows: (1) X-ray radiation and LYNXEYE TM detector; (2) 40 kV, 25 mA X-ray power; and (3) the sample powder is dispersed on a zero background sample holder. The general measurement conditions of XRPD are: starting angle of 3 degrees; ending angle of 30 degrees; sampling of 0.015 degrees; and scanning speed of 2 degrees / min.

[0830] Differential Scanning Calorimetry (DSC)

[0831] DSC was obtained from a TA Instruments Differential Scanning Calorimeter Discovery DSC 2500 with an autosampler. The DSC instrument conditions were as follows: 20°C-300°C, 10°C / min; Tzero aluminum sample pan and cover; and nitrogen flow rate of 50 mL / min.

[0832] Thermogravimetric analysis (TGA)

[0833] TGA was obtained from a TA Instruments thermogravimetric analyzer Discovery TGA5500 with an autosampler. The general experimental conditions for TGA were: ramp from 25°C to 300°C at 10°C / min; nitrogen purge flow rate of 25 mL / min; platinum sample holder.

[0834] Formula (I) Free base form I

[0835] The crystalline free base of the compound of formula (I) as obtained in Examples 1 and 2 was characterized and is referred to herein as Form I. The Form I free base was characterized by XRPD, DSC and TGA. The XRPD pattern is shown in Figure 1 and Fig.28 , and XRPD data are provided in Tables 1a and 1b, which confirm that Form I is a crystalline solid.

[0836] DSC thermogram is shown in Figure 2 The DSC thermogram revealed a major endothermic event with an onset temperature of 191.7°C and a peak temperature of 193.6°C (the peak temperature was considered to be the melting / decomposition temperature of the compound).

[0837] A second DSC was obtained using a Q200 V24.11 DSC using a 10°C / min ramp to 300°C. The DSC is shown in Fig.29 The DSC thermogram revealed a major endothermic event with an onset temperature of 191.3°C and a peak temperature of 193.3°C (the peak temperature was considered to be the melting / decomposition temperature of the compound).

[0838] TGA thermogram is shown in Figure 3 A weight loss of 0.96% was observed below 200°C. The compound started to decompose above 200°C.

[0839] Table 1a. XRPD data of crystalline free base Form I

[0840]

[0841]

[0842] Table 1b. XRPD data of crystalline free base Form I

[0843] 2-θ(°) high H% 7.5 235900 83.2 10.6 30976 10.9 13.0 205684 72.6 14.7 42552 15.0 15.3 38144 13.5 16.2 121679 42.9 16.6 113132 39.9 17.6 27890 9.8 20.5 283366 100 20.8 85984 30.3 21.4 265761 93.8 23.3 71442 25.2 24.0 53028 18.7 25.2 29928 10.6 25.9 38144 13.5 27.1 136962 48.3 28.0 64762 22.8 28.9 29217 10.3 30.5 12495 4.4 32.8 14303 5.0 37.5 10129 3.6 39.4 2725 1.0 40.3 8331 29.4

[0844] Formula (I) maleate

[0845] Preparation of maleate salt of formula (I)

[0846] In 20mL transparent glass vial, 574.0mg free alkali is dissolved in 8mL 1:1 dichloromethane (DCM) / methanol under stirring. 191.3mg maleic acid (1.2eq) is added to the solution and mixed thoroughly. The solution is evaporated to dryness overnight without cover at room temperature. 5mL acetone is added to the obtained solid, and stirred at room temperature for 2 hours. Solid is collected by filtration, washed with acetone and dried under vacuum at 50°C for 2 hours. The salt ratio between free alkali and maleic acid is determined to be 1.0 by NMR analysis.

[0847] The maleate salt was confirmed to be a crystalline solid according to XRPD analysis. The XRPD pattern is shown in Figure 4 , and the peak data are provided in Table 1.

[0848] DSC thermogram is shown in Figure 5 The DSC thermogram revealed a major endothermic event with an onset temperature of 180.4°C and a peak temperature of 181.9°C (the peak temperature was considered to be the melting / decomposition temperature of the compound).

[0849] TGA thermogram is shown in Figure 6 A weight loss of 19.9% ​​was observed between 100°C and 260°C.

[0850] Table 2. XRPD data of maleate salt

[0851]

[0852]

[0853] Formula (I) benzenesulfonate

[0854] Preparation of benzenesulfonate of formula (I)

[0855] In a 4mL transparent glass vial, 104.98mg of the free alkali of formula (I) is dissolved in 2mL 1:1 dichloromethane (DCM) / methanol under stirring. 47.75mg benzenesulfonic acid (1.2eq) is added to the solution and mixed thoroughly. The solution is evaporated into an oily substance overnight without a cover at room temperature. Under stirring at room temperature, 1mL acetonitrile is added to the obtained oily substance to obtain a solution. The solution is evaporated into an oily substance overnight without a cover again at room temperature. Then 1mL acetone is added to the oily substance, and slurried into a solid for 1-2 hours at room temperature. Benzenesulfonate is collected by filtration, washed with acetone, and dried under vacuum at 50°C for 1 hour. The salt ratio between the free alkali and benzenesulfonic acid is determined to be 2.0 by NMR analysis.

[0856] According to XRPD analysis, the benzenesulfonate salt was confirmed to be a crystalline solid. The XRPD pattern is shown in Figure 7 and the peak data are provided in Table 3.

[0857] DSC thermogram is shown in Figure 8 The DSC thermogram revealed a major endothermic event with an onset temperature of 160.4°C and a peak temperature of 163.4°C (the peak temperature was considered to be the melting / decomposition temperature of the compound).

[0858] TGA thermogram is shown in Fig. 9 A weight loss of 1.0% was observed below 150°C, and above 150°C a significant weight loss occurred due to decomposition of the compound.

[0859] Table 3. XRPD data of benzenesulfonate salt

[0860]

[0861]

[0862] Formula (I) Methanesulfonate

[0863] Preparation of methanesulfonate of formula (I)

[0864] In 4mL transparent glass vial, 108.57mg free alkali of formula (I) is dissolved in 2mL 1:1 dichloromethane (DCM) / methanol under stirring.20.2 μL methanesulfonic acid (1.2eq) is added to the solution and mixed thoroughly.The solution is evaporated into an oily substance overnight without cover at room temperature.1mL acetone is added to the obtained oily substance, and slurried into solid for 1 hour at room temperature.Mesylate is collected by filtration, washed with acetone, and dried in vacuo at 50°C for 1 hour.The salt ratio between free alkali and methanesulfonic acid is determined to be 1.2 by NMR analysis.

[0865] According to XRPD analysis, the mesylate salt was confirmed to be a crystalline solid. The XRPD pattern is shown in Fig.10 and the peak data are provided in Table 4.

[0866] DSC thermogram is shown in Fig.11 The DSC thermogram revealed a first dehydration with an onset temperature of 24.6°C and a peak temperature of 61.1°C and a second endothermic event with an onset temperature of 134.4°C and a peak temperature of 150.1°C (the peak temperature was considered to be the melting / decomposition temperature of the compound).

[0867] TGA thermogram is shown in Fig.12 A weight loss of 0.65% was observed below 125°C, and significant weight loss occurred above 150°C due to decomposition of the compound.

[0868] Table 4. XRPD data of mesylate salt

[0869]

[0870]

[0871] Formula (I) Toluenesulfonate

[0872] Preparation of toluenesulfonate of formula (I)

[0873] In 4mL transparent glass vial, 121.81mg free alkali of formula (I) is dissolved in 2mL 1:1 dichloromethane (DCM) / methanol under stirring. 67.03mg p-toluenesulfonic acid monohydrate (1.2eq) is added to the solution and mixed thoroughly. The solution is evaporated into an oily substance overnight without cover at room temperature. Under stirring at room temperature, 1mL acetonitrile is added to the obtained oily substance to obtain a solution. The solution is evaporated into an oily substance / semi-solid overnight without cover again at room temperature. Then 1mL acetone is added, and slurried into a solid at room temperature for 1 hour. Toluenesulfonate is collected by filtration, washed with acetone, and dried in vacuo at 50°C for 1 hour. The salt ratio between free alkali and toluenesulfonic acid is determined to be 2.0 by NMR analysis.

[0874] XRPD analysis confirmed that the tosylate salt was a crystalline solid. The XRPD pattern is shown in Fig.13 and the peak data are provided in Table 5.

[0875] DSC thermogram is shown in Fig.14 The DSC thermogram revealed an exothermic event with an onset temperature of 99.6°C and a peak temperature of 110.5°C and an endothermic event with an onset temperature of 216.1°C and a peak temperature of 218.7°C (the peak temperature is considered to be the melting / decomposition temperature of the compound).

[0876] TGA thermogram is shown in Fig.15A weight loss of 0.76% was observed below 150°C, and significant weight loss occurred above 200°C due to decomposition of the compound.

[0877] Table 5. XRPD data of tosylate salt

[0878]

[0879]

[0880] Formula (I) monohydrochloride

[0881] Preparation of monohydrochloride of formula (I)

[0882] In a 4mL transparent glass vial, 102.7mg of the free alkali of formula (I) was dissolved in 2mL 1:1 dichloromethane (DCM) / methanol under stirring. 49 μL of 6M hydrochloric acid aqueous solution (1.2eq) was added to the solution and mixed thoroughly. The solution was evaporated to dry solid overnight without cover at room temperature. 1mL acetone was added to the obtained solid, and slurried for 1 hour at room temperature. The monohydrochloride was collected by filtration, washed with acetone and dried under vacuum at 50°C for 1 hour. The salt ratio between the free alkali and the hydrochloric acid was determined to be 1.08 by ion chromatography.

[0883] According to XRPD analysis, the monohydrochloride salt was confirmed to be a crystalline solid. The XRPD pattern is shown in Fig.16 and the peak data are provided in Table 6.

[0884] DSC thermogram is shown in Fig.17 The DSC thermogram revealed one major endothermic event with an onset temperature of 196.0°C and a peak temperature of 212.2°C (the peak temperature was considered to be the melting / decomposition temperature of the compound).

[0885] TGA thermogram is shown in Fig.18 A weight loss of 9.4% was observed below 225°C. Weight loss continued above 225°C due to decomposition of the compound.

[0886] Table 6. XRPD data of monohydrochloride salt

[0887]

[0888]

[0889] Formula (I) dihydrochloride

[0890] Preparation of dihydrochloride of formula (I)

[0891] In 4mL transparent glass vial, 100.35mg free alkali of formula (I) is dissolved in 2mL 1:1 dichloromethane (DCM) / methanol under stirring. 88μL of 6M hydrochloric acid aqueous solution (2.2eq) is added to the solution and mixed thoroughly. The solution is evaporated to 0.2-0.3mL (containing solid) overnight without cover at room temperature. Then 1mL acetone is added, and slurry is made at room temperature for 1 hour. Dihydrochloride is collected by filtration, washed with acetone, and dried under vacuum at 50°C for 1 hour. The salt ratio between free alkali and hydrochloric acid is determined to be 1.50 by ion chromatography.

[0892] According to XRPD analysis, the dihydrochloride salt was confirmed to be a crystalline solid. The XRPD pattern is shown in Fig.19 and the peak data are provided in Table 7.

[0893] DSC thermogram is shown in Fig. 20 The DSC thermogram revealed a major endothermic event with an onset temperature of 182.1°C and a peak temperature of 206.4°C (the peak temperature was considered to be the melting / decomposition temperature of the compound).

[0894] TGA thermogram is shown in Fig.21 Weight loss was observed in multiple steps: 8.3% below 175° C. and 7.3% between 170° C. and 240° C. Weight loss continued above 240° C. due to compound decomposition.

[0895] Table 7. XRPD data of dihydrochloride salt

[0896]

[0897]

[0898] Example 6

[0899] Formula (I) Research

[0900] Solubility measurements

[0901] The solubility of the compound of formula (I) Form I was measured at 25°C and at 50°C.

[0902] Solubility measurements at 25°C were performed according to the following procedure. 5 mL of solvent (see Table 8) was added to each vial. Form I of the compound of formula (I) was added to the vial to obtain a turbid solution at 25°C. Approximately 20 mg of Form I of the compound of formula (I) was further added to the turbid solution. The mixture was stirred at 25±1°C for 48 h, which was ETS-D5 temperature controller and RCT basic safety control was used for control. The supernatant was filtered using a syringe filter (0.22 μm). The saturated solution was pipetted into an HPLC vial and diluted with MeOH or acetone. The samples were analyzed by HPLC and the corresponding solubility was calculated as indicated in Table 8.

[0903] Solubility measurements at 50°C were performed according to the following procedure. 5 mL of solvent (see Table 8) was added to each vial. Form I of the compound of formula (I) was added to the vial to obtain a turbid solution at 50°C. Approximately 20-25 mg of Form I of the compound of formula (I) was further added. The mixture was stirred at 50±1°C for 24 h, which was ETS-D5 temperature controller and RCT basic safety control is controlled. The supernatant is quickly filtered using a warm syringe filter (0.22 μm) at 50 ± 1 ° C. The saturated solution is pipetted into an HPLC vial and diluted with MeOH or acetone. The samples are analyzed by HPLC and the corresponding solubility is calculated, as indicated in Table 8.

[0904] Table 8. Solubility of Form I of the compound of formula (I) in various solvents (mg / mL)

[0905]

[0906]

[0907] At 25°C, Form I of the compound of formula (I) has excellent solubility in CHCl3, dimethylformamide (DMF), 1,4-dioxane, 2-methoxyethanol, DMSO, and THF (>50 mg / mL). The form has relatively good solubility in dichloromethane, MeOH, acetone, methyl ethyl ketone (15 mg / mL<solubility<50 mg / mL). The form is slightly soluble in acetonitrile, methyl isobutyl ketone, EtOH, n-propanol, isopropanol, n-butanol, EtOAc, isopropyl acetate, isobutyl acetate, ethyl formate, 2-methyl THF, EtOH containing 3% water, and EtOH containing 6% water (1 mg / mL<solubility<15 mg / mL). The form has poor solubility (<1 mg / mL) in toluene, tert-butyl methyl ether (MTBE), water, 2-methylTHF / H2O / heptane (volume ratio 1:1.5%:1), and 2-methylTHF / H2O / heptane (volume ratio 1:3%:1). The form is completely insoluble in heptane.

[0908] At 50°C, Form I of the compound of formula (I) has excellent solubility in CHCl3, dimethylformamide (DMF), 1,4-dioxane, 2-methoxyethanol, DMSO, and THF (>50 mg / mL). The form has relatively good solubility in acetonitrile, dichloromethane, MeOH, EtOH, acetone, methyl ethyl ketone, ethyl formate, 2-methyl THF, EtOH containing 3% water, and EtOH containing 6% water (15 mg / mL<solubility<50 mg / mL). The form is slightly soluble in methyl isobutyl ketone, n-propanol, isopropanol, n-butanol, EtOAc, isopropyl acetate, and isobutyl acetate (1 mg / mL<solubility<15 mg / mL). The form has poor solubility (<1 mg / mL) in toluene, tert-butyl methyl ether (MTBE), water, 2-methylTHF / H2O / heptane (volume ratio 1:1.5%:1), and 2-methylTHF / H2O / heptane (volume ratio 1:3%:1). The form is completely insoluble in heptane.

[0909] Phase equilibrium

[0910] Phase equilibrium studies were performed to identify the major crystalline form for phase identification. Based on the solubility of the compound of formula (I) Form I in various solvent systems (Table 8), it was equilibrated in a representative set of solvents at 25 ± 1 ° C and 50 ± 1 ° C. The compound of formula (I) Form I was added to the solvent until a turbid solution was obtained, and then approximately 20 mg of the compound of formula (I) Form I was added to the turbid solution. The mixture was stirred at 25 ± 1 ° C or 50 ± 1 ° C for 48 hours or 24 hours, respectively. The solid was filtered, dried in vacuum, and analyzed by XRPD.

[0911] In all solvents tested, the material obtained showed crystalline Form I in phase equilibrium at 25° C. and 50° C. The results are shown in Table 9 (N / A indicates not tested).

[0912] Table 9. Crystalline forms of phase equilibrium

[0913]

[0914]

[0915] Evaporation research

[0916] Evaporation studies were performed to identify the major crystalline form during uncontrolled precipitation. XRPD was used to study the solid state morphology of the crystalline form of the evaporated samples at 25±1° C. and 50±1° C. The results are shown in Table 10 (N / A indicates that the amount of precipitate was too small to be analyzed by XRPD).

[0917] Table 10. Crystalline forms from evaporation

[0918]

[0919]

[0920] Compared to the XRPD pattern of the starting material (Formula (I) compound Form I), the solid obtained after evaporation in dichloromethane, acetonitrile, ethanol and IPA at 25°C has a different XRPD pattern and is referred to as Form II. Compared to the XRPD patterns of Forms I and II, the solid obtained after evaporation in 1,4-dioxane at 25°C has a different XRPD pattern and is referred to as Form III.

[0921] Antisolvent addition

[0922] Saturated and near-saturated solutions of Form I of the compound of Formula (I) were prepared at room temperature in the solvents listed in Table 11. Antisolvents were added dropwise to induce precipitation. As indicated in Table 11, only Form I was observed.

[0923] Table 11. Precipitation from Antisolvent Addition

[0924] Solvent (mL) Antisolvent (mL) Solid form DMF (1.0) MTBE(10) I DMF (1.0) <![CDATA[H2O(10)]]> I 1,4-Dioxane (1.0) MTBE(10) I 1,4-Dioxane (1.0) <![CDATA[H2O(10)]]> I 2-Methoxy-ethanol (1.0) MTBE(10) I 2-Methoxy-ethanol (1.0) <![CDATA[H2O(10)]]> I THF(1.0) MTBE I THF(1.0) <![CDATA[H2O(10)]]> I

[0925] Add in reverse

[0926] Saturated and near-saturated solutions of Form I of the compound of Formula (I) were prepared in the solvents listed in Table 12 at 25°C and added dropwise to a larger volume of a miscible antisolvent. As shown in Table 12, no new polymorphic forms were identified in the reverse addition experiments.

[0927] Table 12. Precipitation from reverse addition

[0928]

[0929]

[0930] Quenching of saturated solution

[0931] A saturated or near-saturated solution of a compound of formula (I) prepared at 25° C. was quenched to about −20° C. to about −30° C. to induce precipitation of a higher energy form. Representative solvents were selected based on solubility data measured at 25° C. and 50° C. As shown in Table 13, Form III solids were observed in 1,4-dioxane.

[0932] Table 13. Crystal forms from quench experiments

[0933] Solvents Solid form DMF N / A(viscous) 1,4-Dioxane III MeOH I 2-Methoxy-ethanol N / A(viscous) THF I

[0934] Crystallization of saturated solutions under heating and cooling cycles

[0935] This experiment was conducted to identify a more stable form of the compound of formula (I) than form I. A saturated solution of the compound of formula (I) was prepared at 50°C and slowly cooled in a bath using a programmed circulating bath. About 10 mg of the compound of formula (I) form I was added to the clear solution to obtain a slurry. The formed slurry was then heated at 50°C for 2 hours and then cooled to 5°C over 2 hours. This process was repeated for 3 days and the solid was filtered for further analysis. The solvent used was 1,4-dioxane, methanol or THF. The experiment only produced form I.

[0936] Stability Relationship

[0937] The relative stability of three forms (Forms I-III) of the compound of formula (I) was studied and compared by mixture phase equilibrium experiments in three solvent systems (EtOH containing 3% water [volume ratio], using 3 volumes of solvent; EtOH containing 3% water, using 5 volumes of solvent; and EtOH containing 6% water, using 5 volumes of solvent). The three crystalline forms were mixed and slurried at 50° C. for more than 6 hours. After six hours of stirred competitive slurrying, the mixture of the three forms converted to Form I in the three specific solvents.

[0938] Example 7

[0939] Characterization of Form II

[0940] The compound of formula (I) Form II was prepared by evaporation in CH2Cl2, CH3CN, EtOH and IPA at 25°C (see Example 6, Table 10). 1 Form II (obtained in CH2Cl2) was characterized by H NMR, XRPD, DSC and TGA. The XRPD pattern is shown in Fig. 22 and the XRPD data are provided in Table 14.

[0941] DSC thermogram is shown in Fig.23 In comparing the DSC of Form I and Form II, it was observed that the Form II solid contained two peaks ( Fig.23 ), the starting point of the latter peak (≈191.0°C) and T max (193.4°C) similar to the peak onset and T of Form I max ( Figure 2 ). Form II changes to Form I during the heating process (see Example 6).

[0942] TGA thermogram is shown in Fig.24 middle.

[0943] Table 14. XRPD data from Form III

[0944]

[0945]

[0946] Example 8

[0947] Characterization of Form III

[0948] The compound of formula (I) Form III was prepared by evaporation in 1,4-dioxane at 25°C (see Example 6, Table 10) and quenching experiments in 1,4-dioxane (see Example 6, Table 13). 1 Form III was characterized by H NMR, XRPD, DSC and TGA. The XRPD pattern is shown in Fig.25 and the XRPD data are provided in Table 15.

[0949] Quantification 1 H NMR showed that the residual 1,4-dioxane (wt%) in the solid was about 4.98%. The residual solvent could not be removed by conventional drying methods. This suggests that the obtained solid is likely to be a solvate, which is supported by TGA experiments (weight loss up to 5.00% at 180 °C; Fig. 27 The stoichiometric ratio of the compound of formula (I) to 1,4-dioxane may be 4:1. The DSC of the solid ( Fig.26 ) contains the peak starting point, the next peak starting point (≈192.6℃) and T max (194.3°C) is similar to the peak onset (191.3°C) and T of Form I. max (193.3℃)( Figure 2 ). Form III changes to Form I during the heating process (see Example 6).

[0950] Table 15. XRPD data from Form III

[0951]

[0952]

[0953] Example A. CDK2 / Cyclin E1 HTRF enzyme activity assay

[0954] The CDK2 / cyclin E1 enzyme activity assay utilized full-length human CDK2 co-expressed as an N-terminally GST-tagged protein with FLAG-cyclin E1 in a baculovirus expression system (Carna product number 04-165). The assay was performed in a white 384-well polystyrene plate with a final reaction volume of 8 μL. CDK2 / cyclin E1 (0.25 nM) was incubated with the compounds of each example (40 nL serially diluted in DMSO) in the presence of ATP (50 μM or 1 mM) and 50 nM ULight TM The labeled eIF4E binding protein 1 (THR37 / 46) peptide (PerkinElmer) was incubated together in an assay buffer (containing 50mM HEPES pH 7.5, 1mM EGTA, 10mM MgCl2, 2mM DTT, 0.05mg / mL BSA and 0.01% Tween 20) at room temperature for 60 minutes. The reaction was terminated by adding EDTA and europium-labeled anti-phospho-4E-BP1 antibodies (PerkinElmer) at final concentrations of 15mM and 1.5nM, respectively. After 1 hour at room temperature, the HTRF signal was read on a PHERAstar FS plate reader (BMG Labtech). The data were analyzed using a three-parameter or four-parameter dose-response curve using IDBS XLFit and GraphPad Prism 5.0 software to determine the IC of each compound. 50 IC of the compound of formula (I) measured at 1 mM ATP in the assay of Example A 50 The data are shown in Table 16.

[0955] Table 16

[0956] Example <![CDATA[IC 50 (nM)]]> Compound of formula (I) +

[0957] + refers to ≤20nM

[0958] According to the foregoing description, various modifications of the present invention other than those modifications set forth herein will also be apparent to those skilled in the art. Such modifications are also intended to fall within the scope of the appended claims. Each reference cited in this application (including all patents, patent applications and disclosures) is incorporated herein by reference in its entirety.

Claims

1. A solid form of a compound of formula (I): The form is Form I, which is crystalline.

2. The solid form of claim 1, wherein the form has at least four XRPD peaks, expressed as 2-θ (±0.2°), selected from 7.3, 10.5, 12.8, 14.5, 15.2, 16.4, 20.3, 21.3, 21.6, and 27.

0.

3. The solid form of claim 1, wherein the form has at least four XRPD peaks, expressed as 2-θ (± 0.2°), selected from 7.5, 13.0, 14.7, 15.3, 16.2, 16.6, 20.5, 20.8, 21.4, 23.3, 24.0, and 27.

1.

4. The solid form of claim 1, wherein the form has at least ten XRPD peaks, expressed as 2-theta (±0.2°), selected from 7.3, 10.5, 12.8, 14.5, 15.2, 16.4, 20.3, 21.3, 21.6, and 27.

0.

5. The solid form of claim 1, wherein the form has at least ten XRPD peaks, expressed as 2-theta (± 0.2°), selected from 7.5, 13.0, 14.7, 15.3, 16.2, 16.6, 20.5, 20.8, 21.4, 23.3, 24.0, and 27.

1.

6. The solid form of claim 1, wherein the form has an XRPD pattern substantially as shown in Figure 1.

7. The solid form of any one of claims 1 to 6, which has an endothermic peak with an onset temperature (±3°C) of 191.7°C and a maximum value of 193.6°C.

8. The solid form of any one of claims 1-6, wherein the form has a DSC thermogram substantially as shown in Figure 2.

9. The solid form of any one of claims 1-8, wherein the form has a TGA thermogram substantially as shown in Figure 3.

10. A solid form of a compound of formula (I): The form is Form II, which is crystalline.

11. The solid form of claim 10, wherein the form has at least four XRPD peaks, expressed as 2-theta (±0.2°), selected from 5.8, 7.6, 11.4, 12.5, 14.4, 17.2, 17.9, and 25.

3.

12. The solid form of claim 10, wherein the form has an XRPD pattern substantially as shown in Figure 22.

13. The solid form of any one of claims 10-12, which has an endothermic peak with an onset temperature (±3°C) of 191.0°C and a maximum value of 193.4°C.

14. A solid form of a compound of formula (I): The form is Form III, which is crystalline.

15. The solid form of claim 14, wherein the form has at least four XRPD peaks, expressed as 2-theta (± 0.2°), selected from 5.5, 9.8, 10.5, 12.1, 13.9, 16.3, 19.8, 22.0, 24.4, and 27.

3.

16. The solid form of claim 14, wherein the form has an XRPD pattern substantially as shown in Figure 25.

17. The solid form of any one of claims 14-16, which has an endothermic peak with an onset temperature (±3°C) of 192.6°C and a maximum value of 194.3°C.

18. A salt of a compound of formula (I): The salt is selected from: A monomaleate salt of the compound of formula (I); The dibenzenesulfonate salt of the compound of formula (I); The monomethanesulfonate salt of the compound of formula (I); The xylenesulfonate salt of the compound of formula (I); The monohydrochloride salt of the compound of formula (I); and The dihydrochloride salt of the compound of formula (I).

19. The salt according to claim 18, which is a monomaleate salt of the compound of formula (I).

20. The salt of claim 19, which is crystalline.

21. The salt of claim 19 or 20, wherein the salt has at least four XRPD peaks, expressed as 2-theta (±0.2°), selected from 10.4, 11.6, 12.0, 14.1, 15.1, 17.2, 18.1, 19.1, 21.3, 21.9, 22.9, 24.2 and 25.

9.

22. The salt according to any one of claims 19 to 21, which has an endothermic peak having an onset temperature (±3°C) of 180.4°C and a maximum temperature (±3°C) of 181.8°C.

23. The salt according to claim 18, which is a dibenzenesulfonate salt of the compound of formula (I).

24. The salt of claim 23, which is crystalline.

25. The salt of claim 23 or 24, wherein the salt has at least four XRPD peaks, expressed as 2-theta (±0.2°), selected from 6.3, 9.9, 12.1, 12.6, 15.9, 17.4, 18.7, 19.0, 19.6 and 25.

1.

26. The salt according to any one of claims 23 to 25, which has an endothermic peak having an onset temperature (±3°C) of 160.4°C and a maximum temperature (±3°C) of 163.4°C.

27. The salt of claim 18, which is a monomethanesulfonate salt of the compound of formula (I).

28. The salt of claim 27, which is crystalline.

29. The salt of claim 27 or 28, wherein the salt has at least four XRPD peaks, expressed as 2-theta (±0.2°), selected from 4.8, 7.0, 11.9, 14.1, 14.9, 17.7, 18.9, 20.2, 22.1 and 26.

1.

30. The salt according to any one of claims 27 to 29, which has a first endothermic peak with a maximum temperature (±3°C) of 61.1°C and a second endothermic peak with an onset temperature (±3°C) of 134.4°C and a maximum temperature (±3°C) of 150.1°C.

31. The salt of claim 18, which is a xylenesulfonate salt of the compound of formula (I).

32. The salt of claim 31 which is crystalline.

33. The salt of claim 31 or 32, wherein the salt has at least four XRPD peaks, expressed as 2-theta (±0.2°), selected from 5.7, 7.8, 8.1, 9.3, 13.7, 13.9, 16.2, 18.8 and 20.

6.

34. The salt according to any one of claims 31 to 33, which has an exothermic peak with an onset temperature (±3°C) of 99.6°C and a maximum temperature (±3°C) of 110.5°C, and an endothermic peak with an onset temperature (±3°C) of 216.1°C and a maximum temperature (±3°C) of 218.7°C.

35. The salt of claim 18, which is the monohydrochloride salt of the compound of formula (I).

36. The salt of claim 35, which is crystalline.

37. The salt of claim 35 or 36, wherein the salt has at least four XRPD peaks, expressed as 2-theta (±0.2°), selected from 5.7, 8.5, 11.3, 14.1, 15.0, 18.4, 19.3, 20.5, 21.8, 22.8 and 25.

7.

38. The salt according to any one of claims 35 to 37, which has an endothermic peak having an onset temperature (±3°C) of 196.0°C and a maximum temperature (±3°C) of 212.2°C.

39. The salt of claim 18, which is the dihydrochloride salt of the compound of formula (I).

40. The salt of claim 39, which is crystalline.

41. The salt of claim 39 or 40, wherein the salt has at least four XRPD peaks, expressed as 2-theta (±0.2°), selected from 9.9, 10.7, 12.3, 13.0, 14.0, 15.2, 19.9, 21.8, 22.3 and 24.

8.

42. The salt according to any one of claims 39 to 41, which has an endothermic peak having an onset temperature (±3°C) of 182.1°C and a maximum temperature (±3°C) of 206.4°C.

43. A pharmaceutical composition comprising the solid form of any one of claims 1-17 or the salt of any one of claims 18-42 and a pharmaceutically acceptable carrier.

44. A method of inhibiting CDK2, the method comprising contacting the CDK2 with the solid form of any one of claims 1-9 or the salt of any one of claims 18-42.

45. A method of inhibiting CDK2 in a patient, the method comprising administering to the patient the solid form of any one of claims 1-9 or the salt of any one of claims 18-42.

46. ​​A method of treating a disease or condition associated with CDK2 in a patient, the method comprising administering to the patient a therapeutically effective amount of the solid form of any one of claims 1-9 or the salt of any one of claims 18-42.

47. The method of claim 45 or 46, wherein the disease or condition is associated with amplification of the Cyclin E1 (CCNE1) gene and / or overexpression of CCNE1.

48. A method of treating a human subject having a disease or condition associated with cyclin dependent kinase 2 (CDK2), the method comprising administering to the human subject a solid form of any one of claims 1-9 or a salt of any one of claims 18-42, wherein the human subject has previously been determined to: (i) (a) having a nucleotide sequence encoding a p16 protein comprising the amino acid sequence of SEQ ID NO: 1; and / or (b) having a cyclin-dependent kinase inhibitor 2A (CDKN2A) gene lacking one or more inactivating nucleic acid substitutions and / or deletions; (ii) (a) having an amplification of the cyclin E1 (CCNE1) gene; and / or (b) having an expression level of CCNE1 higher than a control expression level of CCNE1 in a biological sample obtained from the human subject.

49. A method of treating a human subject suffering from a disease or condition associated with cyclin-dependent kinase 2 (CDK2), the method include: (i) identifying in a biological sample obtained from said human subject: (a) a nucleotide sequence encoding a p16 protein comprising the amino acid sequence of SEQ ID NO: 1; and / or (b) a cyclin-dependent kinase inhibitor 2A (CDKN2A) gene lacking one or more inactivating nucleic acid substitutions; (ii) identifying in a biological sample obtained from said human subject: (a) amplification of the cyclin E1 (CCNE1) gene; and / or (b) an expression level of CCNE1 that is greater than a control expression level of CCNE1; and (iii) administering to the human subject the solid form of any one of claims 1-9 or the salt of any one of claims 18-42.

50. The method of claim 49, wherein include: (i) identifying in a biological sample obtained from said human subject: (a) a nucleotide sequence encoding a p16 protein comprising the amino acid sequence of SEQ ID NO: 1; and / or (b) a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and / or deletions; (ii) identifying in a biological sample obtained from said human subject: (a) amplification of the CCNE1 gene; and (iii) administering the compound or the salt to the human subject.

51. A method of evaluating a human subject suffering from a disease or condition associated with cyclin dependent kinase 2 (CDK2) for response to a solid form of any one of claims 1-9 or a salt of any one of claims 18-42, the method include: (a) administering the compound or the salt to the human subject, wherein the human subject has previously been determined to have an amplification of the Cyclin E1 (CCNE1) gene and / or an expression level of CCNE1 that is higher than a control expression level of CCNE1; (b) measuring the phosphorylation level of retinoblastoma (Rb) protein at serine corresponding to amino acid position 780 of SEQ ID NO: 3 in a biological sample obtained from the subject after said administering of step (a), wherein a decrease in the level of Rb phosphorylation at serine corresponding to amino acid position 780 of SEQ ID NO:3 as compared to a control level of Rb phosphorylation at serine corresponding to amino acid position 780 of SEQ ID NO:3 indicates that the human subject is responsive to the compound or the salt.

52. The method of any one of claims 46-51, wherein the disease or disorder is cancer.

53. A method of preparing the solid form of any one of claims 1-9, the method comprising cooling a solution of the compound of formula (I) in a solvent component comprising ethanol and water.

54. A method for preparing a solid form according to any one of claims 10 to 13, comprising evaporating the compound of formula (I) at 25°C in a solution selected from CH 2 Cl 2 , CH 3 Solutions in solvents of CN, EtOH and IPA.

55. A process for preparing the solid form of any one of claims 14-17, the process comprising evaporating a solution of the compound of formula (I) in 1,4-dioxane at 25°C.

56. A method for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof; a solid form as claimed in any one of claims 1 to 9; or a salt as claimed in any one of claims 18 to 42, the method comprising: include: The compound of formula (1c): With the compound of formula (1b): or a salt thereof via a Buchwald coupling reaction to form a compound of formula (1a): Where X 1 It is a halogen group.

57. The method of claim 56, wherein X 1 For Br.

58. The method of claim 56 or 57, wherein the compound of formula (1b) or a salt thereof is an HCl salt.

59. The method of any one of claims 56-58, wherein the Buchwald coupling reaction comprises reacting the compound of formula (1c) with the compound of formula (1b) or a salt thereof in the presence of a Buchwald catalyst or procatalyst and a base.

60. The process of claim 59, wherein the base is an alkali metal alkoxide.

61. The method of any one of claims 56-60, wherein the method further comprises reacting the compound of formula (1a) with an organic acid to form a salt of the compound of formula (1a).

62. The method of claim 61, wherein the organic acid is succinic acid.

63. The method of claim 62, wherein the salt of the compound of formula (1) is the hemisuccinate salt of the compound of formula (1a).

64. The method of any one of claims 56-63, wherein the method further comprises deprotecting the compound of formula (1a) or a salt thereof to form the compound of formula (I).

65. The method of any one of claims 56-60, further comprising deprotecting the compound of formula (1a) to form the compound of formula (I).

66. The method of any one of claims 56-65, wherein the compound of formula (1c) is prepared by a method comprising: The compound of formula (1d): or a salt thereof is reacted with a halogenating agent to form the compound of formula (1c).

67. The method of claim 66, wherein the compound of formula (1d) or a salt thereof is prepared by a method comprising: The compound of formula 1(e): The mixture is reacted with hydroxylamine hydrochloride and a base component to form the compound of formula (1d) or a salt thereof.

68. A compound selected from: or a salt thereof.

69. A hemisuccinate salt of a compound of formula (1a):